PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 2575439-8 1989 4) The peripherally acting alpha 2 antagonist DG-5128 blocked only the PRL secretory response to UK 14304 whereas the peripherally and centrally active yohimbine blocked the PRL and GH responses. Yohimbine 152-161 growth hormone 1 Homo sapiens 182-184 2575440-3 1989 It has been suggested that the stimulation of the secretion of PRL by the alpha 2 adrenergic receptor antagonists (yohimbine, piperoxane) results from blockade of an inhibitory influence imposed on PRL release by the central alpha 2 receptors (7, 15). Yohimbine 115-124 prolactin Homo sapiens 63-66 2575440-3 1989 It has been suggested that the stimulation of the secretion of PRL by the alpha 2 adrenergic receptor antagonists (yohimbine, piperoxane) results from blockade of an inhibitory influence imposed on PRL release by the central alpha 2 receptors (7, 15). Yohimbine 115-124 prolactin Homo sapiens 198-201 2575440-5 1989 RAU was more effective in activation of PRL secretion than either YOH or Wy 26392 although it had a similar alpha 2 antagonist activity, while IDAZ, the most potent alpha 2 blocker among the four compounds, did not stimulate PRL secretion. Yohimbine 0-3 prolactin Homo sapiens 40-43 2575440-6 1989 2) The PRL-releasing effect of YOH or Wy 26392 was reversed by the alpha 2 agonist clonidine but the same effect of RAU was not, speaking against a common alpha 2-mediated mechanism of action of the three antagonists. Yohimbine 31-34 prolactin Homo sapiens 7-10 2575440-7 1989 3) The PRL-stimulating effect of YOH, RAU or Wy 26392 persisted following inhibition of NE synthesis and presumably release with FLA 63, DDC or combination of reserpine and DDC. Yohimbine 33-36 prolactin Homo sapiens 7-10 2583236-3 1989 Conditions that increase the biophase concentration of norepinephrine, longer stimulation trains or application of yohimbine, decreased the potentiation by NPY, although in the presence of cocaine potentiation by NPY was unchanged. Yohimbine 115-124 neuropeptide Y Oryctolagus cuniculus 156-159 2626080-2 1989 Interaction of angiotensin II with yohimbine. Yohimbine 35-44 angiotensinogen Rattus norvegicus 15-29 2626080-5 1989 Yohimbine (1 and 3 mg/kg) significantly reduced the stimulatory effects of AT II, mainly on ambulation. Yohimbine 0-9 angiotensinogen Rattus norvegicus 75-80 2626080-7 1989 An interaction between AT II receptors and NA-ergic neurotransmission in the brain might be taken into consideration as an explanation of the influence of yohimbine on AT II effects in open field behavior. Yohimbine 155-164 angiotensinogen Rattus norvegicus 23-28 2626080-7 1989 An interaction between AT II receptors and NA-ergic neurotransmission in the brain might be taken into consideration as an explanation of the influence of yohimbine on AT II effects in open field behavior. Yohimbine 155-164 angiotensinogen Rattus norvegicus 168-173 2552342-3 1989 We also evaluated the tonic nature of alpha 2-inhibition of the sympathetic nervous system (SNS) and of AVP release into plasma by measuring the response of plasma NE and plasma AVP to yohimbine. Yohimbine 185-194 arginine vasopressin Homo sapiens 178-181 2479528-3 1989 Intravenous injection of yohimbine (YOM; an alpha 2-antagonist), chlorpromazine (CPZ), and haloperidol (HAL; dopamine and alpha-adrenergic antagonists) completely suppressed this pulsatile GH secretion (mean 6-h GH levels, 2.98 +/- 0.24, 3.48 +/- 0.24, and 2.91 +/- 0.29 ng/ml, respectively; P less than 0.001), whereas prazosin (an alpha 1-antagonist), pimozide (a selective dopamine antagonist), sulpiride, and YM-09151-2 (YM; D2-specific antagonists) failed to affect the GH secretory pattern (mean 6-h GH levels, 6.61 +/- 0.73, 6.71 +/- 0.56, 5.44 +/- 0.44, and 6.87 +/- 1.44 ng/ml, respectively). Yohimbine 25-34 somatotropin Oryctolagus cuniculus 189-191 2479528-3 1989 Intravenous injection of yohimbine (YOM; an alpha 2-antagonist), chlorpromazine (CPZ), and haloperidol (HAL; dopamine and alpha-adrenergic antagonists) completely suppressed this pulsatile GH secretion (mean 6-h GH levels, 2.98 +/- 0.24, 3.48 +/- 0.24, and 2.91 +/- 0.29 ng/ml, respectively; P less than 0.001), whereas prazosin (an alpha 1-antagonist), pimozide (a selective dopamine antagonist), sulpiride, and YM-09151-2 (YM; D2-specific antagonists) failed to affect the GH secretory pattern (mean 6-h GH levels, 6.61 +/- 0.73, 6.71 +/- 0.56, 5.44 +/- 0.44, and 6.87 +/- 1.44 ng/ml, respectively). Yohimbine 25-34 somatotropin Oryctolagus cuniculus 212-214 2479528-3 1989 Intravenous injection of yohimbine (YOM; an alpha 2-antagonist), chlorpromazine (CPZ), and haloperidol (HAL; dopamine and alpha-adrenergic antagonists) completely suppressed this pulsatile GH secretion (mean 6-h GH levels, 2.98 +/- 0.24, 3.48 +/- 0.24, and 2.91 +/- 0.29 ng/ml, respectively; P less than 0.001), whereas prazosin (an alpha 1-antagonist), pimozide (a selective dopamine antagonist), sulpiride, and YM-09151-2 (YM; D2-specific antagonists) failed to affect the GH secretory pattern (mean 6-h GH levels, 6.61 +/- 0.73, 6.71 +/- 0.56, 5.44 +/- 0.44, and 6.87 +/- 1.44 ng/ml, respectively). Yohimbine 25-34 somatotropin Oryctolagus cuniculus 212-214 2479528-3 1989 Intravenous injection of yohimbine (YOM; an alpha 2-antagonist), chlorpromazine (CPZ), and haloperidol (HAL; dopamine and alpha-adrenergic antagonists) completely suppressed this pulsatile GH secretion (mean 6-h GH levels, 2.98 +/- 0.24, 3.48 +/- 0.24, and 2.91 +/- 0.29 ng/ml, respectively; P less than 0.001), whereas prazosin (an alpha 1-antagonist), pimozide (a selective dopamine antagonist), sulpiride, and YM-09151-2 (YM; D2-specific antagonists) failed to affect the GH secretory pattern (mean 6-h GH levels, 6.61 +/- 0.73, 6.71 +/- 0.56, 5.44 +/- 0.44, and 6.87 +/- 1.44 ng/ml, respectively). Yohimbine 25-34 somatotropin Oryctolagus cuniculus 212-214 2479528-3 1989 Intravenous injection of yohimbine (YOM; an alpha 2-antagonist), chlorpromazine (CPZ), and haloperidol (HAL; dopamine and alpha-adrenergic antagonists) completely suppressed this pulsatile GH secretion (mean 6-h GH levels, 2.98 +/- 0.24, 3.48 +/- 0.24, and 2.91 +/- 0.29 ng/ml, respectively; P less than 0.001), whereas prazosin (an alpha 1-antagonist), pimozide (a selective dopamine antagonist), sulpiride, and YM-09151-2 (YM; D2-specific antagonists) failed to affect the GH secretory pattern (mean 6-h GH levels, 6.61 +/- 0.73, 6.71 +/- 0.56, 5.44 +/- 0.44, and 6.87 +/- 1.44 ng/ml, respectively). Yohimbine 36-39 somatotropin Oryctolagus cuniculus 189-191 2479528-3 1989 Intravenous injection of yohimbine (YOM; an alpha 2-antagonist), chlorpromazine (CPZ), and haloperidol (HAL; dopamine and alpha-adrenergic antagonists) completely suppressed this pulsatile GH secretion (mean 6-h GH levels, 2.98 +/- 0.24, 3.48 +/- 0.24, and 2.91 +/- 0.29 ng/ml, respectively; P less than 0.001), whereas prazosin (an alpha 1-antagonist), pimozide (a selective dopamine antagonist), sulpiride, and YM-09151-2 (YM; D2-specific antagonists) failed to affect the GH secretory pattern (mean 6-h GH levels, 6.61 +/- 0.73, 6.71 +/- 0.56, 5.44 +/- 0.44, and 6.87 +/- 1.44 ng/ml, respectively). Yohimbine 36-39 somatotropin Oryctolagus cuniculus 212-214 2479528-3 1989 Intravenous injection of yohimbine (YOM; an alpha 2-antagonist), chlorpromazine (CPZ), and haloperidol (HAL; dopamine and alpha-adrenergic antagonists) completely suppressed this pulsatile GH secretion (mean 6-h GH levels, 2.98 +/- 0.24, 3.48 +/- 0.24, and 2.91 +/- 0.29 ng/ml, respectively; P less than 0.001), whereas prazosin (an alpha 1-antagonist), pimozide (a selective dopamine antagonist), sulpiride, and YM-09151-2 (YM; D2-specific antagonists) failed to affect the GH secretory pattern (mean 6-h GH levels, 6.61 +/- 0.73, 6.71 +/- 0.56, 5.44 +/- 0.44, and 6.87 +/- 1.44 ng/ml, respectively). Yohimbine 36-39 somatotropin Oryctolagus cuniculus 212-214 2479528-3 1989 Intravenous injection of yohimbine (YOM; an alpha 2-antagonist), chlorpromazine (CPZ), and haloperidol (HAL; dopamine and alpha-adrenergic antagonists) completely suppressed this pulsatile GH secretion (mean 6-h GH levels, 2.98 +/- 0.24, 3.48 +/- 0.24, and 2.91 +/- 0.29 ng/ml, respectively; P less than 0.001), whereas prazosin (an alpha 1-antagonist), pimozide (a selective dopamine antagonist), sulpiride, and YM-09151-2 (YM; D2-specific antagonists) failed to affect the GH secretory pattern (mean 6-h GH levels, 6.61 +/- 0.73, 6.71 +/- 0.56, 5.44 +/- 0.44, and 6.87 +/- 1.44 ng/ml, respectively). Yohimbine 36-39 somatotropin Oryctolagus cuniculus 212-214 2575615-14 1989 The electrically induced increase in blood pressure subsequent to administration of high doses of prazosin, rauwolscine plus propranolol was diminished by suramin and by the low and high dose of mATP. Yohimbine 108-119 solute carrier family 45, member 2 Mus musculus 195-199 2570572-3 1989 The response was diminished in the absence of extracellular Ca2+ and was inhibited more efficiently by phentolamine and prazosin than by propranolol or yohimbine, indicating alpha 1-adrenergic mediation. Yohimbine 152-161 adrenoceptor alpha 1D Homo sapiens 174-181 2475029-6 1989 BHT-920, an alpha 2-adrenoceptor agonist, reduced VIP output markedly by a rauwolscine-sensitive mechanism. Yohimbine 75-86 vasoactive intestinal peptide Canis lupus familiaris 50-53 2568481-7 1989 The inhibitory effect of clonidine on pineal NAT activity was blocked by yohimbine, an alpha-2 adrenergic receptor antagonist. Yohimbine 73-82 arylamine N-acetyltransferase, liver isozyme Gallus gallus 45-48 2811604-13 1989 The alpha 2 antagonist, yohimbine reduced the neurotensin induced ICS contraction from 31.6 +/- 3.4 to 21.9 +/- 3.3 mm Hg, p less than 0.05. Yohimbine 24-33 neurotensin Felis catus 46-57 2566353-10 1989 Plasma insulin was weakly enhanced by yohimbine (+120%) as compared to the increase given by procaterol (+500%). Yohimbine 38-47 insulin Canis lupus familiaris 7-14 2537740-0 1989 [3H]rauwolscine labels alpha 2-adrenoceptors and 5-HT1A receptors in human cerebral cortex. Yohimbine 4-15 5-hydroxytryptamine receptor 1A Homo sapiens 23-55 2551545-0 1989 Yohimbine and aldosterone responsiveness to angiotensin II or corticotrophin in normal subjects. Yohimbine 0-9 angiotensinogen Homo sapiens 44-58 2547477-11 1989 In the presence of AVP, pressor responses to UK-14,304 were resistant to 0.05 microM prazosin and susceptible to antagonism by 1 microM rauwolscine (-log Kb 7.65 +/- 0.15). Yohimbine 136-147 arginine vasopressin Rattus norvegicus 19-22 2547477-12 1989 Similarly, responses to NA in the presence of 0.05 microM prazosin and AVP were inhibited by 1 microM rauwolscine. Yohimbine 102-113 arginine vasopressin Rattus norvegicus 71-74 2853751-9 1988 The results show that yohimbine increased renin release by 310 +/- 60% in group I, but by only 80 +/- 45% in group II (P less than 0.01). Yohimbine 22-31 renin Homo sapiens 42-47 2565196-4 1989 Inhibition of VIP-stimulated cyclic AMP production by clonidine, epinephrine, isoproterenol, and dopamine is blocked by yohimbine but not by prazosin. Yohimbine 120-129 VIP peptides Oryctolagus cuniculus 14-17 2566928-5 1989 The stimulated release of noradrenaline and NPY was increased by the alpha 2-adrenoceptor antagonist yohimbine (1 microM) to 170 +/- 10% and 199 +/- 26%, and attenuated by the alpha 2-adrenoceptor agonist B-HT 920 (1 microM) to 70 +/- 9% and 68 +/- 9%, respectively. Yohimbine 101-110 pro-neuropeptide Y Cavia porcellus 44-47 2566928-8 1989 Uptake1 blockade with desipramine (100 nM) or nisoxetine (100 nM) prior to the second stimulation significantly increased noradrenaline overflow and attenuated that of NPY; the attenuation of the stimulation-evoked overflow of NPY was abolished by yohimbine (1 microM). Yohimbine 248-257 pro-neuropeptide Y Cavia porcellus 168-171 2905003-6 1988 Yohimbine perfusion induced a dose-dependent increase in plasma nonesterified fatty acids (NEFA) and immunoreactive insulin concentrations. Yohimbine 0-9 insulin Canis lupus familiaris 116-123 2465449-5 1988 The depressor effect of intrathecal NPY was attenuated by prior treatment with yohimbine and propranolol but not prazosin. Yohimbine 79-88 neuropeptide Y Rattus norvegicus 36-39 2903597-2 1988 It is well known that yohimbine, an alpha 2-adrenoceptor-blocking agent, reduces the secretion of insulin and the platelet factors. Yohimbine 22-31 insulin Homo sapiens 98-105 2841088-9 1988 At the same time, plasma IR-ANF decreased from 113.3 +/- 32.2 to 30.3 +/- 11.4 after yohimbine and to 24.6 +/- 12.1 pg/ml after naloxone treatment (P less than 0.05). Yohimbine 85-94 natriuretic peptide A Rattus norvegicus 28-31 3134891-7 1988 The binding of phenoxybenzamine to calmodulin was fairly selective in that other alpha-adrenergic agents such as prazosin, yohimbine and clonidine failed to bind to calmodulin when examined under the same experimental conditions. Yohimbine 123-132 calmodulin 1 Homo sapiens 35-45 2907171-11 1988 We have shown in the rat: (1) that CGRP stimulates basal insulin and glucagon secretion; (2) that CGRP inhibits stimulated insulin and glucagon secretion; (3) that CGRP and somatostatin more rapidly induce a potent inhibitory action on glucose-stimulated insulin secretion when given together; and (4) that the alpha 2-adrenoceptor antagonist, yohimbine, counteracts the inhibitory action of CGRP on glucose-stimulated insulin secretion. Yohimbine 344-353 calcitonin-related polypeptide alpha Rattus norvegicus 98-102 2907171-11 1988 We have shown in the rat: (1) that CGRP stimulates basal insulin and glucagon secretion; (2) that CGRP inhibits stimulated insulin and glucagon secretion; (3) that CGRP and somatostatin more rapidly induce a potent inhibitory action on glucose-stimulated insulin secretion when given together; and (4) that the alpha 2-adrenoceptor antagonist, yohimbine, counteracts the inhibitory action of CGRP on glucose-stimulated insulin secretion. Yohimbine 344-353 calcitonin-related polypeptide alpha Rattus norvegicus 98-102 2907171-11 1988 We have shown in the rat: (1) that CGRP stimulates basal insulin and glucagon secretion; (2) that CGRP inhibits stimulated insulin and glucagon secretion; (3) that CGRP and somatostatin more rapidly induce a potent inhibitory action on glucose-stimulated insulin secretion when given together; and (4) that the alpha 2-adrenoceptor antagonist, yohimbine, counteracts the inhibitory action of CGRP on glucose-stimulated insulin secretion. Yohimbine 344-353 calcitonin-related polypeptide alpha Rattus norvegicus 98-102 2969309-7 1988 In a second large vessel group ANF completely reversed constriction induced by the alpha 1-adrenoceptor agonist, phenylephrine, in the presence of 5 X 10(-7) M yohimbine. Yohimbine 160-169 natriuretic peptide A Rattus norvegicus 31-34 3279873-0 1988 Yohimbine increases plasma insulin concentrations and reverses xylazine-induced hypoinsulinemia in dogs. Yohimbine 0-9 insulin Canis lupus familiaris 27-34 2843379-5 1988 Prazosin (0.4-3 micrograms min-1) effectively blocked the vasoconstrictor effect of phenylephrine but not clonidine, while yohimbine (30-70 micrograms min-1) blocked the effect of clonidine but not phenylephrine. Yohimbine 123-132 CD59 molecule (CD59 blood group) Homo sapiens 151-156 2843379-7 1988 In the 20 degrees C room, yohimbine (30-70 micrograms min-1) produced a significant increase in finger blood flow (7.8 +/- 2.8 to 23.4 +/- 6.8 ml, P less than 0.01) and decrease in vascular resistance (20.5 +/- 5.7 to 6.0 +/- 2.2 units, P less than 0.01). Yohimbine 26-35 CD59 molecule (CD59 blood group) Homo sapiens 54-59 3381901-6 1988 Additionally, this response was mimicked by administration of yohimbine, an alpha 2-antagonist, into the MnPO, which suggests that noradrenergic mechanisms are involved in the baroreflex-mediated facilitation of bradycardia by AVP at the level of the MnPO. Yohimbine 62-71 vasopressin-neurophysin 2-copeptin Oryctolagus cuniculus 227-230 3409962-0 1988 Angiotensin II contributes to blood pressure maintenance in conscious rats treated with yohimbine. Yohimbine 88-97 angiotensinogen Rattus norvegicus 0-14 3409962-4 1988 We conclude that yohimbine-induced renin release, and the resultant rise in plasma angiotensin II concentration, prevents the decrease in MAP which would result from the blockade of vascular alpha-adrenoceptors by yohimbine. Yohimbine 17-26 angiotensinogen Rattus norvegicus 83-97 3409962-4 1988 We conclude that yohimbine-induced renin release, and the resultant rise in plasma angiotensin II concentration, prevents the decrease in MAP which would result from the blockade of vascular alpha-adrenoceptors by yohimbine. Yohimbine 214-223 angiotensinogen Rattus norvegicus 83-97 2899516-5 1988 The dissimilarity in action of LON-954 and yohimbine on clonidine-induced hypothermia could be due to the fact that the anticlonidine effect of yohimbine on hypothermia is mediated through its antiserotonin action. Yohimbine 144-153 lon peptidase 1, mitochondrial Rattus norvegicus 31-34 3279873-2 1988 Yohimbine (0.11 mg/kg, IV), an alpha 2-adrenoreceptor antagonist, given 5 minutes after xylazine, reversed effects of xylazine, whereas yohimbine alone increased plasma insulin and decreased plasma glucose concentrations. Yohimbine 0-9 insulin Canis lupus familiaris 169-176 3279873-2 1988 Yohimbine (0.11 mg/kg, IV), an alpha 2-adrenoreceptor antagonist, given 5 minutes after xylazine, reversed effects of xylazine, whereas yohimbine alone increased plasma insulin and decreased plasma glucose concentrations. Yohimbine 136-145 insulin Canis lupus familiaris 169-176 3206173-0 1988 Influence of yohimbine on the formation of desmosine cross-links in elastin. Yohimbine 13-22 elastin Homo sapiens 68-75 2824175-10 1987 On the other hand, the alpha 2-adrenoreceptor antagonist yohimbine significantly attenuated the NPY-induced LH increments. Yohimbine 57-66 neuropeptide Y Rattus norvegicus 96-99 3691641-9 1987 The adrenoreceptor antagonists phentolamine, prazosin and yohimbine all inhibited the increase in cardiac content of NPY-LI seen after clonidine treatment. Yohimbine 58-67 pro-neuropeptide Y Cavia porcellus 117-120 3036595-2 1987 The inhibition of insulin secretion from permeabilised islets was blocked by the alpha 2-adrenoreceptor antagonist, yohimbine. Yohimbine 116-125 insulin Homo sapiens 18-25 3285225-0 1988 The mechanism of yohimbine-induced renin release in the conscious rat. Yohimbine 17-26 renin Rattus norvegicus 35-40 3285225-1 1988 These studies were designed to determine the role of the central nervous system, the sympathetic nervous system, the adrenal glands and the renal sympathetic nerves in yohimbine-induced renin release in conscious rats. Yohimbine 168-177 renin Rattus norvegicus 186-191 3285225-2 1988 Yohimbine (0.3-10 mg/kg, s.c.) caused time- and dose-related increases in plasma renin activity (PRA) and concentration (PRC) which were accompanied by time- and dose-related elevations of plasma norepinephrine (NE) and epinephrine (Epi) concentrations. Yohimbine 0-9 renin Rattus norvegicus 81-86 3285225-6 1988 An increase in circulating plasma catecholamine concentrations appeared to mediate yohimbine-induced renin release since propranolol prevented the rise in PRA caused by yohimbine in renal denervated rats. Yohimbine 83-92 renin Rattus norvegicus 101-106 3285225-11 1988 Based on these results, we conclude that 1) the stimulation of renin release by yohimbine is a secondary neurohormonal consequence of the generalized increase in sympathetic activity caused by yohimbine, 2) the sympathoadrenal activation produced by yohimbine results from an action in the brain which is amplified by the simultaneous blockade of prejunctional alpha 2-adrenoceptors. Yohimbine 80-89 renin Rattus norvegicus 63-68 3285225-11 1988 Based on these results, we conclude that 1) the stimulation of renin release by yohimbine is a secondary neurohormonal consequence of the generalized increase in sympathetic activity caused by yohimbine, 2) the sympathoadrenal activation produced by yohimbine results from an action in the brain which is amplified by the simultaneous blockade of prejunctional alpha 2-adrenoceptors. Yohimbine 193-202 renin Rattus norvegicus 63-68 3285225-11 1988 Based on these results, we conclude that 1) the stimulation of renin release by yohimbine is a secondary neurohormonal consequence of the generalized increase in sympathetic activity caused by yohimbine, 2) the sympathoadrenal activation produced by yohimbine results from an action in the brain which is amplified by the simultaneous blockade of prejunctional alpha 2-adrenoceptors. Yohimbine 193-202 renin Rattus norvegicus 63-68 2820251-2 1987 During the normotensive period, treatment with prazosin and yohimbine both increased plasma lysine vasopressin concentration (vehicle = 3.4 +/- 1.21 microU/ml; prazosin = 35.8 +/- 10.8 microU/ml; and yohimbine = 20.1 +/- 9.5 microU/ml). Yohimbine 60-69 vasopressin Sus scrofa 99-110 2820251-5 1987 In contrast, on hemorrhage of yohimbine-treated piglets, the increase in plasma lysine vasopressin concentration was augmented remarkably (527.0 +/- 103.2 microU/ml) in comparison to the other groups. Yohimbine 30-39 vasopressin Sus scrofa 87-98 2820251-6 1987 We conclude that, in unanesthetized newborn pigs, treatment with the alpha 2-adrenoreceptor antagonist yohimbine increased plasma lysine vasopressin concentration and markedly accentuated the vasopressin response to hemorrhage. Yohimbine 103-112 vasopressin Sus scrofa 137-148 2820251-6 1987 We conclude that, in unanesthetized newborn pigs, treatment with the alpha 2-adrenoreceptor antagonist yohimbine increased plasma lysine vasopressin concentration and markedly accentuated the vasopressin response to hemorrhage. Yohimbine 103-112 vasopressin Sus scrofa 192-203 3035429-9 1987 Clonidine-stimulated ANF secretion was partially inhibited by yohimbine from 457.1 +/- 66.3 pg/ml (mean +/- S.E.M.) Yohimbine 62-71 natriuretic peptide A Rattus norvegicus 21-24 2885275-7 1987 Doxazosin enhanced renin secretion in the kidney by 10 +/- 4% over levels in controls (0.05 less than p less than 0.10), whereas yohimbine increased renin release by 80 +/- 23% (p less than 0.01). Yohimbine 129-138 renin Homo sapiens 149-154 3617010-2 1987 In the presence of 1mM external calcium, epinephrine augmented the increase in cytoplasmic free calcium in response to collagen or thrombin, and this was inhibited by yohimbine. Yohimbine 167-176 coagulation factor II, thrombin Homo sapiens 131-139 3035429-11 1987 Moreover, yohimbine in highest doses (50 micrograms) decreased the basal plasma IR-ANF from 34.0 +/- 7.0 pg/ml (means +/- S.E.M.) Yohimbine 10-19 natriuretic peptide A Rattus norvegicus 83-86 3296886-6 1987 Serum insulin concentration was unchanged in mares given saline solution, but transiently increased in mares given yohimbine alone. Yohimbine 115-124 insulin Homo sapiens 6-13 3660339-2 1987 SPA was associated with release of TXA2 and was only partially inhibited by ADP-inhibitor apyrase and alpha 2-adrenoceptor blocker yohimbine. Yohimbine 131-140 surfactant protein A2 Homo sapiens 0-3 3031661-3 1987 Studies utilizing alpha-adrenergic and dopamine receptor antagonists revealed that neuropeptide Y-mediated relaxation was blocked only by the alpha 2 antagonist yohimbine. Yohimbine 161-170 pro-neuropeptide Y Cavia porcellus 83-97 3031661-4 1987 Neuropeptide Y also antagonized muscle response to electric field stimulation that was reversed by yohimbine. Yohimbine 99-108 pro-neuropeptide Y Cavia porcellus 0-14 3582495-5 1987 The alpha 2-adrenoceptor antagonist yohimbine blocked the synergistic effects of adrenaline or clonidine associated to PAF-acether, reducing aggregation to that due to PAF-acether alone. Yohimbine 36-45 PCNA clamp associated factor Homo sapiens 119-122 3582495-5 1987 The alpha 2-adrenoceptor antagonist yohimbine blocked the synergistic effects of adrenaline or clonidine associated to PAF-acether, reducing aggregation to that due to PAF-acether alone. Yohimbine 36-45 PCNA clamp associated factor Homo sapiens 168-171 3547411-0 1987 Yohimbine increases plasma insulin concentrations of dogs. Yohimbine 0-9 insulin Canis lupus familiaris 27-34 3547411-2 1987 In the present study, iv injections of 0.1 and 0.3 mg/kg of yohimbine, an alpha 2-adrenoreceptor antagonist, resulted in increased plasma insulin and decreased plasma glucose concentrations in the dog. Yohimbine 60-69 insulin Canis lupus familiaris 138-145 2884329-5 1987 Two alpha 2-adrenergic receptor blocking agents, tolazoline and yohimbine, were administered intravenously for prevention (0.1-0.4 mg/kg) or reversal (0.4-1.2 mg/kg) of these effects. Yohimbine 64-73 adrenoceptor alpha 2A Bos taurus 4-31 3028832-2 1986 This effect was reversed by yohimbine (1 mg X kg-1) which caused a three-fold increase of the plasma NPY-LI. Yohimbine 28-37 pro-neuropeptide Y Cavia porcellus 101-104 3435250-4 1987 Yohimbine administration increased plasma renin activity by 27 to 41% which are not affected by OKY administration. Yohimbine 0-9 LOW QUALITY PROTEIN: renin Oryctolagus cuniculus 42-47 2455192-4 1987 The release of both enkephalins and NPY was enhanced by phentolamine or yohimbine and diminished by cocaine. Yohimbine 72-81 pro-neuropeptide Y Cavia porcellus 36-39 3031208-3 1987 The locomotor stimulant action provoked by TRH was antagonized by pretreatment of ventromedial hypothalamus with either an alpha-adrenergic receptor antagonist (yohimbine), a dopaminergic receptor antagonist (haloperidol) or an opiate receptor antagonist (naloxone), but not with a beta-adrenergic receptor antagonist (propranolol). Yohimbine 161-170 thyrotropin releasing hormone Rattus norvegicus 43-46 2873027-5 1986 The stimulatory effect of clonidine (10(-4) M) on GRF release in the presence of propranolol was inhibited by yohimbine (10(-4) M), an alpha 2-adrenergic blocking agent. Yohimbine 110-119 growth hormone releasing hormone Rattus norvegicus 50-53 3015973-8 1986 When propranolol (10(-6) M), a beta-antagonist was included in the perfusion fluid, rauwolscine no longer potentiated responses to NA but reduced them at all concentrations. Yohimbine 84-95 amyloid beta precursor protein Rattus norvegicus 29-35 3005829-4 1986 Following demethylation of rauwolscine or yohimbine, the resultant carboxylic acid derivatives were reacted with 4-aminophenethylamine to yield the respective 4-aminophenethyl carboxamides, 17 alpha-hydroxy-20 alpha-yohimban-16 beta-[N-4-amino-phenethyl]carboxamide (rau-pAPC) and 17 alpha-hydroxy-20 beta-yohimban-16 alpha-[N-4-aminophenethyl]carboxamide. Yohimbine 27-38 protocadherin 8 Homo sapiens 271-275 3963600-0 1986 Effect of yohimbine hydrochloride on serum prolactin concentration in the rat: possible antagonist for fescue toxicosis. Yohimbine 10-33 prolactin Rattus norvegicus 43-52 3963600-7 1986 Given intraperitoneally once a day for 8 days, yohimbine hydrochloride increased serum prolactin concentrations. Yohimbine 47-70 prolactin Rattus norvegicus 87-96 3963600-9 1986 The effects of yohimbine on prolactin concentrations were dependent on the dosages and routes of administration. Yohimbine 15-24 prolactin Rattus norvegicus 28-37 3963600-10 1986 The inability of yohimbine, when given orally, to increase serum prolactin levels decreased its potential usefulness for prolonged treatment of fescue toxicosis. Yohimbine 17-26 prolactin Rattus norvegicus 65-74 3005555-4 1986 Responses to norepinephrine in the presence of rauwolscine were antagonized by prazosin and are therefore mediated predominantly by alpha-1 adrenoceptors. Yohimbine 47-58 adrenoceptor alpha 1D Homo sapiens 132-139 3007555-10 1986 Competition experiments with prazosin and yohimbine confirmed the predominance of the alpha 1-receptor subtype, although the presence of alpha 2-receptors cannot be completely ruled out. Yohimbine 42-51 adrenoceptor alpha 1D Homo sapiens 86-93 3013108-5 1986 Inhibition of clonidine-induced increase in plasma cyclic GMP by yohimbine, hexamethonium and atropine, but not by prazosin suggests that the effect of clonidine is mediated by the central alpha 2-adrenoceptors, activating the muscarinic receptor-linked guanylate cyclase through the stimulation of vagal activity. Yohimbine 65-74 5'-nucleotidase, cytosolic II Mus musculus 58-61 3005829-5 1986 In competitive inhibition studies using rat renal membranes and the radioligand [3H]rauwolscine, rau-pAPC (Ki = 11 +/- 1 nM) exhibited a 14-fold greater affinity than the corresponding yohimbine derivative (Ki = 136 +/- 45 nM). Yohimbine 185-194 protocadherin 8 Homo sapiens 101-105 3005829-8 1986 In competition studies, alpha-adrenergic antagonists and agonists inhibited the binding of 125I-rau-pAPC with a potency order consistent with an interaction at alpha 2-adrenergic receptors (rauwolscine greater than phentolamine greater than prazosin; clonidine greater than (-)-epinephrine greater than (-)-norepinephrine greater than dopamine greater than (+)-epinephrine). Yohimbine 190-201 protocadherin 8 Homo sapiens 100-104 3703161-4 1986 The central administration of the alpha-1 antagonist corynanthine (20 micrograms) had no effect on the plasma vasopressin concentration; however, increases in plasma vasopressin levels were observed when either the alpha-2 antagonist yohimbine (20 micrograms) or the beta antagonist propranolol (20 micrograms) were given. Yohimbine 234-243 arginine vasopressin Rattus norvegicus 166-177 3025757-8 1986 Yohimbine-induced prolactin release was reversed by UK-14,304 at doses of 0.2 and 1.0 mg/kg, but not at the lowest dose studied, 0.05 mg/kg. Yohimbine 0-9 prolactin Rattus norvegicus 18-27 3006688-3 1986 These transient elevations in cytosolic Ca2+ were dose-dependently inhibited by alpha-adrenergic antagonists, the order of potency being prazosin greater than phentolamine greater than yohimbine, irrespective of the presence of extracellular Ca2+. Yohimbine 185-194 carbonic anhydrase 2 Rattus norvegicus 40-43 3025757-2 1986 Yohimbine administration alone, at doses ranging from 0.2 to 5.0 mg/kg, resulted in a dose-related elevation of plasma prolactin levels from a basal level of 8 +/- 2 to 65 +/- 6 ng/ml at the highest dose. Yohimbine 0-9 prolactin Rattus norvegicus 119-128 3025757-6 1986 All three doses of clonidine completely reversed yohimbine-induced prolactin release. Yohimbine 49-58 prolactin Rattus norvegicus 67-76 2864269-12 1985 The cardiovascular effects of intramedullary injected SS28 were also blocked with an ipsilateral NTS injection of yohimbine or tolazoline 10 min prior to SS28. Yohimbine 114-123 somatostatin Rattus norvegicus 54-58 2990239-6 1985 This suppression by E in PCT and CCT was inhibited by 5 X 10(-6) M yohimbine or 5 X 10(-7) M phentolamine but not by 5 X 10(-6) M prazosin. Yohimbine 67-76 FLVCR heme transporter 2 Rattus norvegicus 33-36 2991614-5 1985 Comparison of pA2 values of prazosin and yohimbine in both the tissues with those values found in the literature for these compounds in a variety of tissues containing alpha-1 or alpha-2 adrenergic receptor indicates that the postsynaptic alpha adrenergic receptor subtype in the human urinary bladder base and prostatic urethra is the alpha-1 type, not the alpha-2 type. Yohimbine 41-50 adrenoceptor alpha 1D Homo sapiens 168-175 2981281-5 1985 In IAP/NAD-pretreated membranes, however, [3H]yohimbine binding was no longer affected by GTP, although IAP/NAD significantly (p less than 0.01) increased [3H]yohimbine binding compared to control. Yohimbine 159-168 Cd47 molecule Rattus norvegicus 104-107 4036649-4 1985 The alpha-adrenergic blocker yohimbin (1 X 10(-7) M) and compound 1b (1 X 10(-6) M) increase the contractions of electrically stimulated mouse vas deferens. Yohimbine 29-37 arginine vasopressin Rattus norvegicus 143-146 2990161-3 1985 We have identified alpha 1- and alpha 2-adrenergic receptors in myometrial membranes using the newly developed radiolabelled specific antagonists [3H]-prazosin and [3H]-rauwolscine. Yohimbine 169-180 adrenoceptor alpha 1D Homo sapiens 19-26 2860247-4 1985 The suppression of pigment dispersion by catecholamines was blocked by the simultaneous presence of yohimbine but not prazosin, indicating that the catecholamines antagonize the alpha-MSH signal by inhibitory action on the adenylate cyclase system through an alpha-2 receptor. Yohimbine 100-109 proopiomelanocortin Homo sapiens 178-187 6323192-0 1984 Yohimbine induces sympathetically mediated renin release in the conscious rat. Yohimbine 0-9 renin Rattus norvegicus 43-48 6152103-10 1984 However, the low slope value of the Schild plot for rauwolscine may indicate the presence of a small population of alpha 1-adrenoceptors. Yohimbine 52-63 adrenoceptor alpha 1D Homo sapiens 115-122 6151010-5 1984 The inhibitory effect of clonidine on TRH-induced acid secretion was reversed by yohimbine, an alpha-2 adrenergic antagonist, and phentolamine. Yohimbine 81-90 thyrotropin releasing hormone Rattus norvegicus 38-41 6095132-2 1984 The GH response was blunted following each antagonist used, PRL secretion was higher after yohimbine and diminished after phentolamine when compared to controls. Yohimbine 91-100 prolactin Homo sapiens 60-63 6147817-5 1984 (3) The inhibition of VIP action by epinephrine is reversed by the alpha antagonists dihydroergotamine, phentolamine and the alpha 2 antagonist yohimbine, while unaffected by the beta antagonist propranolol and the alpha 1 antagonist prazosin, (4) Epinephrine inhibits VIP-stimulated adenylate cyclase activity in preparations of colonic plasma membranes. Yohimbine 144-153 vasoactive intestinal peptide Homo sapiens 22-25 6149693-5 1984 The effect of methoxamine (5 micrograms/min) on renin release was abolished by the intrarenal alpha 1-adrenoceptor blockade with prazosin (3 micrograms/min) but was not affected by the intrarenal alpha 2-adrenoceptor blockade with yohimbine (30 micrograms/min). Yohimbine 231-240 renin Canis lupus familiaris 48-53 6329483-2 1984 Further, yohimbine and tolazoline, alpha 2-adrenoceptor antagonists, augment the drinking response to both peripherally administered isoproterenol and angiotensin II. Yohimbine 9-18 angiotensinogen Rattus norvegicus 151-165 6329483-6 1984 Yohimbine (300 micrograms/kg, SC) reversed the antidipsogenic effect of centrally administered clonidine (32 micrograms/kg, IVT) on angiotensin II-induced (200 micrograms/kg, SC) water intake. Yohimbine 0-9 angiotensinogen Rattus norvegicus 132-146 6329497-6 1984 Yohimbine (2 mg/kg) increased the ED50 values of neurotensin and adrenergic agonists. Yohimbine 0-9 neurotensin Canis lupus familiaris 49-60 6141513-1 1984 In previous studies we have shown that the alpha 2 -adrenergic receptor agonist clonidine (CLON) releases growth hormone (GH) in conscious dogs, an effect abolished by the selective alpha 2-receptor antagonist yohimbine (YOH) and by reserpine, but not by the alpha 1-receptor antagonist prazosin (1). Yohimbine 210-219 somatotropin Canis lupus familiaris 106-120 6141513-1 1984 In previous studies we have shown that the alpha 2 -adrenergic receptor agonist clonidine (CLON) releases growth hormone (GH) in conscious dogs, an effect abolished by the selective alpha 2-receptor antagonist yohimbine (YOH) and by reserpine, but not by the alpha 1-receptor antagonist prazosin (1). Yohimbine 210-219 somatotropin Canis lupus familiaris 122-124 6141513-1 1984 In previous studies we have shown that the alpha 2 -adrenergic receptor agonist clonidine (CLON) releases growth hormone (GH) in conscious dogs, an effect abolished by the selective alpha 2-receptor antagonist yohimbine (YOH) and by reserpine, but not by the alpha 1-receptor antagonist prazosin (1). Yohimbine 221-224 somatotropin Canis lupus familiaris 106-120 6141513-1 1984 In previous studies we have shown that the alpha 2 -adrenergic receptor agonist clonidine (CLON) releases growth hormone (GH) in conscious dogs, an effect abolished by the selective alpha 2-receptor antagonist yohimbine (YOH) and by reserpine, but not by the alpha 1-receptor antagonist prazosin (1). Yohimbine 221-224 somatotropin Canis lupus familiaris 122-124 6141513-4 1984 In contrast, a 10-day-pretreatment with YOH greatly enhanced the GH-releasing effect of CLON (2 /micrograms/Kg iv). Yohimbine 40-43 somatotropin Canis lupus familiaris 65-67 6323192-1 1984 The preferential alpha 2-adrenergic antagonist yohimbine (4 mg/kg s.c.) caused a time-related increase in serum renin activity and heart rate in conscious Sprague-Dawley rats. Yohimbine 47-56 renin Rattus norvegicus 112-117 6323192-4 1984 Yohimbine (0.3, 1, 3 and 10 mg/kg s.c.) elicited a dose-related increase in serum renin activity and heart rate (30 min post-injection). Yohimbine 0-9 renin Rattus norvegicus 82-87 6323192-7 1984 The beta-adrenergic receptor antagonist propranolol (1.5 mg/kg s.c.), blocked the renin release and tachycardia caused by yohimbine (1 and 3 mg/kg s.c.), and the ganglionic blocking agent chlorisondamine partially inhibited the renin release elicited by 3 mg/kg (s.c.) of yohimbine. Yohimbine 122-131 renin Rattus norvegicus 82-87 6323192-9 1984 Thus, the increase in renin release caused by yohimbine appears to be mediated by the sympathetic nervous system. Yohimbine 46-55 renin Rattus norvegicus 22-27 6323192-10 1984 Because the smaller doses of yohimbine increase renin release in the absence of a decrease in mean arterial pressure, it is unlikely that yohimbine stimulates renin release by baroreflex-mediated activation of the renal sympathetic nerves. Yohimbine 29-38 renin Rattus norvegicus 48-53 6327329-1 1983 The inhibitory effect of dopamine on the action of MSH on the Anolis melanophore is blocked by the alpha 2-adrenoceptor antagonists, yohimbine and compound RX 781094, suggesting that the action of dopamine is mediated by alpha 2-adrenoceptors. Yohimbine 133-142 msh homeobox 2 Homo sapiens 51-54 6100312-10 1984 Pharmacological manipulations (yohimbine, haloperidol, ouabain) resulted in mono-amine metabolite fluctuations in CSF similar to those previously described in brain tissue. Yohimbine 31-40 colony stimulating factor 2 Rattus norvegicus 114-117 6139733-4 1983 Systemic administration of the alpha 2-adrenoceptor antagonists, yohimbine and piperoxane, to dark-adapted rats significantly stimulated TH activity. Yohimbine 65-74 tyrosine hydroxylase Rattus norvegicus 137-139 6139768-3 1983 Amitriptyline (10 mg/kg, twice daily) in combination with yohimbine (5 mg/kg, twice daily) decreased 5HT2 receptor binding after 4 days of treatment, whereas amitriptyline alone required 10 days to decrease the density of 5HT2 receptors. Yohimbine 58-67 5-hydroxytryptamine receptor 2A Homo sapiens 101-114 6854307-4 1983 Furthermore, it was found that the fever reactions induced by intrahypothalamic vasopressin was antagonized by pretreatment of animals with an intrahypothalamic dose of either yohimbine (an alpha-adrenergic receptor antagonist), propranolol (a beta-adrenergic receptor antagonist), or sodium acetylsalicylate (a prostaglandin synthetase inhibitor). Yohimbine 176-185 arginine vasopressin Rattus norvegicus 80-91 6304565-2 1983 The behavioural excitation caused by TRH was antagonized by pretreatment of the rats with either a narcotic receptor antagonist, naloxone, an alpha-adrenergic receptor antagonists, yohimbine, or a dopaminergic receptor antagonist, haloperidol, but not with a beta-adrenergic receptor antagonist, propranolol. Yohimbine 181-190 thyrotropin releasing hormone Rattus norvegicus 37-40 6299443-1 1983 1--Displacement of tritiated prazosin binding to rat liver plasma membranes and tritiated yohimbine human platelet membranes shows that (+)-yohimbine, alloyohimbine and alpha-yohimbine (rauwolscine) are selective alpha 2-adrenoceptor antagonists (KD alpha 1/KD alpha 2:635, 46.6 and 112 respectively) whereas corynanthine is more alpha 1-selective (KD alpha 1/KD alpha 2:0.036). Yohimbine 136-149 adrenoceptor alpha 1D Homo sapiens 250-257 6299443-1 1983 1--Displacement of tritiated prazosin binding to rat liver plasma membranes and tritiated yohimbine human platelet membranes shows that (+)-yohimbine, alloyohimbine and alpha-yohimbine (rauwolscine) are selective alpha 2-adrenoceptor antagonists (KD alpha 1/KD alpha 2:635, 46.6 and 112 respectively) whereas corynanthine is more alpha 1-selective (KD alpha 1/KD alpha 2:0.036). Yohimbine 136-149 adrenoceptor alpha 1D Homo sapiens 330-337 6299443-1 1983 1--Displacement of tritiated prazosin binding to rat liver plasma membranes and tritiated yohimbine human platelet membranes shows that (+)-yohimbine, alloyohimbine and alpha-yohimbine (rauwolscine) are selective alpha 2-adrenoceptor antagonists (KD alpha 1/KD alpha 2:635, 46.6 and 112 respectively) whereas corynanthine is more alpha 1-selective (KD alpha 1/KD alpha 2:0.036). Yohimbine 136-149 adrenoceptor alpha 1D Homo sapiens 330-337 6299443-3 1983 3--It is concluded that the aromatic A ring, the Nb atom, and the carboxymethyl moiety are important for the binding of yohimbine to the alpha-adrenoceptor, the carboxymethyl group being important for the alpha 1/alpha 2 specificity of the molecule. Yohimbine 120-129 adrenoceptor alpha 1D Homo sapiens 205-220 6824960-0 1983 Effects of yohimbine and tolazoline on isoproterenol and angiotensin II-induced water intake in rats. Yohimbine 11-20 angiotensinogen Rattus norvegicus 57-71 6294278-0 1983 Effect of yohimbine on rat prolactin secretion. Yohimbine 10-19 prolactin Rattus norvegicus 27-36 6294278-5 1983 Clonidine, an alpha-2 adrenergic agonist, produced a partial, non-dose-dependent inhibition of the YOH-induced rise in serum PRL levels. Yohimbine 99-102 prolactin Rattus norvegicus 125-128 6294278-6 1983 Two antagonists of the H1 histamine receptor, diphenhydramine and promethazine, markedly antagonized the PRL-releasing effect of YOH, but another H1 blocker, chlorpheniramine, and an H2 antagonist, metiamide, had no effect. Yohimbine 129-132 prolactin Rattus norvegicus 105-108 6294278-8 1983 Nevertheless, the PRL-releasing effect of YOH was potentiated 24 hr after the administration of reserpine or para-chlorophenylalanine, an inhibitor of serotonin synthesis. Yohimbine 42-45 prolactin Rattus norvegicus 18-21 6294278-9 1983 Thus, the mechanisms by which YOH stimulates rat PRL secretion has has not been fully elucidated. Yohimbine 30-33 prolactin Rattus norvegicus 49-52 6294278-10 1983 It is possible that YOH may stimulate PRL secretion by a novel mechanism, possibly through the intervention of a PRL-releasing factor. Yohimbine 20-23 prolactin Rattus norvegicus 38-41 6289135-5 1982 The calcium-dependent electrically evoked overflow of 3H-noradrenaline from slices of occipital cortex was inhibited by clonidine and enhanced by yohimbine in Quaking as well as in normal mice. Yohimbine 146-155 quaking, KH domain containing RNA binding Mus musculus 159-166 6294278-10 1983 It is possible that YOH may stimulate PRL secretion by a novel mechanism, possibly through the intervention of a PRL-releasing factor. Yohimbine 20-23 prolactin Rattus norvegicus 113-116 6420515-5 1983 Furthermore, the fever induced by intrahypothalamic administration of TRH was greatly reduced by pretreatment with intrahypothalamic administration of either yohimbine (a blocking agent of alpha-adrenergic receptors), phentolamine (a blocking agent of alpha-adrenergic receptors) or DL-propranolol (a blocking agent of beta-adrenergic receptors) in the rat. Yohimbine 158-167 thyrotropin releasing hormone Rattus norvegicus 70-73 6290242-0 1982 Radioenzymatic assay measurement of yohimbine"s influence on adrenergic neurotransmission of rat vas deferens: unique consequence of using normetanephrine as an uptake2-blocking agent. Yohimbine 36-45 arginine vasopressin Rattus norvegicus 97-100 6286924-0 1982 Influence of adrenocorticotropin hormone and yohimbine on antidepressant-induced declines in rat brain neurotransmitter receptor binding and function. Yohimbine 45-54 glutamate ionotropic receptor NMDA type subunit 1 Rattus norvegicus 103-128 6124632-2 1982 Prazosin, WB-4101 and corynanthine were found to be effective central alpha-1 adrenoceptor antagonists and piperoxane, yohimbine and rauwolscine were found to be effective central alpha-2 adrenoceptor antagonists. Yohimbine 22-34 adrenoceptor alpha 1D Homo sapiens 70-77 6124632-4 1982 However, piperoxane, yohimbine and rauwolscine in addition to their alpha-2 adrenoceptor actions, also displayed significant alpha-1 adrenoceptor antagonist properties. Yohimbine 21-30 adrenoceptor alpha 1D Homo sapiens 125-132 6124632-4 1982 However, piperoxane, yohimbine and rauwolscine in addition to their alpha-2 adrenoceptor actions, also displayed significant alpha-1 adrenoceptor antagonist properties. Yohimbine 35-46 adrenoceptor alpha 1D Homo sapiens 125-132 6289168-1 1982 The indolalkylamine alkaloid yohimbine induced two phenomenologically-different types of sodium current (INa) inhibition in the voltage-clamped frog node of Ranvier, a tonic and a phasic ("use-dependent") block. Yohimbine 29-38 internexin neuronal intermediate filament protein alpha Homo sapiens 105-108 6127872-3 1982 Prazosin, but not yohimbine, caused a significant increment in plasma glucose concentrations during the infusion of both prazosin and yohimbine, suggesting that the inhibitory effect of somatostatin is not mediated via a direct action on alpha 1- or alpha 2-adrenoceptors. Yohimbine 134-143 somatostatin Rattus norvegicus 186-198 6127872-5 1982 A marked increment in insulin release occurred in response to cessation of the somatostatin infusion, both during prazosin- and yohimbine-treatment. Yohimbine 128-137 somatostatin Rattus norvegicus 79-91 6289168-5 1982 Yohimbine blocked the outward INa much more strongly than the inward ones. Yohimbine 0-9 internexin neuronal intermediate filament protein alpha Homo sapiens 30-33 6289168-6 1982 Reduction of external Na+ ions concentration from 112 to 55 mM caused a shift in the voltage-department of yohimbine block to more negative voltages, which coincided with the shift of INa reversal potential. Yohimbine 107-116 internexin neuronal intermediate filament protein alpha Homo sapiens 184-187 6101988-4 1980 Stimulation of cyclic AMP formation by epinephrine in the C-2 area was antagonized by nanomolar concentrations of both phentolamine and yohimbine. Yohimbine 136-145 complement C2 Rattus norvegicus 58-61 6279501-0 1982 Antibodies to the alpha 1- and alpha 2-selective antagonists prazosin and yohimbine as probes of the alpha-adrenergic binding sites. Yohimbine 74-83 adrenoceptor alpha 1D Homo sapiens 18-38 6291085-10 1982 On the other hand, chronic treatment with yohimbine, which should cause denervation supersensitivity of alpha 2 receptors, led to enhanced GH responses to CLON. Yohimbine 42-51 gonadotropin releasing hormone receptor Rattus norvegicus 139-141 6106165-1 1980 We attempted to determine whether release of endogenous somatostatin (SS) in rats might mediate the apparent inhibition of growth hormone (GH) secretion produced by metergoline of yohimbine injection. Yohimbine 180-189 somatostatin Rattus norvegicus 56-68 6106165-1 1980 We attempted to determine whether release of endogenous somatostatin (SS) in rats might mediate the apparent inhibition of growth hormone (GH) secretion produced by metergoline of yohimbine injection. Yohimbine 180-189 somatostatin Rattus norvegicus 70-72 6106165-1 1980 We attempted to determine whether release of endogenous somatostatin (SS) in rats might mediate the apparent inhibition of growth hormone (GH) secretion produced by metergoline of yohimbine injection. Yohimbine 180-189 gonadotropin releasing hormone receptor Rattus norvegicus 123-137 6122611-6 1982 The relative order of the potency is phenoxybenzamine = dibenamine greater than phentolamine greater than yohimbine greater than prazosin greater than tolazoline, and the first four drugs in this series were selective inhibitors of calmodulin action. Yohimbine 106-115 calmodulin-1 Bos taurus 232-242 6257762-7 1981 Yohimbine (0.1 muM) greatly enhanced these actions whereas prazosin was without effect. Yohimbine 0-9 latexin Homo sapiens 15-18 33220278-9 2021 DEX inhibited LPS-induced TNFalpha, IL-6, and PGE2 productions and COX-2 mRNA expression, and the effects of DEX were reversed by yohimbine. Yohimbine 130-139 tumor necrosis factor Mus musculus 26-34 34027562-0 2021 CYP2D6 phenotype explains reported yohimbine concentrations in four severe acute intoxications. Yohimbine 35-44 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 0-6 34027562-1 2021 The indole alkaloid yohimbine is an alpha-2 receptor antagonist used for its sympathomimetic effects. Yohimbine 20-29 glycoprotein hormone subunit alpha 2 Homo sapiens 36-43 34027562-6 2021 We used recently reported knowledge on the metabolism of yohimbine together with state-of-the art nonlinear mixed-effects modelling and simulation and show that a patient"s cytochrome P450 2D6 (CYP2D6) phenotype can explain the large differences observed in the measured concentration after intake of the same yohimbine dose. Yohimbine 57-66 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 173-192 34027562-6 2021 We used recently reported knowledge on the metabolism of yohimbine together with state-of-the art nonlinear mixed-effects modelling and simulation and show that a patient"s cytochrome P450 2D6 (CYP2D6) phenotype can explain the large differences observed in the measured concentration after intake of the same yohimbine dose. Yohimbine 57-66 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 194-200 34027562-6 2021 We used recently reported knowledge on the metabolism of yohimbine together with state-of-the art nonlinear mixed-effects modelling and simulation and show that a patient"s cytochrome P450 2D6 (CYP2D6) phenotype can explain the large differences observed in the measured concentration after intake of the same yohimbine dose. Yohimbine 310-319 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 173-192 34027562-6 2021 We used recently reported knowledge on the metabolism of yohimbine together with state-of-the art nonlinear mixed-effects modelling and simulation and show that a patient"s cytochrome P450 2D6 (CYP2D6) phenotype can explain the large differences observed in the measured concentration after intake of the same yohimbine dose. Yohimbine 310-319 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 194-200 33860721-8 2021 Compared to the placebo condition hydrocortisone significantly increased salivary cortisol and yohimbine significantly increased sAA. Yohimbine 95-104 serum amyloid A1 cluster Homo sapiens 129-132 526075-1 1979 Pimozide (5--10 ng/ml), haloperidol (0.5--5 ng/ml) and yohimbine (2--5 ng/ml) selectively potentiated dopamine-induced and methoxamine-induced contractions of the rat vas deferens. Yohimbine 55-64 arginine vasopressin Rattus norvegicus 167-170 33220278-9 2021 DEX inhibited LPS-induced TNFalpha, IL-6, and PGE2 productions and COX-2 mRNA expression, and the effects of DEX were reversed by yohimbine. Yohimbine 130-139 interleukin 6 Mus musculus 36-40 33220278-9 2021 DEX inhibited LPS-induced TNFalpha, IL-6, and PGE2 productions and COX-2 mRNA expression, and the effects of DEX were reversed by yohimbine. Yohimbine 130-139 cytochrome c oxidase II, mitochondrial Mus musculus 67-72 33358539-7 2021 Skin conductance responses as well as explicit rating data revealed that yohimbine intake led to enhanced fear memory expression, i.e. an enhanced responding to the CS+ but not to stimuli resembling the CS+. Yohimbine 73-82 citrate synthase Homo sapiens 165-167 33489031-5 2020 Clonidine and yohimbine were injected intra-CA1. Yohimbine 14-23 carbonic anhydrase 1 Rattus norvegicus 44-47 32789555-0 2021 Yohimbine Ameliorates Temporomandibular Joint Chondrocyte Inflammation with Suppression of NF-kappaB Pathway. Yohimbine 0-9 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 91-100 32789555-6 2021 NE (10-6 M) triggered inflammatory cytokine secretion by TMJ chondrocytes, and Yohimbine suppressed IL-1beta- or NE-induced IL-6 upregulation in TMJ chondrocytes with the nuclear factor (NF)-kappaB pathway inhibition. Yohimbine 79-88 interleukin 1 alpha Mus musculus 100-108 32789555-6 2021 NE (10-6 M) triggered inflammatory cytokine secretion by TMJ chondrocytes, and Yohimbine suppressed IL-1beta- or NE-induced IL-6 upregulation in TMJ chondrocytes with the nuclear factor (NF)-kappaB pathway inhibition. Yohimbine 79-88 interleukin 6 Mus musculus 124-128 32789555-8 2021 Interestingly, alphampT, a tyrosine hydroxylase inhibitor, reversed the effects of Yohimbine by activating the NF-kappaB pathway. Yohimbine 83-92 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 111-120 32789555-9 2021 Collectively, these findings show that Yohimbine ameliorated TMJ chondrocyte inflammation and the suppression of NF-kappaB pathway contributes to this effect. Yohimbine 39-48 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 113-122 33179100-6 2021 Mice were pretreated with dexmedetomidine, either alone or together with yohimbine, an alpha2 adrenoceptor inhibitor, then exposed to 3% sevoflurane in 25% oxygen. Yohimbine 73-82 ST3 beta-galactoside alpha-2,3-sialyltransferase 5 Mus musculus 87-93 32583013-4 2020 OBJECTIVE: The present study aimed at assessing dose-dependent effects of yohimbine, an alpha-2 adrenoceptor antagonist, on working memory performance in healthy humans. Yohimbine 74-83 glycoprotein hormone subunit alpha 2 Homo sapiens 88-95 32060866-0 2020 Oral Yohimbine as a New Probe Drug to Predict CYP2D6 Activity: Results of a Fixed-Sequence Phase I Trial. Yohimbine 5-14 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 46-52 32246467-0 2020 TAAR 1 Agonists Attenuate Extended Access Cocaine Self-administration and Yohimbine-induced Reinstatement of Cocaine-seeking. Yohimbine 74-83 trace amine associated receptor 1 Homo sapiens 0-6 32246467-9 2020 Furthermore, RO5263397 and the selective TAAR1 full agonist RO5166017 reduced yohimbine-induced reinstatement of cocaine-seeking behavior. Yohimbine 78-87 trace amine associated receptor 1 Homo sapiens 41-46 32342432-7 2020 Dex preconditioning significantly increased expression of protein HO-1 and decreased expressions of proteins RIPK1 and RIPK3 induced by H2O2, while all these protective effects of Dex were reversed by YOH (all p < 0.05, Dex + H2O2 vs. H2O2; and YOH + Dex + H2O2 vs. Dex + H2O2). Yohimbine 201-204 heme oxygenase 1 Rattus norvegicus 66-70 33133459-9 2020 However, the antinociceptive effect of crocetin (5.00 mug muL-1) was inhibited by prior administration of famotidine (10.00 mug muL-1) and yohimbine (10.00 mug muL-1). Yohimbine 139-148 mitochondrial E3 ubiquitin protein ligase 1 Rattus norvegicus 58-63 32060866-7 2020 RESULTS: Pharmacokinetics of yohimbine were highly variable and a CYP2D6 genotype dependent clearance was observed. Yohimbine 29-38 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 66-72 32060866-11 2020 CONCLUSIONS: The pharmacokinetics of yohimbine were highly correlated with CYP2D6, which was further supported by the clearance inhibition caused by the CYP2D6 inhibitor paroxetine. Yohimbine 37-46 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 75-81 32060866-11 2020 CONCLUSIONS: The pharmacokinetics of yohimbine were highly correlated with CYP2D6, which was further supported by the clearance inhibition caused by the CYP2D6 inhibitor paroxetine. Yohimbine 37-46 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 153-159 32060866-12 2020 With these data, yohimbine is proposed to be a suitable probe drug to predict CYP2D6 activity. Yohimbine 17-26 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 78-84 32377745-4 2020 Dex and yohimbine hydrochloride (YOH), an alpha2-AR inhibitor, were administered before inducing CLP. Yohimbine 33-36 adenosine A2a receptor Mus musculus 42-51 32600363-7 2020 All participants receive a single dose of HCQ 400 mg. Additionally, CYP3A4 and CYP2D6 phenotyping with microdosed probe drugs is performed using midazolam and yohimbine as enzyme activity markers, respectively. Yohimbine 161-170 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 70-76 32600363-7 2020 All participants receive a single dose of HCQ 400 mg. Additionally, CYP3A4 and CYP2D6 phenotyping with microdosed probe drugs is performed using midazolam and yohimbine as enzyme activity markers, respectively. Yohimbine 161-170 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 81-87 32342432-7 2020 Dex preconditioning significantly increased expression of protein HO-1 and decreased expressions of proteins RIPK1 and RIPK3 induced by H2O2, while all these protective effects of Dex were reversed by YOH (all p < 0.05, Dex + H2O2 vs. H2O2; and YOH + Dex + H2O2 vs. Dex + H2O2). Yohimbine 201-204 receptor-interacting serine-threonine kinase 3 Rattus norvegicus 119-124 32321314-9 2021 Co-treatment of 100 microg/kg A2 with the alpha2 blocker yohimbine exhibited an increase of BF significantly. Yohimbine 57-66 UDP glucuronosyltransferase 1 family, polypeptide A7C Rattus norvegicus 30-32 32321314-9 2021 Co-treatment of 100 microg/kg A2 with the alpha2 blocker yohimbine exhibited an increase of BF significantly. Yohimbine 57-66 UDP glucuronosyltransferase 1 family, polypeptide A7C Rattus norvegicus 42-48 32321314-12 2021 Phosphorylation of aortic endothelial nitric oxide synthase (eNOS) increased with 10 microg/kg A2 alone or co-treatment with 100 microg/kg A2 and yohimbine, but not with co-treatment of 10 microg/kg A2 and carvedilol or 100 microg/kg A2 alone. Yohimbine 146-155 nitric oxide synthase 3 Rattus norvegicus 26-59 32321314-12 2021 Phosphorylation of aortic endothelial nitric oxide synthase (eNOS) increased with 10 microg/kg A2 alone or co-treatment with 100 microg/kg A2 and yohimbine, but not with co-treatment of 10 microg/kg A2 and carvedilol or 100 microg/kg A2 alone. Yohimbine 146-155 nitric oxide synthase 3 Rattus norvegicus 61-65 30923836-13 2019 Additionally, OXT administration produced a similar decrease in alcohol relapse-like behavior triggered by the pharmacological stressor yohimbine in both sexes. Yohimbine 136-145 oxytocin Mus musculus 14-17 31935395-10 2020 Moreover, yohimbine suppressed cytokine mRNA and iNOS expression enhanced by LPS. Yohimbine 10-19 nitric oxide synthase 2 Rattus norvegicus 49-53 31935395-11 2020 However, anti-inflammatory cytokine IL-10 mRNA levels were augmented by yohimbine. Yohimbine 72-81 interleukin 10 Rattus norvegicus 36-41 31935395-14 2020 In addition, phosphorylation of extracellular signal-regulated kinase (ERK) and cAMP response element binding protein (CREB) were enhanced with yohimbine. Yohimbine 144-153 Eph receptor B1 Rattus norvegicus 32-69 31935395-14 2020 In addition, phosphorylation of extracellular signal-regulated kinase (ERK) and cAMP response element binding protein (CREB) were enhanced with yohimbine. Yohimbine 144-153 Eph receptor B1 Rattus norvegicus 71-74 31935395-14 2020 In addition, phosphorylation of extracellular signal-regulated kinase (ERK) and cAMP response element binding protein (CREB) were enhanced with yohimbine. Yohimbine 144-153 cAMP responsive element binding protein 1 Rattus norvegicus 80-117 31935395-14 2020 In addition, phosphorylation of extracellular signal-regulated kinase (ERK) and cAMP response element binding protein (CREB) were enhanced with yohimbine. Yohimbine 144-153 cAMP responsive element binding protein 1 Rattus norvegicus 119-123 31935395-15 2020 These results suggest that yohimbine can prevent LPS-induced sepsis associated with kidney injury by suppressing inflammatory cytokine and iNOS expression as well as enhancing IL-10 expression via ERK/CREB phosphorylation. Yohimbine 27-36 nitric oxide synthase 2 Rattus norvegicus 139-143 31935395-15 2020 These results suggest that yohimbine can prevent LPS-induced sepsis associated with kidney injury by suppressing inflammatory cytokine and iNOS expression as well as enhancing IL-10 expression via ERK/CREB phosphorylation. Yohimbine 27-36 interleukin 10 Rattus norvegicus 176-181 31935395-15 2020 These results suggest that yohimbine can prevent LPS-induced sepsis associated with kidney injury by suppressing inflammatory cytokine and iNOS expression as well as enhancing IL-10 expression via ERK/CREB phosphorylation. Yohimbine 27-36 Eph receptor B1 Rattus norvegicus 197-200 31935395-15 2020 These results suggest that yohimbine can prevent LPS-induced sepsis associated with kidney injury by suppressing inflammatory cytokine and iNOS expression as well as enhancing IL-10 expression via ERK/CREB phosphorylation. Yohimbine 27-36 cAMP responsive element binding protein 1 Rattus norvegicus 201-205 31066114-8 2020 The number of Fos-protein positive nuclei was increased in the prefrontal cortex and extended amygdala after home-cage yohimbine compared to naive- and vehicle-treated rats. Yohimbine 119-128 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 14-17 31066114-9 2020 Yohimbine-induced reinstatement increased the number of Fos-protein expressing nuclei in multiple other regions including the thalamus, hypothalamus and hippocampus. Yohimbine 0-9 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 56-59 31066114-10 2020 We then examined inter-regional correlations in Fos-protein expression for all 42 brain regions, which showed Fos expression was more strongly positively correlated following yohimbine-induced reinstatement of alcohol seeking, compared to home-cage yohimbine. Yohimbine 175-184 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 48-51 31066114-10 2020 We then examined inter-regional correlations in Fos-protein expression for all 42 brain regions, which showed Fos expression was more strongly positively correlated following yohimbine-induced reinstatement of alcohol seeking, compared to home-cage yohimbine. Yohimbine 175-184 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 110-113 32741943-9 2020 Moreover, the positive effects of oxymetazoline were attenuated by yohimbine and BRL44408, which are selective alpha2- and alpha2A-adrenoceptor antagonists, respectively. Yohimbine 67-76 ST3 beta-galactoside alpha-2,3-sialyltransferase 5 Mus musculus 111-117 32741943-9 2020 Moreover, the positive effects of oxymetazoline were attenuated by yohimbine and BRL44408, which are selective alpha2- and alpha2A-adrenoceptor antagonists, respectively. Yohimbine 67-76 adrenergic receptor, alpha 2a Mus musculus 123-143 31847911-4 2019 METHODS: We first looked at the spatial distribution of the noradrenaline (NA)-synthesizing enzyme, DBH (dopamine beta-hydroxylase), in comparison with NA receptors-beta1, beta2, and beta3 adrenergic receptors (beta1-AR, beta2-AR, and beta3-AR)-after which we examined the effects of the beta-blocker propranolol and alpha-blockers prazosin and yohimbine on stress-induced microglial activation. Yohimbine 345-354 dopamine beta hydroxylase Mus musculus 100-103 31260683-8 2019 In addition, by adding inhibitors yohimbine and 2-methoxyestradiol (2ME2), we found that DEX could activate HIF-1alpha/p53 signaling pathway. Yohimbine 34-43 hypoxia inducible factor 1 subunit alpha Rattus norvegicus 108-118 31260683-8 2019 In addition, by adding inhibitors yohimbine and 2-methoxyestradiol (2ME2), we found that DEX could activate HIF-1alpha/p53 signaling pathway. Yohimbine 34-43 Wistar clone pR53P1 p53 pseudogene Rattus norvegicus 119-122 30414973-6 2019 In Experiment 3, we determined the potential role of KOR in the pro-impulsive effects of yohimbine (1.25 mg/kg) and nicotine (0.3 mg/kg) by the prior administration of the KOR antagonist nor-BNI (10 mg/kg). Yohimbine 89-98 opioid receptor kappa 1 Homo sapiens 53-56 31242442-7 2019 We hypothesized that P rats would show increased sensitivity to yohimbine-induced reinstatement that is also mediated by NK1R in the CeA. Yohimbine 64-73 tachykinin receptor 1 Rattus norvegicus 121-125 31242442-7 2019 We hypothesized that P rats would show increased sensitivity to yohimbine-induced reinstatement that is also mediated by NK1R in the CeA. Yohimbine 64-73 carcinoembryonic antigen gene family 4 Rattus norvegicus 133-136 31242442-8 2019 Using Fos staining, site-specific infusion of NK1R antagonist, and viral vector overexpression, we examined the influence of NK1R on the sensitivity to yohimbine-induced reinstatement of alcohol seeking. Yohimbine 152-161 tachykinin receptor 1 Rattus norvegicus 125-129 31242442-9 2019 We found that P rats displayed increased sensitivity to yohimbine-induced reinstatement as well as increased neuronal activation in the CeA after yohimbine injection compared to the control Wistar strain. Yohimbine 146-155 carcinoembryonic antigen gene family 4 Rattus norvegicus 136-139 31242442-10 2019 Intra-CeA infusion of NK1R antagonist attenuates yohimbine-induced reinstatement in P rats. Yohimbine 49-58 carcinoembryonic antigen gene family 4 Rattus norvegicus 6-9 31242442-10 2019 Intra-CeA infusion of NK1R antagonist attenuates yohimbine-induced reinstatement in P rats. Yohimbine 49-58 tachykinin receptor 1 Rattus norvegicus 22-26 31242442-11 2019 Conversely, upregulation of NK1R within the CeA of Wistar rats increases alcohol consumption and sensitivity to yohimbine-induced reinstatement. Yohimbine 112-121 tachykinin receptor 1 Rattus norvegicus 28-32 31242442-11 2019 Conversely, upregulation of NK1R within the CeA of Wistar rats increases alcohol consumption and sensitivity to yohimbine-induced reinstatement. Yohimbine 112-121 carcinoembryonic antigen gene family 4 Rattus norvegicus 44-47 31411489-1 2019 Aim: Pharmacokinetics after oral microdosing of the anticipated CYP2D6 substrate yohimbine and its metabolite 11-OH-yohimbine is potentially useful for drug-drug interaction trials and profiling of CYP2D6 enzyme activity. Yohimbine 81-90 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 64-70 31411489-1 2019 Aim: Pharmacokinetics after oral microdosing of the anticipated CYP2D6 substrate yohimbine and its metabolite 11-OH-yohimbine is potentially useful for drug-drug interaction trials and profiling of CYP2D6 enzyme activity. Yohimbine 81-90 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 198-204 31411489-5 2019 Conclusion: Ultrasensitive quantification of yohimbine and its metabolite enables the determination of their concentrations in plasma after microdosing which would be applicable to use in CYP2D6 phenotyping. Yohimbine 45-54 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 188-194 30266597-9 2019 Acute psychological (swim) and pharmacological (yohimbine) stress stimulated Fos-protein expression in PVN CRF neurons. Yohimbine 48-57 FBJ osteosarcoma oncogene Mus musculus 77-80 30930327-8 2019 The expression of phosphorylated ERK1/2 and phosphorylated CREB in the Dex group was increased, whereas the expression of phosphorylated ERK1/2 and phosphorylated CREB in the yohimbine + Dex group was lower than in the Dex group (P < 0.05). Yohimbine 175-184 mitogen activated protein kinase 3 Rattus norvegicus 137-143 30930327-8 2019 The expression of phosphorylated ERK1/2 and phosphorylated CREB in the Dex group was increased, whereas the expression of phosphorylated ERK1/2 and phosphorylated CREB in the yohimbine + Dex group was lower than in the Dex group (P < 0.05). Yohimbine 175-184 cAMP responsive element binding protein 1 Rattus norvegicus 163-167 30665845-2 2019 We previously revealed that pre-treatment with yohimbine or JP-1302 attenuated renal ischemia/reperfusion injury by inhibition of alpha2C-adrenoceptor antagonist. Yohimbine 47-56 adrenoceptor alpha 2C Rattus norvegicus 130-150 30414973-9 2019 Yohimbine-, but not nicotine-induced increases in premature responding were blocked by nor-BNI, suggesting that impulsivity induced by yohimbine is KOR dependent. Yohimbine 0-9 opioid receptor kappa 1 Homo sapiens 148-151 30414973-9 2019 Yohimbine-, but not nicotine-induced increases in premature responding were blocked by nor-BNI, suggesting that impulsivity induced by yohimbine is KOR dependent. Yohimbine 135-144 opioid receptor kappa 1 Homo sapiens 148-151 30414973-10 2019 This may suggests a potential role for KOR-mediated increases in impulsivity in yohimbine-induced reinstatement. Yohimbine 80-89 opioid receptor kappa 1 Homo sapiens 39-42 29668464-0 2018 Effects of alpha-(prazosin and yohimbine) and beta-receptors activity on cAMP generation and UCP1 gene expression in brown adipocytes. Yohimbine 31-40 uncoupling protein 1 Homo sapiens 93-97 30071571-7 2019 The data also shows that anti-immobility effect of BF (10 mg/kg) in the TST was reversed by prazosin, yohimbine, haloperidol, sulpiride, metagoline and PCPA but not with propranolol. Yohimbine 102-111 thiosulfate sulfurtransferase Homo sapiens 72-75 29637719-7 2018 A novel indole alkaloid, 11-hydroxycorynanthine, is isolated from N. benthamiana plants transiently expressing CYP2D6 and supplemented with corynanthine, and its structure was elucidated. Yohimbine 35-47 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 111-117 30322021-5 2018 Adolescent corticosterone (CORT) exposure increased alcohol, but not sucrose, self-administration, and enhanced stress-induced reinstatement with yohimbine in adulthood. Yohimbine 146-155 cortistatin Homo sapiens 27-31 30322021-8 2018 We found that intra-amygdala infusion of a peptidergic GRK2 inhibitor reduced alcohol seeking, as measured by progressive ratio and stress reinstatement tests, and induced by the alpha2AAR antagonist yohimbine. Yohimbine 200-209 G protein-coupled receptor kinase 2 Homo sapiens 55-59 30322021-8 2018 We found that intra-amygdala infusion of a peptidergic GRK2 inhibitor reduced alcohol seeking, as measured by progressive ratio and stress reinstatement tests, and induced by the alpha2AAR antagonist yohimbine. Yohimbine 200-209 adrenoceptor alpha 2A Homo sapiens 179-188 29700576-9 2018 However, rats overexpressing Crhr1 in the CeA increased responding in the stress-induced reinstatement task with yohimbine serving as a pharmacological stressor. Yohimbine 113-122 corticotropin releasing hormone receptor 1 Rattus norvegicus 29-34 29758386-4 2018 We found that escalated alcohol consumption induced by both yohimbine injection and intermittent access is attenuated by systemic administration of the NK1R antagonist L822429. Yohimbine 60-69 tachykinin receptor 1 Rattus norvegicus 152-156 29758386-7 2018 Taken together, these results suggest that NK1R upregulation contributes to escalated alcohol consumption that is induced by genetic selection, yohimbine injection, and intermittent access. Yohimbine 144-153 tachykinin receptor 1 Rattus norvegicus 43-47 30245586-6 2018 INa inhibition by dexmedetomidine was blocked by yohimbine, a competitive alpha2-adrenoceptor antagonist. Yohimbine 49-58 internexin neuronal intermediate filament protein alpha Homo sapiens 0-3 30059510-11 2018 In addition, combination treatment with 10-1 mg/kg A2 and yohimbine, an alpha2 adrenalin blocker, remarkably increased UCP-1 mRNA levels. Yohimbine 58-67 uncoupling protein 1 (mitochondrial, proton carrier) Mus musculus 119-124 29700576-9 2018 However, rats overexpressing Crhr1 in the CeA increased responding in the stress-induced reinstatement task with yohimbine serving as a pharmacological stressor. Yohimbine 113-122 carcinoembryonic antigen gene family 4 Rattus norvegicus 42-45 28441717-12 2017 Western blot analysis showed that the expression of nNOS, PKCgamma and PAR2 was significantly decreased in DEX group compared with Sham group, whereas these effects of DEX on nNOS, PKCgamma and PAR2 were blocked by both yohimbine and idazoxan, indicating that the analgesic effect of DEX is mediated by both alpha2 adrenergic receptor and imidazoline receptor. Yohimbine 220-229 nitric oxide synthase 1 Rattus norvegicus 52-56 29504865-0 2018 Novel effect of alpha-lactalbumin on the yohimbine-induced hot flush increase of the tail skin temperature in ovariectomized rats. Yohimbine 41-50 lactalbumin, alpha Rattus norvegicus 16-33 28795276-12 2017 Pretreatment of animals with DOM, BIC, KET and YOH inhibited TPM-induced neuroprotection and increased oxidative stress, neuroinflammation, neuroapoptosis and neurodegeneration while reducing CREB, BDNF and Akt protein expressions. Yohimbine 47-50 cAMP responsive element binding protein 1 Rattus norvegicus 192-196 28795276-12 2017 Pretreatment of animals with DOM, BIC, KET and YOH inhibited TPM-induced neuroprotection and increased oxidative stress, neuroinflammation, neuroapoptosis and neurodegeneration while reducing CREB, BDNF and Akt protein expressions. Yohimbine 47-50 brain-derived neurotrophic factor Rattus norvegicus 198-202 28795276-12 2017 Pretreatment of animals with DOM, BIC, KET and YOH inhibited TPM-induced neuroprotection and increased oxidative stress, neuroinflammation, neuroapoptosis and neurodegeneration while reducing CREB, BDNF and Akt protein expressions. Yohimbine 47-50 AKT serine/threonine kinase 1 Rattus norvegicus 207-210 28623711-6 2017 The antinociceptive effect of PSAP (1mg/kg) was abolished when the animals were pre-treated with prazosin (alpha1-adrenergic antagonist receptor, 0.15mg/kg, intraperitoneally, ip), yohimbine (alpha2-adrenergic antagonist receptor, 1mg/kg, ip) and sulpiride (D2/D3 dopamine antagonist, 5mg/kg, ip). Yohimbine 181-190 prosaposin Mus musculus 30-34 29725523-8 2018 Furthermore, the reductions in these mRNAs by 10 microM guanabenz and 20 microM clonidine in the presence of RANKL were attenuated by 20 microM yohimbine or idazoxan (P<0.05). Yohimbine 144-153 tumor necrosis factor (ligand) superfamily, member 11 Mus musculus 109-114 28726252-7 2017 Furthermore, we assessed CeA neuronal activation following yohimbine-induced reinstatement of alcohol seeking and the role of the relaxin-3/RXFP3 signalling within the CeA in yohimbine-induced reinstatement to alcohol seeking. Yohimbine 175-184 relaxin 3 Rattus norvegicus 130-139 28726252-7 2017 Furthermore, we assessed CeA neuronal activation following yohimbine-induced reinstatement of alcohol seeking and the role of the relaxin-3/RXFP3 signalling within the CeA in yohimbine-induced reinstatement to alcohol seeking. Yohimbine 175-184 relaxin family peptide receptor 3 Rattus norvegicus 140-145 28726252-7 2017 Furthermore, we assessed CeA neuronal activation following yohimbine-induced reinstatement of alcohol seeking and the role of the relaxin-3/RXFP3 signalling within the CeA in yohimbine-induced reinstatement to alcohol seeking. Yohimbine 175-184 carcinoembryonic antigen gene family 4 Rattus norvegicus 168-171 28726252-9 2017 Furthermore, yohimbine-induced reinstatement of alcohol seeking increased Fos activation in CeA corticotrophin-releasing factor, dynorphin and GABA neurons compared with naive and vehicle controls. Yohimbine 13-22 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 74-77 28726252-9 2017 Furthermore, yohimbine-induced reinstatement of alcohol seeking increased Fos activation in CeA corticotrophin-releasing factor, dynorphin and GABA neurons compared with naive and vehicle controls. Yohimbine 13-22 carcinoembryonic antigen gene family 4 Rattus norvegicus 92-95 28726252-10 2017 Bilateral intra-CeA injections of the selective RXFP3 antagonist, R3(B1-22)R, attenuated yohimbine-induced reinstatement of alcohol seeking. Yohimbine 89-98 carcinoembryonic antigen gene family 4 Rattus norvegicus 16-19 28726252-10 2017 Bilateral intra-CeA injections of the selective RXFP3 antagonist, R3(B1-22)R, attenuated yohimbine-induced reinstatement of alcohol seeking. Yohimbine 89-98 relaxin family peptide receptor 3 Rattus norvegicus 48-53 28726252-11 2017 CONCLUSIONS: Collectively, these data suggest that the CeA is a node where yohimbine acts to induce reinstatement of alcohol seeking and implicate the relaxin-3/RXFP3 system within the CeA in this process. Yohimbine 75-84 carcinoembryonic antigen gene family 4 Rattus norvegicus 55-58 28726252-11 2017 CONCLUSIONS: Collectively, these data suggest that the CeA is a node where yohimbine acts to induce reinstatement of alcohol seeking and implicate the relaxin-3/RXFP3 system within the CeA in this process. Yohimbine 75-84 relaxin 3 Rattus norvegicus 151-160 28082019-11 2017 Pretreatment of animals with DOM, BIC, KET and YOH inhibited TPM-induced neuroprotection and increased oxidative stress, neuroinflammation, neuroapoptosis and neurodegeneration while reducing BDNF expressions. Yohimbine 47-50 brain-derived neurotrophic factor Rattus norvegicus 192-196 28441717-12 2017 Western blot analysis showed that the expression of nNOS, PKCgamma and PAR2 was significantly decreased in DEX group compared with Sham group, whereas these effects of DEX on nNOS, PKCgamma and PAR2 were blocked by both yohimbine and idazoxan, indicating that the analgesic effect of DEX is mediated by both alpha2 adrenergic receptor and imidazoline receptor. Yohimbine 220-229 nitric oxide synthase 1 Rattus norvegicus 175-179 28441717-12 2017 Western blot analysis showed that the expression of nNOS, PKCgamma and PAR2 was significantly decreased in DEX group compared with Sham group, whereas these effects of DEX on nNOS, PKCgamma and PAR2 were blocked by both yohimbine and idazoxan, indicating that the analgesic effect of DEX is mediated by both alpha2 adrenergic receptor and imidazoline receptor. Yohimbine 220-229 protein kinase C, gamma Rattus norvegicus 181-189 28441717-12 2017 Western blot analysis showed that the expression of nNOS, PKCgamma and PAR2 was significantly decreased in DEX group compared with Sham group, whereas these effects of DEX on nNOS, PKCgamma and PAR2 were blocked by both yohimbine and idazoxan, indicating that the analgesic effect of DEX is mediated by both alpha2 adrenergic receptor and imidazoline receptor. Yohimbine 220-229 F2R like trypsin receptor 1 Rattus norvegicus 194-198 28260990-7 2017 The effect of rauwolscine on the dexmedetomidine-mediated change in phenylephrine-induced endothelial nitric oxide synthase (eNOS) phosphorylation in human umbilical vein endothelial cells was examined using western blotting. Yohimbine 14-25 nitric oxide synthase 3 Homo sapiens 90-123 28237805-9 2017 By contrast, chronic alpha2-adrenergic receptor blockade with the antagonist yohimbine reduced PSA-NCAM and DCX positive cells in the piriform cortex of adult rats. Yohimbine 77-86 doublecortin Rattus norvegicus 108-111 28239660-4 2017 Remarkably, yohimbine also restored the obstructive apnea-induced long-term facilitation of hypoglossal motoneuron activity (hLTF), a much-neglected form of noradrenergic-dependent neuroplasticity that could provide a second-line motor defense against OSA but was also depressed during REM sleep. Yohimbine 12-21 lactotransferrin Homo sapiens 125-129 28239660-5 2017 Corroborating immunohistologic, optogenetic, and pharmacologic evidence confirmed that yohimbine"s beneficial effects on baseline hypoglossal motoneuron activity and hLTF were mediated mainly through activation of pontine A7 and A5 noradrenergic neurons. Yohimbine 87-96 lactotransferrin Homo sapiens 166-170 27739173-8 2017 Pretreatment of animals by ketamine, topiramate, and yohimbine inhibited the MPH-induced oxidative stress and inflammation; it significantly decreased lipid peroxidation, GSSG level, IL-1beta and TNF-alpha levels and increased GSH content, SOD, GPx, and GR activities in hippocampus and cerebral cortex of acutely MPH-treated rats. Yohimbine 53-62 interleukin 1 beta Rattus norvegicus 183-191 27739173-8 2017 Pretreatment of animals by ketamine, topiramate, and yohimbine inhibited the MPH-induced oxidative stress and inflammation; it significantly decreased lipid peroxidation, GSSG level, IL-1beta and TNF-alpha levels and increased GSH content, SOD, GPx, and GR activities in hippocampus and cerebral cortex of acutely MPH-treated rats. Yohimbine 53-62 tumor necrosis factor Rattus norvegicus 196-205 27739173-8 2017 Pretreatment of animals by ketamine, topiramate, and yohimbine inhibited the MPH-induced oxidative stress and inflammation; it significantly decreased lipid peroxidation, GSSG level, IL-1beta and TNF-alpha levels and increased GSH content, SOD, GPx, and GR activities in hippocampus and cerebral cortex of acutely MPH-treated rats. Yohimbine 53-62 glutathione-disulfide reductase Rattus norvegicus 254-256 27028940-9 2017 Also, YCL showed effective anti-inflammatory activity as it significantly decreased the expression of COX-2, TNF-alpha, and NF-kB. Yohimbine 6-9 cytochrome c oxidase II, mitochondrial Rattus norvegicus 102-107 27028940-9 2017 Also, YCL showed effective anti-inflammatory activity as it significantly decreased the expression of COX-2, TNF-alpha, and NF-kB. Yohimbine 6-9 tumor necrosis factor Rattus norvegicus 109-118 27028940-9 2017 Also, YCL showed effective anti-inflammatory activity as it significantly decreased the expression of COX-2, TNF-alpha, and NF-kB. Yohimbine 6-9 nuclear factor kappa B subunit 1 Rattus norvegicus 124-129 27028940-10 2017 The therapeutic effect of YCL against RA was also evident from lower arthritis scoring and reduced hematological parameter (ESR, WBC, and C-reactive protein level). Yohimbine 26-29 C-reactive protein Rattus norvegicus 138-156 27845775-9 2016 This effect was associated with decreased hemodynamic brain activity in the CRFBP-downregulated CeA and increased hemodynamic activity in the caudate putamen during yohimbine administration. Yohimbine 165-174 corticotropin releasing hormone binding protein Homo sapiens 76-81 27714428-10 2017 Activation of PPARgamma by pioglitazone also abolishes yohimbine-induced reinstatement of heroin seeking and reduces heroin-induced reinstatement, while it does not affect cue-induced relapse. Yohimbine 55-64 peroxisome proliferator-activated receptor gamma Rattus norvegicus 14-23 27845775-9 2016 This effect was associated with decreased hemodynamic brain activity in the CRFBP-downregulated CeA and increased hemodynamic activity in the caudate putamen during yohimbine administration. Yohimbine 165-174 CEA cell adhesion molecule 3 Homo sapiens 96-99 26608656-10 2016 Yohimbine, an alpha2-adrenergic receptor antagonist, upregulated plasma NE and NGF expression by activating the protein translation and degradation pathways in naive rats. Yohimbine 0-9 nerve growth factor Rattus norvegicus 79-82 27395787-8 2016 Bilateral NI injections of TCS-OX2-29 attenuated yohimbine-induced reinstatement of alcohol seeking. Yohimbine 49-58 CD200 antigen Mus musculus 31-34 27395787-11 2016 These data suggest an excitatory orexinergic input to NI contributes to yohimbine-induced reinstatement of alcohol seeking, predominantly via OX2 receptor signalling. Yohimbine 72-81 CD200 receptor 1 Rattus norvegicus 142-154 27316790-1 2016 A large body of evidence has shown that the Corticotropin Releasing Factor (CRF) system, which plays a key role in stress modulation, is deeply involved in relapse to alcohol seeking induced by exposure to stressful events such as foot shock or yohimbine injections. Yohimbine 245-254 corticotropin releasing hormone Rattus norvegicus 44-74 27291858-2 2016 Based on the available evidence, the aim of our study was to investigate consequences of the activation and deactivation of CA1 alpha2 adrenergic receptors (by clonidine and yohimbine, respectively) on the impairment of memory retention induced by total sleep deprivation (TSD) and the reversal of circadian rhythm (RCR) in a rat model. Yohimbine 174-183 carbonic anhydrase 1 Rattus norvegicus 124-127 27291858-5 2016 The post-training intra-CA1 administration of yohimbine (alpha2 adrenergic receptor antagonist) on its own, at the dose of 0.1mug/rat, decreased the step-through latency and locomotor activity in the TSD- sham treated but not undisturbed sleep rats. Yohimbine 46-55 carbonic anhydrase 1 Rattus norvegicus 24-27 27376152-7 2016 As compared with overexpression of a wild-type ADRA2A construct in human embryonic kidney-293 cells and differentiated 3T3-L1 adipocytes, the mutant ADRA2A produced more cAMP and glycerol, which were resistant to the effects of the alpha2-adrenergic receptor agonist clonidine and the alpha2-adrenergic receptor antagonist yohimbine, suggesting loss of function. Yohimbine 323-332 adrenoceptor alpha 2A Homo sapiens 149-155 27082997-0 2016 Berberine in combination with yohimbine attenuates sepsis-induced neutrophil tissue infiltration and multiorgan dysfunction partly via IL-10-mediated inhibition of CCR2 expression in neutrophils. Yohimbine 30-39 interleukin 10 Mus musculus 135-140 27082997-0 2016 Berberine in combination with yohimbine attenuates sepsis-induced neutrophil tissue infiltration and multiorgan dysfunction partly via IL-10-mediated inhibition of CCR2 expression in neutrophils. Yohimbine 30-39 chemokine (C-C motif) receptor 2 Mus musculus 164-168 27706026-7 2016 Rauwolscine, Y-27632, chelerythrine, and ML-7 hydrochloride attenuated the dexmedetomidine-induced phosphorylation of CPI-17 and MLC20. Yohimbine 0-11 protein phosphatase 1, regulatory (inhibitor) subunit 14A Rattus norvegicus 118-124 27706026-7 2016 Rauwolscine, Y-27632, chelerythrine, and ML-7 hydrochloride attenuated the dexmedetomidine-induced phosphorylation of CPI-17 and MLC20. Yohimbine 0-11 myosin light chain 12B Rattus norvegicus 129-134 27020784-5 2016 In experiment 2, we determined potential central sites of action by analyzing effects of prazosin (1 mg/kg) on yohimbine (1.25 mg/kg)-induced Fos expression. Yohimbine 111-120 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 142-145 27020784-8 2016 Systemic prazosin reduced yohimbine-induced Fos expression in the prefrontal cortex, accumbens shell, ventral bed nucleus of the stria terminalis, and basolateral amygdala (46-67 % decreases). Yohimbine 26-35 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 44-47 26275374-6 2015 NK1 receptor antagonism also attenuated yohimbine-induced reinstatement of alcohol seeking at all doses tested but had no effect on cue-induced reinstatement of alcohol seeking. Yohimbine 40-49 tachykinin receptor 1 Rattus norvegicus 0-12 26435028-10 2015 Dexmedetomidine suppressed cAMP formation and enhanced P-selectin expression in platelets, and these effects were inhibited by yohimbine. Yohimbine 127-136 selectin P Homo sapiens 55-65 25818186-7 2015 Rauwolscine (Rau; 10, 15, 20 mug), a selective alpha2C-adrenoreceptor, was able to block the peripheral antinociception induced by NSAIDs. Yohimbine 0-11 adrenoceptor alpha 2C Rattus norvegicus 47-69 26366943-0 2015 Yohimbine is a 5-HT1A agonist in rats in doses exceeding 1 mg/kg. Yohimbine 0-9 5-hydroxytryptamine receptor 1A Rattus norvegicus 15-21 26366943-4 2015 In this report we characterized dose-dependent autonomic and behavioral effects of yohimbine and its interaction with an antagonist of 5-HT1A receptors, WAY 100,635. Yohimbine 83-92 5-hydroxytryptamine receptor 1A Rattus norvegicus 135-141 26366943-9 2015 Our data confirm that yohimbine possesses 5-HT1A properties, and demonstrated that in doses above 1mg/kg significantly activate these receptors. Yohimbine 22-31 5-hydroxytryptamine receptor 1A Rattus norvegicus 42-48 25818186-7 2015 Rauwolscine (Rau; 10, 15, 20 mug), a selective alpha2C-adrenoreceptor, was able to block the peripheral antinociception induced by NSAIDs. Yohimbine 0-3 adrenoceptor alpha 2C Rattus norvegicus 47-69 26046083-3 2015 Second they showed that blocking alpha2AAR with yohimbine dose-dependently improves the reduced insulin secretion during an oral glucose tolerance test in patients with the risk variant. Yohimbine 48-57 adrenoceptor alpha 2A Homo sapiens 33-42 25761941-8 2015 The alpha2-AR antagonist yohimbine or alpha2A-AR antagonist BRL44408 but not alpha2B-AR antagonist imiloxan blocked the inhibition of Nav1.8 currents by DEX. Yohimbine 25-34 sodium voltage-gated channel alpha subunit 10 Rattus norvegicus 134-140 25572945-11 2015 Yohimbine abolished these effects of GDNF. Yohimbine 0-9 glial cell derived neurotrophic factor Rattus norvegicus 37-41 25757803-5 2015 Conversely, the alpha2-antagonist yohimbine produces a greater increase in blood pressure in MSA compared to PAF, although significant overlap exists. Yohimbine 34-43 glycoprotein hormone subunit alpha 2 Homo sapiens 16-22 25560581-7 2015 RESULTS: VFX potentiated antinociceptive action of MRF after acute administration of VFX and this effect was decreased by pretreatment of NLX, YOH and PCA. Yohimbine 143-146 myelin regulatory factor Rattus norvegicus 51-54 25561369-6 2015 The effect of A on CD11b was antagonized by yohimbine and propranolol, and increased by prazosin. Yohimbine 44-53 integrin subunit alpha M Homo sapiens 19-24 25560581-8 2015 On the contrary, VFX administered for 21 days prior to MRF significantly decreased the analgesic action of MRF; this effect was augmented only after YOH pretreatment. Yohimbine 149-152 myelin regulatory factor Rattus norvegicus 107-110 25928910-11 2015 The tritium overflow was lower in the explants exposed to the 5 muM NPY and 1 muM rauwolscine than to rauwolscine only. Yohimbine 102-113 neuropeptide Y Sus scrofa 68-71 25298321-4 2014 A total of 50 type 2 diabetes patients were recruited on the basis of ADRA2A genotype for a randomized placebo-controlled intervention study with the alpha(2A)AR antagonist yohimbine. Yohimbine 173-182 adrenoceptor alpha 2A Homo sapiens 150-161 25080599-9 2014 After yohimbine plus cue reinstatement, the actions of CRF-R2 on GABA and glutamate release were reversed. Yohimbine 6-15 corticotropin releasing hormone receptor 2 Rattus norvegicus 55-61 24682087-8 2014 Furthermore, prazosin and yohimbine protected against restraint-induced hepatocytes apoptosis through attenuating the activation of caspases-9 and -3 and reducing the Bax/Bcl-2 ratio. Yohimbine 26-35 caspase 9 Mus musculus 132-149 24173499-4 2014 Here, we explored the effect of the NK1R antagonist L822429 on yohimbine-induced reinstatement of alcohol or cocaine seeking in Long-Evans rats. Yohimbine 63-72 tachykinin receptor 1 Rattus norvegicus 36-40 24682087-8 2014 Furthermore, prazosin and yohimbine protected against restraint-induced hepatocytes apoptosis through attenuating the activation of caspases-9 and -3 and reducing the Bax/Bcl-2 ratio. Yohimbine 26-35 BCL2-associated X protein Mus musculus 167-170 24682087-8 2014 Furthermore, prazosin and yohimbine protected against restraint-induced hepatocytes apoptosis through attenuating the activation of caspases-9 and -3 and reducing the Bax/Bcl-2 ratio. Yohimbine 26-35 B cell leukemia/lymphoma 2 Mus musculus 171-176 23736277-6 2013 Pretreatment with the corticotrophin-releasing factor type-1 receptor (CRF1R) antagonist CP154,526 produced a region-dependent inhibition of yohimbine-induced activation in the amygdala, striatum, and cingulate cortex, while the orexin type-1 receptor (OX1R) antagonists GSK1059865 robustly inhibited the response in fronto-hippocampal regions as well as in several key components of the extended amygdala. Yohimbine 141-150 hypocretin receptor 1 Rattus norvegicus 229-251 24107430-9 2014 Antidiuresis of either atipamezole or yohimbine was not related to the area under the curve for AVP level, although the highest dose of both atipamezole and yohimbine initially and temporarily increased plasma AVP levels, suggesting that this may partly influence the antidiuretic effects of both agents. Yohimbine 157-166 arginine vasopressin Felis catus 210-213 24361988-10 2014 This effect depends on beta2 adrenoceptors but not on alpha2 adrenoceptors, as shown by the blockade with repeated co-administration of the beta2 adrenoceptor antagonist ICI118551 but not with repeated co-administration of the alpha2 adrenoceptor antagonist yohimbine. Yohimbine 258-267 adrenergic receptor, beta 2 Mus musculus 23-41 23736277-6 2013 Pretreatment with the corticotrophin-releasing factor type-1 receptor (CRF1R) antagonist CP154,526 produced a region-dependent inhibition of yohimbine-induced activation in the amygdala, striatum, and cingulate cortex, while the orexin type-1 receptor (OX1R) antagonists GSK1059865 robustly inhibited the response in fronto-hippocampal regions as well as in several key components of the extended amygdala. Yohimbine 141-150 hypocretin receptor 1 Rattus norvegicus 253-257 23691077-6 2013 Reserpine that exhausted cardiac NE without markedly decreasing plasma NE level abrogated the inhibitory effects of YHB on cardiac TNF-alpha and iNOS expression as well as cardiac dysfunction, but not the suppressive effects of YHB on plasma TNF-alpha and NO elevation in LPS-challenged mice. Yohimbine 116-119 tumor necrosis factor Mus musculus 131-140 23707289-9 2013 Yohimbine reversibly unmasked contralateral hindlimb allodynia and hyperalgesia of all modalities and increased dorsal horn c-fos expression to an innocuous brush stimulus. Yohimbine 0-9 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 124-129 23747494-5 2013 RESULTS: The anti-immobility effect elicited by AE in the TST was prevented by the pre-treatment of mice with the antagonists, NAN-190 (5-HT(1A) receptor), ketanserin (5-HT(2A/2C) receptor), prazosin (alpha1-adrenoceptor), yohimbine (alpha2-adrenoceptor), SCH23390 (dopamine D1 receptor), or sulpiride (dopamine D2 receptor). Yohimbine 223-232 thiosulfate sulfurtransferase, mitochondrial Mus musculus 58-61 23770668-5 2013 The agonist-induced translocation of AGS3 was reversed by the alpha2-AR antagonist rauwolscine. Yohimbine 83-94 G protein signaling modulator 1 Homo sapiens 37-41 23603244-6 2013 Pre-test intra-CA1 administration of the alpha2-adrenoceptor antagonist yohimbine (1 and 2 mug/mouse) improved memory retention, although the low dose of the drug (0.5 mug/mouse) did not affect memory retention. Yohimbine 72-81 carbonic anhydrase 1 Mus musculus 15-18 23603244-8 2013 Pre-test intra-CA1 administration of certain doses of yohimbine (0.25 and 0.5 mug/mouse), doses which were ineffective when given alone, improved pre-training muscimol (0.1 mug/mouse)-induced retrieval impairment. Yohimbine 54-63 carbonic anhydrase 1 Mus musculus 15-18 23691077-0 2013 Yohimbine promotes cardiac NE release and prevents LPS-induced cardiac dysfunction via blockade of presynaptic alpha2A-adrenergic receptor. Yohimbine 0-9 toll-like receptor 4 Mus musculus 51-54 23691077-6 2013 Reserpine that exhausted cardiac NE without markedly decreasing plasma NE level abrogated the inhibitory effects of YHB on cardiac TNF-alpha and iNOS expression as well as cardiac dysfunction, but not the suppressive effects of YHB on plasma TNF-alpha and NO elevation in LPS-challenged mice. Yohimbine 116-119 nitric oxide synthase 2, inducible Mus musculus 145-149 23691077-0 2013 Yohimbine promotes cardiac NE release and prevents LPS-induced cardiac dysfunction via blockade of presynaptic alpha2A-adrenergic receptor. Yohimbine 0-9 adrenergic receptor, alpha 2a Mus musculus 111-138 23691077-7 2013 Furthermore, both reserpine and YHB significantly inhibited LPS-induced myocardial apoptosis. Yohimbine 32-35 toll-like receptor 4 Mus musculus 60-63 23691077-2 2013 We have recently demonstrated that alpha2-adrenoceptor (AR) antagonist, yohimbine (YHB), attenuates lipopolysaccharide (LPS)-induced myocardial depression. Yohimbine 72-81 toll-like receptor 4 Mus musculus 120-123 23691077-2 2013 We have recently demonstrated that alpha2-adrenoceptor (AR) antagonist, yohimbine (YHB), attenuates lipopolysaccharide (LPS)-induced myocardial depression. Yohimbine 83-86 toll-like receptor 4 Mus musculus 120-123 23691077-4 2013 Here, we demonstrated that YHB decreased nitric oxide (NO) and tumor necrosis factor-alpha (TNF-alpha) levels in the myocardium and plasma, attenuated cardiac and hepatic dysfunction, but not kidney and lung injuries in endotoxemic mice. Yohimbine 27-30 tumor necrosis factor Mus musculus 63-90 23691077-8 2013 alpha1-AR, beta2-AR, but not beta1-AR antagonists reversed the inhibitory effect of YHB on LPS-stimulated myocardial apoptosis. Yohimbine 84-87 toll-like receptor 4 Mus musculus 91-94 23691077-4 2013 Here, we demonstrated that YHB decreased nitric oxide (NO) and tumor necrosis factor-alpha (TNF-alpha) levels in the myocardium and plasma, attenuated cardiac and hepatic dysfunction, but not kidney and lung injuries in endotoxemic mice. Yohimbine 27-30 tumor necrosis factor Mus musculus 92-101 23691077-5 2013 Immunohistochemical analysis revealed that cardiac alpha2A-AR was mostly located in sympathetic nerve presynaptic membrane; YHB decreased cardiac alpha2A-AR level and promoted cardiac norepinephrine (NE) release in endotoxemic mice. Yohimbine 124-127 adrenergic receptor, alpha 2a Mus musculus 51-61 23691077-5 2013 Immunohistochemical analysis revealed that cardiac alpha2A-AR was mostly located in sympathetic nerve presynaptic membrane; YHB decreased cardiac alpha2A-AR level and promoted cardiac norepinephrine (NE) release in endotoxemic mice. Yohimbine 124-127 adrenergic receptor, alpha 2a Mus musculus 146-156 23691077-9 2013 However, beta1-AR antagonist attenuated LPS-caused cardiomyocyte apoptosis, partly abolished the protective effect of YHB on the left ventricular ejection fraction in endotoxemic mice. Yohimbine 118-121 adrenergic receptor, beta 1 Mus musculus 9-17 23691077-10 2013 Altogether, these findings indicate that YHB attenuates LPS-induced cardiac dysfunction, at least in part, through blocking presynaptic alpha2A-AR and thus increasing cardiac NE release. Yohimbine 41-44 toll-like receptor 4 Mus musculus 56-59 23691077-10 2013 Altogether, these findings indicate that YHB attenuates LPS-induced cardiac dysfunction, at least in part, through blocking presynaptic alpha2A-AR and thus increasing cardiac NE release. Yohimbine 41-44 adrenergic receptor, alpha 2a Mus musculus 136-146 23691077-11 2013 YHB-elevated cardiac NE improves cardiac function via suppressing cardiac iNOS and TNF-alpha expression, activating beta1-AR and inhibiting cardiomyocyte apoptosis through alpha1- and beta2-AR in endotoxemic mice. Yohimbine 0-3 nitric oxide synthase 2, inducible Mus musculus 74-78 23691077-11 2013 YHB-elevated cardiac NE improves cardiac function via suppressing cardiac iNOS and TNF-alpha expression, activating beta1-AR and inhibiting cardiomyocyte apoptosis through alpha1- and beta2-AR in endotoxemic mice. Yohimbine 0-3 tumor necrosis factor Mus musculus 83-92 23691077-11 2013 YHB-elevated cardiac NE improves cardiac function via suppressing cardiac iNOS and TNF-alpha expression, activating beta1-AR and inhibiting cardiomyocyte apoptosis through alpha1- and beta2-AR in endotoxemic mice. Yohimbine 0-3 adrenergic receptor, beta 1 Mus musculus 116-124 23691077-11 2013 YHB-elevated cardiac NE improves cardiac function via suppressing cardiac iNOS and TNF-alpha expression, activating beta1-AR and inhibiting cardiomyocyte apoptosis through alpha1- and beta2-AR in endotoxemic mice. Yohimbine 0-3 adrenergic receptor, beta 2 Mus musculus 172-192 21967606-0 2013 Role of corticotropin-releasing factor in the median raphe nucleus in yohimbine-induced reinstatement of alcohol seeking in rats. Yohimbine 70-79 corticotropin releasing hormone Rattus norvegicus 8-38 23348107-9 2013 Phenoxybenzamine, yohimbine, propranolol, methysergide, cyproheptadine, atropine, bicuculline and nitro-l-arginine prevented the action of kisspeptin-13 on passive avoidance learning, but haloperidol and naloxone did not block the effects of kisspeptin-13. Yohimbine 18-27 KiSS-1 metastasis-suppressor Mus musculus 139-149 23283335-9 2013 Dorsal mPFC light delivery attenuated yohimbine-induced Fos immunoreactivity and disrupted neural activity during in vivo electrophysiological recording in awake rats. Yohimbine 38-47 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 56-59 23302980-8 2013 Antinociception induced by anandamide or PEA was antagonized by the nonselective alpha2 adrenoceptor antagonist yohimbine, 05 microg/paw, 10 microg/paw, and 20 microg/paw, and by the selective alpha2C adrenoceptor antagonist rauwolscine, 10 microg/paw, 15 microg/paw, and 20 microg/paw, but not by the selective antagonists for alpha2A, alpha2B, and alpha2D adrenoceptor subtypes, 20 mug/paw. Yohimbine 112-121 adrenoceptor alpha 2C Rattus norvegicus 193-213 23063894-16 2013 Furthermore, the inhibitory effect of yohimbine was partly reversed by the ghrelin receptor agonist, GHRP-6. Yohimbine 38-47 ghrelin and obestatin prepropeptide Rattus norvegicus 75-82 22933299-8 2012 DEX treatment decreased the HDAC2, HDAC5, TNF-alpha, and MCP-1 expression, but increased BMP-7 and acetyl histone H3 expression, whose effects were blocked by yohimbine, an alpha(2)-AR antagonist. Yohimbine 159-168 histone deacetylase 2 Rattus norvegicus 28-33 22933299-8 2012 DEX treatment decreased the HDAC2, HDAC5, TNF-alpha, and MCP-1 expression, but increased BMP-7 and acetyl histone H3 expression, whose effects were blocked by yohimbine, an alpha(2)-AR antagonist. Yohimbine 159-168 histone deacetylase 5 Rattus norvegicus 35-40 22933299-8 2012 DEX treatment decreased the HDAC2, HDAC5, TNF-alpha, and MCP-1 expression, but increased BMP-7 and acetyl histone H3 expression, whose effects were blocked by yohimbine, an alpha(2)-AR antagonist. Yohimbine 159-168 tumor necrosis factor Rattus norvegicus 42-51 22933299-8 2012 DEX treatment decreased the HDAC2, HDAC5, TNF-alpha, and MCP-1 expression, but increased BMP-7 and acetyl histone H3 expression, whose effects were blocked by yohimbine, an alpha(2)-AR antagonist. Yohimbine 159-168 C-C motif chemokine ligand 2 Rattus norvegicus 57-62 22933299-8 2012 DEX treatment decreased the HDAC2, HDAC5, TNF-alpha, and MCP-1 expression, but increased BMP-7 and acetyl histone H3 expression, whose effects were blocked by yohimbine, an alpha(2)-AR antagonist. Yohimbine 159-168 bone morphogenetic protein 7 Rattus norvegicus 89-94 22617356-0 2012 Yohimbine depresses excitatory transmission in BNST and impairs extinction of cocaine place preference through orexin-dependent, norepinephrine-independent processes. Yohimbine 0-9 hypocretin Mus musculus 111-117 22890081-2 2012 YO promotes increased transmitter release from noradrenergic (NA) axon terminals in the central nucleus of the amygdala (CEA), bed nucleus of the stria terminalis (BST), hypothalamus, and other brain regions implicated in physiological and behavioral responses to stressful and threatening stimuli. Yohimbine 0-2 carcinoembryonic antigen gene family 4 Rattus norvegicus 121-124 22892388-5 2012 [(3)H]-rauwolscine binding assay showed that a 7-day intracortical antisense ODN treatment in the malnourished rats resulted in 50% knockdown of alpha(2C)-adrenoceptor expression and, in addition, completely rescued the ability of the occipital cortex to develop and maintain long-term potentiation. Yohimbine 7-18 adrenoceptor alpha 2C Rattus norvegicus 145-167 22617356-3 2012 Recent studies show yohimbine-induced drug-seeking behavior is attenuated by orexin receptor 1 (OX(1)R) antagonists. Yohimbine 20-29 hypocretin Mus musculus 77-83 22617356-3 2012 Recent studies show yohimbine-induced drug-seeking behavior is attenuated by orexin receptor 1 (OX(1)R) antagonists. Yohimbine 20-29 hypocretin (orexin) receptor 1 Mus musculus 96-102 22617356-5 2012 Here, we investigated yohimbine-orexin interactions. Yohimbine 22-31 hypocretin Mus musculus 32-38 22617356-6 2012 Our results demonstrate yohimbine-induced depression of excitatory transmission in the BNST is unaffected by alpha1-AR and corticotropin-releasing factor receptor-1 (CRFR(1)) antagonists, but is (1) blocked by OxR antagonists and (2) absent in brain slices from orexin knockout mice. Yohimbine 24-33 corticotropin releasing hormone receptor 1 Mus musculus 166-173 22617356-6 2012 Our results demonstrate yohimbine-induced depression of excitatory transmission in the BNST is unaffected by alpha1-AR and corticotropin-releasing factor receptor-1 (CRFR(1)) antagonists, but is (1) blocked by OxR antagonists and (2) absent in brain slices from orexin knockout mice. Yohimbine 24-33 hypocretin Mus musculus 262-268 22617356-7 2012 Although the actions of yohimbine were not mimicked by the norepinephrine transporter blocker reboxetine, they were by exogenously applied orexin A. Yohimbine 24-33 hypocretin Mus musculus 139-147 22617356-8 2012 We find that, as with yohimbine, orexin A depression of excitatory transmission in BNST is OX(1)R-dependent. Yohimbine 22-31 hypocretin Mus musculus 33-41 22617356-8 2012 We find that, as with yohimbine, orexin A depression of excitatory transmission in BNST is OX(1)R-dependent. Yohimbine 22-31 hypocretin (orexin) receptor 1 Mus musculus 91-97 22617356-9 2012 Finally, we find these ex vivo effects are paralleled in vivo, as yohimbine-induced impairment of cocaine-CPP extinction is blocked by a systemically administered OX(1)R antagonist. Yohimbine 66-75 hypocretin (orexin) receptor 1 Mus musculus 163-169 22617356-10 2012 These data highlight a new mechanism for orexin on excitatory anxiety circuits and demonstrate that some of the actions of yohimbine may be directly dependent upon orexin signaling and independent of norepinephrine and CRF in the BNST. Yohimbine 123-132 hypocretin Mus musculus 41-47 22617356-10 2012 These data highlight a new mechanism for orexin on excitatory anxiety circuits and demonstrate that some of the actions of yohimbine may be directly dependent upon orexin signaling and independent of norepinephrine and CRF in the BNST. Yohimbine 123-132 hypocretin Mus musculus 164-170 22464882-7 2012 Administration of yohimbine (alpha(2A) adrenergic receptor antagonist) enhanced the level of NE in juvenile rats and reversed the difference seen with age. Yohimbine 18-27 adrenoceptor alpha 2A Rattus norvegicus 29-58 22473744-8 2012 This peripheral effect was antagonized by the nonselective alpha(2) adrenoceptor antagonist yohimbine and by the selective alpha(2C) adrenoceptor antagonist rauwolscine but not by the selective antagonists for alpha(2A), alpha(2B), and alpha(2D) adrenoceptor subtypes (BRL 44 480, imiloxan, and RX 821002, respectively). Yohimbine 157-168 adrenoceptor alpha 2C Rattus norvegicus 123-145 22334120-8 2012 Nevertheless, the CORT-treated rats tended to have more yohimbine-induced impulsive responses at low doses on this task, which was not found to be due to increased pCREB in the lOFC, but could be related to a higher expression/activity of the AMPA receptor subunit GluR1. Yohimbine 56-65 glutamate ionotropic receptor AMPA type subunit 1 Rattus norvegicus 265-270 22548833-15 2012 pretreatment with phentolamine (an alpha(1)-adrenergic blocker) or yohimbine (an alpha(2)-adrenergic blocker) significantly attenuated the blood glucose level and pain behavior induced by IL-1beta administered i.t. Yohimbine 67-76 interleukin 1 beta Mus musculus 188-196 22723688-6 2012 Yohimbine- and pellet-priming-induced reinstatement was associated with Fos and GFP induction in mPFC; both reinstatement and neuronal activation were minimally affected by ovarian hormones in both c-fos-GFP and wild-type rats. Yohimbine 0-9 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 72-75 22290390-7 2012 In conclusion, we have identified and separated alpha(1A)-, alpha(1D)- and alpha(2A)-adrenoceptor antagonist actions of yohimbine against pressor responses. Yohimbine 120-129 adrenoceptor alpha 2A Rattus norvegicus 75-97 22230708-9 2012 Dexmedetomidine preconditioning increased levels of phosphorylated Erk1/2, Akt and eNOS forms before ischemia/reperfusion; being significantly reversed by yohimbine in both models. Yohimbine 155-164 mitogen activated protein kinase 3 Rattus norvegicus 67-73 22230708-9 2012 Dexmedetomidine preconditioning increased levels of phosphorylated Erk1/2, Akt and eNOS forms before ischemia/reperfusion; being significantly reversed by yohimbine in both models. Yohimbine 155-164 AKT serine/threonine kinase 1 Rattus norvegicus 75-78 20643698-7 2012 When contrasted with adult neurobiological models of panic disorder and social anxiety disorder, children studied showed some abnormalities which mirrored those reported in adults, such as altered baseline respiration, altered responses to CO(2) challenge tests and blunted growth hormone response to yohimbine. Yohimbine 301-310 growth hormone 1 Homo sapiens 274-288 22290390-0 2012 Yohimbine antagonises alpha1A- and alpha1D-adrenoceptor mediated components in addition to the alpha2A-adrenoceptor component to pressor responses in the pithed rat. Yohimbine 0-9 adrenoceptor alpha 1D Rattus norvegicus 35-55 25242983-5 2012 OBJECTIVE: Our objectives in this study were (1) to estimate LC activity in rats with estradiol valerate (EV)-induced PCO; (2) to antagonized alpha2a adrenoceptor in systemic conditions with yohimbine. Yohimbine 191-200 adrenoceptor alpha 2A Rattus norvegicus 142-162 22544982-1 2012 A novel MCAP-cycloaddition sequence has been applied to the facile synthesis of beta-carboline intermediates to gain rapid access to novel derivatives of yohimbine-like and corynanthe-like compounds that may be easily diversified by cross-coupling reactions and N-derivatizations to generate small compound libraries. Yohimbine 154-163 bromodomain containing 4 Homo sapiens 8-12 22311903-4 2012 We hypothesized that increasing residual sympathetic outflow with the alpha-2 antagonist yohimbine would potentiate the pressor effect of norepinephrine transporter blockade with atomoxetine and improve orthostatic tolerance in peripheral autonomic failure. Yohimbine 89-98 solute carrier family 6 member 2 Homo sapiens 138-164 22311903-11 2012 In conclusion, the combination of yohimbine and atomoxetine had a synergistic effect on blood pressure and orthostatic tolerance in peripheral autonomic failure, which may be explained by an increased release of norepinephrine in peripheral sympathetic neurons by alpha-2 antagonism combined with a reduced norepinephrine clearance by norepinephrine transporter blockade. Yohimbine 34-43 solute carrier family 6 member 2 Homo sapiens 335-361 22116378-11 2012 Manipulation of noradrenaline levels with YOH was successful, with significantly higher levels of sAA in the YOH group when entering exposure. Yohimbine 109-112 amylase alpha 1A Homo sapiens 98-101 21863233-8 2011 Plasma CORT levels in response to injection of both vehicle and yohimbine were significantly higher in the ethanol-trained animals compared to sucrose controls. Yohimbine 64-73 cortistatin Rattus norvegicus 7-11 22029733-7 2011 The responses to suncus motilin in the stomach were completely abolished by atropine and tetrodotoxin treatment and significantly suppressed by administration of hexamethonium, verapamil, phentolamine, yohimbine, ondansetron, and naloxone, whereas ritanserin, prazosin, timolol, and FK888 did not affect the action of motilin. Yohimbine 202-211 motilin Canis lupus familiaris 24-31 21963947-5 2011 Accordingly, the blockade of alpha2 adrenergic receptors with yohimbine potentiated the production of MCP-1 stimulated by the activation of beta receptors. Yohimbine 62-71 C-C motif chemokine ligand 2 Rattus norvegicus 102-107 22039843-9 2011 Pre-test intra-CA1 microinjection of yohimbine (1 mug/rat) before administration of WIN55,212-2 (0.5 microg/rat, intra-CA1), however, dose-dependently inhibited WIN55,212-2 state-dependent memory. Yohimbine 37-46 carbonic anhydrase 1 Rattus norvegicus 15-18 22039843-9 2011 Pre-test intra-CA1 microinjection of yohimbine (1 mug/rat) before administration of WIN55,212-2 (0.5 microg/rat, intra-CA1), however, dose-dependently inhibited WIN55,212-2 state-dependent memory. Yohimbine 37-46 carbonic anhydrase 1 Rattus norvegicus 119-122 21232580-11 2011 The remaining antinociceptive activity of tapentadol in OPRM1 KO mice was abolished by the alpha2-adrenoceptor antagonist yohimbine. Yohimbine 122-131 opioid receptor, mu 1 Mus musculus 56-61 21542970-0 2011 Yohimbine protects against endotoxin-induced acute lung injury by blockade of alpha 2A adrenergic receptor in rats. Yohimbine 0-9 adrenoceptor alpha 2A Rattus norvegicus 78-106 21542970-3 2011 The present study aimed to investigate the influence of alpha2A AR antagonist, yohimbine, on the severity of endotoxin-induced acute lung injury in rats. Yohimbine 79-88 adrenoceptor alpha 2A Rattus norvegicus 56-66 21564088-11 2011 Moreover, yohimbine attenuated the synergistic orexigenic effect induced by the combination of NPY and agmatine. Yohimbine 10-19 neuropeptide Y Rattus norvegicus 95-98 21564088-12 2011 Agmatine increased NPY immunoreactivity in the PVN fibres and in the cells of the hypothalamic arcuate nucleus (ARC) and this effect was prevented by pretreatment with yohimbine. Yohimbine 168-177 neuropeptide Y Rattus norvegicus 19-22 21542970-13 2011 When compared with the LPS group, the oxygenation index, white blood cell count, the lung histopathological scores and the level of IL-6 in the LPS + yohimbine group were significantly improved at each time interval, and the concentrations of TNF-alpha and IL-1beta were also lower at 24 hours of LPS administration (all P < 0.05). Yohimbine 150-159 interleukin 6 Rattus norvegicus 132-136 21542970-13 2011 When compared with the LPS group, the oxygenation index, white blood cell count, the lung histopathological scores and the level of IL-6 in the LPS + yohimbine group were significantly improved at each time interval, and the concentrations of TNF-alpha and IL-1beta were also lower at 24 hours of LPS administration (all P < 0.05). Yohimbine 150-159 tumor necrosis factor Rattus norvegicus 243-252 21542970-13 2011 When compared with the LPS group, the oxygenation index, white blood cell count, the lung histopathological scores and the level of IL-6 in the LPS + yohimbine group were significantly improved at each time interval, and the concentrations of TNF-alpha and IL-1beta were also lower at 24 hours of LPS administration (all P < 0.05). Yohimbine 150-159 interleukin 1 beta Rattus norvegicus 257-265 21542970-15 2011 CONCLUSIONS: Yohimbine can inhibit TNF-alpha, IL-1beta and IL-6 overproduction and relieve the severity of pulmonary inflammation induced by endotoxin, which is maybe mediated by blockade of alpha2A AR on inflammatory cells. Yohimbine 13-22 tumor necrosis factor Rattus norvegicus 35-44 21542970-15 2011 CONCLUSIONS: Yohimbine can inhibit TNF-alpha, IL-1beta and IL-6 overproduction and relieve the severity of pulmonary inflammation induced by endotoxin, which is maybe mediated by blockade of alpha2A AR on inflammatory cells. Yohimbine 13-22 interleukin 1 beta Rattus norvegicus 46-54 21542970-15 2011 CONCLUSIONS: Yohimbine can inhibit TNF-alpha, IL-1beta and IL-6 overproduction and relieve the severity of pulmonary inflammation induced by endotoxin, which is maybe mediated by blockade of alpha2A AR on inflammatory cells. Yohimbine 13-22 interleukin 6 Rattus norvegicus 59-63 21542970-15 2011 CONCLUSIONS: Yohimbine can inhibit TNF-alpha, IL-1beta and IL-6 overproduction and relieve the severity of pulmonary inflammation induced by endotoxin, which is maybe mediated by blockade of alpha2A AR on inflammatory cells. Yohimbine 13-22 adrenoceptor alpha 2A Rattus norvegicus 191-201 21241763-6 2011 Our results showed that DEX stimulated GDNF release in a time- and dose-dependent manner; and this stimulation was blocked by the alpha2-adrenoreceptor antagonist yohimbine, but not by alpha1-adrenoreceptor antagonist prasozin, demonstrating that DEX induced GDNF release likely acts via activating the alpha2A adrenoreceptor. Yohimbine 163-172 glial cell derived neurotrophic factor Rattus norvegicus 39-43 21241763-6 2011 Our results showed that DEX stimulated GDNF release in a time- and dose-dependent manner; and this stimulation was blocked by the alpha2-adrenoreceptor antagonist yohimbine, but not by alpha1-adrenoreceptor antagonist prasozin, demonstrating that DEX induced GDNF release likely acts via activating the alpha2A adrenoreceptor. Yohimbine 163-172 glial cell derived neurotrophic factor Rattus norvegicus 259-263 21241763-6 2011 Our results showed that DEX stimulated GDNF release in a time- and dose-dependent manner; and this stimulation was blocked by the alpha2-adrenoreceptor antagonist yohimbine, but not by alpha1-adrenoreceptor antagonist prasozin, demonstrating that DEX induced GDNF release likely acts via activating the alpha2A adrenoreceptor. Yohimbine 163-172 adrenoceptor alpha 2A Rattus norvegicus 303-325 21055451-7 2011 Additionally, to further characterize the animals by their biochemical response to a challenge, the neurochemical changes induced by the anxiogenic compound yohimbine were measured in the medial prefrontal cortex (mPFC) of NPY-Y2 KO and compared to WT mice. Yohimbine 157-166 neuropeptide Y Mus musculus 223-226 21055451-8 2011 Dopamine (DA) levels were significantly increased by yohimbine in the WT but unaffected in the KO mice, suggesting that NPY-Y2 receptor exerts a direct control over both the tonic and phasic release of DA and that, although the anxiety-like behavior of these NPY-Y2 KO mice is unaltered, there are clear modifications of DA dynamics. Yohimbine 53-62 neuropeptide Y receptor Y2 Mus musculus 120-135 21055451-8 2011 Dopamine (DA) levels were significantly increased by yohimbine in the WT but unaffected in the KO mice, suggesting that NPY-Y2 receptor exerts a direct control over both the tonic and phasic release of DA and that, although the anxiety-like behavior of these NPY-Y2 KO mice is unaltered, there are clear modifications of DA dynamics. Yohimbine 53-62 neuropeptide Y Mus musculus 120-123 21106912-8 2011 However, rauwolscine+losartan enhanced the ARNA responses to reflex increases in ERSNA (4,680 +- 1,240% s), and renal pelvic release of substance P by 250 pM NE, from 8.3 +- 0.6 to 14.2 +- 0.8 pg/min. Yohimbine 9-20 tachykinin precursor 1 Homo sapiens 136-147 20926983-0 2011 Pretreatment with berberine and yohimbine protects against LPS-induced myocardial dysfunction via inhibition of cardiac I-[kappa]B[alpha] phosphorylation and apoptosis in mice. Yohimbine 32-41 nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha Mus musculus 120-136 20926983-5 2011 LPS-provoked cardiac apoptosis, I-[kappa]B[alpha] phosphorylation, IL-1[beta], TNF-[alpha], and NO production were attenuated by pretreatment with Ber and/or yohimbine, whereas cardiac Toll-like receptor 4 mRNA expression, malondialdehyde content, and superoxide dismutase activity were not affected. Yohimbine 158-167 nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha Mus musculus 32-48 20926983-5 2011 LPS-provoked cardiac apoptosis, I-[kappa]B[alpha] phosphorylation, IL-1[beta], TNF-[alpha], and NO production were attenuated by pretreatment with Ber and/or yohimbine, whereas cardiac Toll-like receptor 4 mRNA expression, malondialdehyde content, and superoxide dismutase activity were not affected. Yohimbine 158-167 interleukin 1 beta Mus musculus 67-76 20926983-5 2011 LPS-provoked cardiac apoptosis, I-[kappa]B[alpha] phosphorylation, IL-1[beta], TNF-[alpha], and NO production were attenuated by pretreatment with Ber and/or yohimbine, whereas cardiac Toll-like receptor 4 mRNA expression, malondialdehyde content, and superoxide dismutase activity were not affected. Yohimbine 158-167 tumor necrosis factor Mus musculus 79-89 20926983-5 2011 LPS-provoked cardiac apoptosis, I-[kappa]B[alpha] phosphorylation, IL-1[beta], TNF-[alpha], and NO production were attenuated by pretreatment with Ber and/or yohimbine, whereas cardiac Toll-like receptor 4 mRNA expression, malondialdehyde content, and superoxide dismutase activity were not affected. Yohimbine 158-167 toll-like receptor 4 Mus musculus 185-205 20962767-9 2011 Yohimbine-induced reinstatement was associated with strong Fos induction in the dorsal mPFC and with weaker Fos induction in the ventral mPFC. Yohimbine 0-9 Fos proto-oncogene, AP-1 transcription factor subunit Homo sapiens 59-62 20962767-9 2011 Yohimbine-induced reinstatement was associated with strong Fos induction in the dorsal mPFC and with weaker Fos induction in the ventral mPFC. Yohimbine 0-9 Fos proto-oncogene, AP-1 transcription factor subunit Homo sapiens 108-111 21525724-0 2011 Effect of long-term prazosin and yohimbine administration on c-Fos expression in spinal neurons: inhibitory effect of alpha-1 and alpha-2 adrenoceptors on afferents from the lower urinary tract. Yohimbine 33-42 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 61-66 21525724-7 2011 Yohimbine reduced the number of c-Fos-positive neurons in part of the dorsal horn. Yohimbine 0-9 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 32-37 20660048-13 2010 Clonidine-induced increase in basal cortisol levels was blocked by the ADRA2A antagonist yohimbine. Yohimbine 89-98 adrenoceptor alpha 2A Homo sapiens 71-77 20605057-8 2010 Yohimbine, an alpha(2)-adrenergic receptor (AR) antagonist, prevented the hyperactivation of the ERK/AP-1 pathway and CREB induced by co-treatment. Yohimbine 0-9 mitogen-activated protein kinase 1 Homo sapiens 97-100 20599923-9 2010 Yohimbine inhibited norepinephrine constrictions in alpha(2C)-adrenoceptor KO veins suggesting that there is upregulation of other alpha(2)-adrenoceptors in alpha(2C)-KO mice. Yohimbine 0-9 adrenergic receptor, alpha 2c Mus musculus 52-60 20599923-9 2010 Yohimbine inhibited norepinephrine constrictions in alpha(2C)-adrenoceptor KO veins suggesting that there is upregulation of other alpha(2)-adrenoceptors in alpha(2C)-KO mice. Yohimbine 0-9 adrenergic receptor, alpha 2c Mus musculus 157-165 20605057-8 2010 Yohimbine, an alpha(2)-adrenergic receptor (AR) antagonist, prevented the hyperactivation of the ERK/AP-1 pathway and CREB induced by co-treatment. Yohimbine 0-9 cAMP responsive element binding protein 1 Homo sapiens 118-122 20163788-6 2010 We then examined whether yohimbine altered activity of cyclic adenosine monophosphate response element binding (CREB) protein-a transcription factor implicated in the stress response-in brain areas that regulate impulsivity. Yohimbine 25-34 cAMP responsive element binding protein 1 Homo sapiens 112-116 20542064-8 2010 The hyperactivity induced by L-DOPA and NSD1015 was reduced by the alpha(2C) antagonist rauwolscine (1 mg/kg) and the 5-HT(2C) agonist MK212 (5 mg/kg), but not by the D2 dopamine receptor antagonist remoxipride (3 mg/kg) or the D1 dopamine receptor antagonist SCH23390 (1 mg/kg). Yohimbine 88-99 dopamine receptor D2 Rattus norvegicus 167-187 20163788-8 2010 RESULTS: Yohimbine increased impulsive responding in rats and selectively increased CREB phosphorylation within the orbitofrontal cortex but not medial prefrontal cortex or nucleus accumbens. Yohimbine 9-18 cAMP responsive element binding protein 1 Rattus norvegicus 84-88 20163788-9 2010 Overexpressing mCREB within the orbitofrontal cortex blocked yohimbine"s effects on impulsivity, whereas overexpressing CREB in this region increased impulsive responding and potentiated the proimpulsive actions of yohimbine. Yohimbine 61-70 cAMP responsive element binding protein 1 Mus musculus 15-20 20163788-9 2010 Overexpressing mCREB within the orbitofrontal cortex blocked yohimbine"s effects on impulsivity, whereas overexpressing CREB in this region increased impulsive responding and potentiated the proimpulsive actions of yohimbine. Yohimbine 61-70 cAMP responsive element binding protein 1 Homo sapiens 16-20 20089918-7 2010 Furthermore, coadministration of the alpha(2)-adrenoceptor antagonist yohimbine with the antidepressant imipramine significantly accelerates effects on hippocampal progenitor proliferation, the morphological maturation of newborn neurons, and the increase in expression of brain derived neurotrophic factor and vascular endothelial growth factor implicated in the neurogenic and behavioral effects of antidepressants. Yohimbine 70-79 brain derived neurotrophic factor Mus musculus 273-306 20012021-0 2010 Neuropeptide Y (NPY) suppresses yohimbine-induced reinstatement of alcohol seeking. Yohimbine 32-41 neuropeptide Y Rattus norvegicus 0-14 20012021-0 2010 Neuropeptide Y (NPY) suppresses yohimbine-induced reinstatement of alcohol seeking. Yohimbine 32-41 neuropeptide Y Rattus norvegicus 16-19 20012021-2 2010 Here, we examined whether neuropeptide Y (NPY), an endogenous anti-stress mediator, blocks reinstatement of alcohol-seeking induced by the pharmacological stressor yohimbine. Yohimbine 164-173 neuropeptide Y Rattus norvegicus 26-40 20012021-2 2010 Here, we examined whether neuropeptide Y (NPY), an endogenous anti-stress mediator, blocks reinstatement of alcohol-seeking induced by the pharmacological stressor yohimbine. Yohimbine 164-173 neuropeptide Y Rattus norvegicus 42-45 20012021-3 2010 MATERIALS AND METHODS: NPY [5.0 or 10.0 mug/rat, intracerebroventricularly (ICV)] dose-dependently blocked the reinstatement of alcohol seeking induced by yohimbine (1.25 mg/kg, i.p.) Yohimbine 155-164 neuropeptide Y Rattus norvegicus 23-26 20012021-6 2010 RESULTS AND DISCUSSION: The analysis was focused on a network of structures previously implicated in yohimbine-induced reinstatement, comprised of central (CeA) and basolateral (BLA) amygdala and the shell of the nucleus accumbens (Nc AccS). Yohimbine 101-110 1-aminocyclopropane-1-carboxylate synthase Rattus norvegicus 235-239 19520131-7 2009 The effect of clonidine on endothelial cell-derived CGRP synthesis and secretion was attenuated in the presence of yohimbine. Yohimbine 115-124 calcitonin related polypeptide alpha Homo sapiens 52-56 19272818-4 2009 All the cases showed greater potency of inhibition of the interaction when yohimbine hydrochloride (YH), a blocker of alpha2A-adrenoreceptor, was used compared to MRS2179, a P2Y1 antagonist, although there was variability in responsiveness to the antiplatelet drugs. Yohimbine 75-98 adrenoceptor alpha 2A Homo sapiens 118-140 19272818-4 2009 All the cases showed greater potency of inhibition of the interaction when yohimbine hydrochloride (YH), a blocker of alpha2A-adrenoreceptor, was used compared to MRS2179, a P2Y1 antagonist, although there was variability in responsiveness to the antiplatelet drugs. Yohimbine 100-102 adrenoceptor alpha 2A Homo sapiens 118-140 19229522-2 2009 Yohimbine also acts as an agonist of 5-hydroxytryptamine (5-HT) 5-HT1A receptors, which have been shown to be involved in alcohol seeking. Yohimbine 0-9 5-hydroxytryptamine receptor 1A Rattus norvegicus 64-70 19229522-3 2009 Here, we determined the contributions of the alpha-2 and 5-HT1A properties of yohimbine to its effects on alcohol seeking. Yohimbine 78-87 5-hydroxytryptamine receptor 1A Rattus norvegicus 57-63 19229522-9 2009 Blockade of 5-HT1A receptors reduced both yohimbine-induced self-administration and reinstatement. Yohimbine 42-51 5-hydroxytryptamine receptor 1A Rattus norvegicus 12-18 19229522-11 2009 On the other hand, yohimbine"s actions on 5-HT1A receptors contribute to its effects on both alcohol self-administration and reinstatement. Yohimbine 19-28 5-hydroxytryptamine receptor 1A Rattus norvegicus 42-48 18793704-10 2008 Yohimbine prevented the effects of Ucn 3 on the immobility, climbing and swimming times. Yohimbine 0-9 urocortin 3 Mus musculus 35-40 19233186-4 2009 Stimulation of food intake caused by neuropeptide Y and beta-endorphin was attenuated by co-injection with yohimbine. Yohimbine 107-116 neuropeptide Y Homo sapiens 37-51 19233186-4 2009 Stimulation of food intake caused by neuropeptide Y and beta-endorphin was attenuated by co-injection with yohimbine. Yohimbine 107-116 proopiomelanocortin Homo sapiens 56-70 19380024-4 2009 The mRNA expression of the ABCB1 gene (previously MDR1) in human colon carcinoma HT-29 cell line was measured after treatment with an adrenergic receptor agonist (adrenaline) and various antagonists (propranolol, prazosin, and yohimbine). Yohimbine 227-236 ATP binding cassette subfamily B member 1 Homo sapiens 27-32 19380024-4 2009 The mRNA expression of the ABCB1 gene (previously MDR1) in human colon carcinoma HT-29 cell line was measured after treatment with an adrenergic receptor agonist (adrenaline) and various antagonists (propranolol, prazosin, and yohimbine). Yohimbine 227-236 ATP binding cassette subfamily B member 1 Homo sapiens 50-54 19380024-8 2009 The alpha2-adrenergic receptor antagonist yohimbine completely abolished the induction of ABCB1 mRNA, the stimulatory effect of adrenaline on Rh123 efflux, and the growth-inhibiting effect of 5-FU. Yohimbine 42-51 ATP binding cassette subfamily B member 1 Homo sapiens 90-95 19225179-5 2009 To identify the alpha(2)AR subtype involved, equilibrium dissociation constants (pK(b)) were determined for the selective alphaAR antagonists atipamezole (8.79), rauwolscine (7.75), 2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane hydrochloride (WB-4101; 6.87), and prazosin (5.71). Yohimbine 162-173 adrenergic receptor, alpha 2a Mus musculus 16-26 18725311-5 2008 We also found that the galanin-induced feeding behavior was attenuated in layer chicks by the co-injection of yohimbine and beta-funaltrexamine, which are the antagonists of adrenergic alpha-2 receptor and opioid mu-receptor, respectively. Yohimbine 110-119 galanin and GMAP prepropeptide Gallus gallus 23-30 18755245-3 2008 In rats, we determined that yohimbine elicits patterns of brain expression of the mRNAs for c-fos, a marker of neuronal activation, and corticotropin-releasing factor (CRF) a stress-related peptide, distinct from that produced by FG-7142. Yohimbine 28-37 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 92-97 18755245-3 2008 In rats, we determined that yohimbine elicits patterns of brain expression of the mRNAs for c-fos, a marker of neuronal activation, and corticotropin-releasing factor (CRF) a stress-related peptide, distinct from that produced by FG-7142. Yohimbine 28-37 corticotropin releasing hormone Rattus norvegicus 136-166 18755245-4 2008 The purpose of the present experiment is to determine if these differential effects of yohimbine and FG-7142 on regional c-fos and CRF mRNA expression generalize to another animal commonly used in alcohol research, the C57 BL/6J mouse. Yohimbine 87-96 FBJ osteosarcoma oncogene Mus musculus 121-126 18755245-6 2008 As we found in the rat, yohimbine selectively increased c-fos mRNA in the mouse NACs, BLA and CeA. Yohimbine 24-33 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 56-61 18755245-6 2008 As we found in the rat, yohimbine selectively increased c-fos mRNA in the mouse NACs, BLA and CeA. Yohimbine 24-33 carcinoembryonic antigen gene family Mus musculus 94-97 18755245-9 2008 The selective induction of c-fos in the NACs, BLA and CeA of mice and rats by yohimbine offers further support for the idea that activation of these structures participates in reinstatement induced by such stressors. Yohimbine 78-87 FBJ osteosarcoma oncogene Mus musculus 27-32 18755245-9 2008 The selective induction of c-fos in the NACs, BLA and CeA of mice and rats by yohimbine offers further support for the idea that activation of these structures participates in reinstatement induced by such stressors. Yohimbine 78-87 carcinoembryonic antigen gene family Mus musculus 54-57 18433425-0 2008 Relationship of cytochrome P450 pharmacogenetics to the effects of yohimbine on gastrointestinal transit and catecholamines in healthy subjects. Yohimbine 67-76 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 27-31 18772254-6 2008 Moreover, alpha(2A)-AR knockout mice exhibited similar cocaine CPP extinction and exacerbated extinction impairing effects of yohimbine. Yohimbine 126-135 adrenergic receptor, alpha 2a Mus musculus 10-22 17957212-6 2008 Consistently, bath-application of guanfacine suppressed eEPSC in layer V/VI pyramidal neurons, and this effect was blocked by the alpha2-AR antagonist yohimbine or the Gi inhibitor NF023. Yohimbine 151-160 adrenoceptor alpha 2A Rattus norvegicus 137-139 18433425-7 2008 As cytochrome P450 enzymes metabolize yohimbine, P450 genotypes (CYP2D6 and CYP3A4) were determined in 25 of 30 subjects who consented to genetic studies. Yohimbine 38-47 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 14-18 18433425-13 2008 These data suggest that CYP2D6 and CYP3A4 genotypes which determine the metabolism of yohimbine may influence its sympathetic and gastrointestinal effects. Yohimbine 86-95 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 24-30 18433425-13 2008 These data suggest that CYP2D6 and CYP3A4 genotypes which determine the metabolism of yohimbine may influence its sympathetic and gastrointestinal effects. Yohimbine 86-95 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 35-41 18416462-12 2008 The alpha2-adrenoceptor antagonist, yohimbine, can inhibit the proliferation of both cell lines and induce their apoptosis, suggesting that yohimbine can be used as an anticancer drug for apoptosis of PC-2 and PC-3 cells. Yohimbine 36-45 chromobox 4 Homo sapiens 201-205 18416462-12 2008 The alpha2-adrenoceptor antagonist, yohimbine, can inhibit the proliferation of both cell lines and induce their apoptosis, suggesting that yohimbine can be used as an anticancer drug for apoptosis of PC-2 and PC-3 cells. Yohimbine 36-45 proprotein convertase subtilisin/kexin type 1 Homo sapiens 210-214 18416462-12 2008 The alpha2-adrenoceptor antagonist, yohimbine, can inhibit the proliferation of both cell lines and induce their apoptosis, suggesting that yohimbine can be used as an anticancer drug for apoptosis of PC-2 and PC-3 cells. Yohimbine 140-149 chromobox 4 Homo sapiens 201-205 18416462-12 2008 The alpha2-adrenoceptor antagonist, yohimbine, can inhibit the proliferation of both cell lines and induce their apoptosis, suggesting that yohimbine can be used as an anticancer drug for apoptosis of PC-2 and PC-3 cells. Yohimbine 140-149 proprotein convertase subtilisin/kexin type 1 Homo sapiens 210-214 17111100-5 2007 We found enhanced panicogenic sensitivity to sodium lactate and an increased intensity and a differential pattern of Fos expression after the administration of yohimbine or caffeine in TgNTRK3. Yohimbine 160-169 FBJ osteosarcoma oncogene Mus musculus 117-120 17884041-9 2007 Blockade of alpha-adrenoceptors by prazosin or yohimbine attenuated pressor response to CDP-choline while these antagonists blocked pressor responses to phosphocholine or choline. Yohimbine 47-56 cut-like homeobox 1 Rattus norvegicus 88-91 17870537-2 2007 The prepared compounds were tested for their activity and selectivity toward the norepinephrine transporter (NET) and serotonin transporter (SERT) using yohimbine-induced mortality and 5-hydroxytryptophan-induced neurotoxicity in mice, respectively. Yohimbine 153-162 solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 Mus musculus 81-107 18287883-11 2008 It also had competitive binding effects in human platelet with [H]yohimbine (alpha2), [H]ketanserin (5-HT2A). Yohimbine 66-75 5-hydroxytryptamine receptor 2A Homo sapiens 101-107 18491567-2 2008 Yohimbine decreased Bax mRNA level in the cerebellum, increased the ratio between Bcl-XL and Bax mRNA levels in the cerebellum, cortex, and hippocampus, and increased Bcl-XL mRNA level in the cortex and hippocampus of 6-day-old-rat pups 24 h after injection. Yohimbine 0-9 BCL2 associated X, apoptosis regulator Rattus norvegicus 20-23 18491567-2 2008 Yohimbine decreased Bax mRNA level in the cerebellum, increased the ratio between Bcl-XL and Bax mRNA levels in the cerebellum, cortex, and hippocampus, and increased Bcl-XL mRNA level in the cortex and hippocampus of 6-day-old-rat pups 24 h after injection. Yohimbine 0-9 Bcl2-like 1 Rattus norvegicus 82-88 18491567-2 2008 Yohimbine decreased Bax mRNA level in the cerebellum, increased the ratio between Bcl-XL and Bax mRNA levels in the cerebellum, cortex, and hippocampus, and increased Bcl-XL mRNA level in the cortex and hippocampus of 6-day-old-rat pups 24 h after injection. Yohimbine 0-9 BCL2 associated X, apoptosis regulator Rattus norvegicus 93-96 18491567-2 2008 Yohimbine decreased Bax mRNA level in the cerebellum, increased the ratio between Bcl-XL and Bax mRNA levels in the cerebellum, cortex, and hippocampus, and increased Bcl-XL mRNA level in the cortex and hippocampus of 6-day-old-rat pups 24 h after injection. Yohimbine 0-9 Bcl2-like 1 Rattus norvegicus 167-173 18491567-3 2008 Administration of clonidine 20 min after yohimbine administration abolished its effect on Bcl-XL mRNA level in the hippocampus. Yohimbine 41-50 Bcl2-like 1 Rattus norvegicus 90-96 17705061-0 2007 The CRF1 receptor antagonist antalarmin attenuates yohimbine-induced increases in operant alcohol self-administration and reinstatement of alcohol seeking in rats. Yohimbine 51-60 corticotropin releasing hormone receptor 1 Rattus norvegicus 4-8 17705061-3 2007 In this study, we assess whether these effects of yohimbine are attenuated by systemic injections of the corticotrotropin-releasing factor 1 (CRF1) receptor antagonist antalarmin. Yohimbine 50-59 corticotropin releasing hormone receptor 1 Rattus norvegicus 142-146 17705061-15 2007 CONCLUSIONS: These results suggest that extrahypothalamic CRF1 receptors are involved in the effect of yohimbine on operant alcohol self-administration and on relapse to alcohol seeking and support the notion that CRF1 receptor antagonists should be considered in alcohol addiction treatment. Yohimbine 103-112 corticotropin releasing hormone receptor 1 Rattus norvegicus 58-62 17974982-5 2007 Activation of STAT3 was inhibited by blockade of the beta1- and beta2-adrenergic receptors with propranolol, and by blocking protein kinase A with KT5720, but not with the alpha receptor blockers prazosin (alpha1) and/or yohimbine (alpha2). Yohimbine 221-230 signal transducer and activator of transcription 3 Mus musculus 14-19 17727392-7 2007 However, GLP-1 plus yohimbine increased (P < 0.001) postprandial gastric accommodation vs placebo and vs GLP-1 alone [postprandial volume change = 542 +/- 29 mL (mean +/- SEM, placebo), 605 +/- 31 mL (GLP-1), 652 +/- 54 mL (yohimbine) and 810 +/- 37 mL (GLP-1 and yohimbine)]. Yohimbine 227-236 glucagon Homo sapiens 9-14 17917852-9 2007 Hyperglycemia elicited by CDP-choline and its metabolites was entirely blocked either by pretreatment with a nonselective -adrenoceptor antagonist phentolamine or by the 2-adrenoceptor antagonist, yohimbine. Yohimbine 197-206 cut-like homeobox 1 Rattus norvegicus 26-29 17727392-7 2007 However, GLP-1 plus yohimbine increased (P < 0.001) postprandial gastric accommodation vs placebo and vs GLP-1 alone [postprandial volume change = 542 +/- 29 mL (mean +/- SEM, placebo), 605 +/- 31 mL (GLP-1), 652 +/- 54 mL (yohimbine) and 810 +/- 37 mL (GLP-1 and yohimbine)]. Yohimbine 227-236 glucagon Homo sapiens 9-14 18069241-3 2007 While the rest of the alkaloids did not show any significant inhibition against AChE, three of the alkaloids, namely retamine, sparteine, and yohimbine, exerted a noteworthy anti-BChE effect as compared to galanthamine, the reference drug. Yohimbine 142-151 butyrylcholinesterase Homo sapiens 179-183 17493708-3 2007 This effect was abolished by the selective adenosine A2A-receptor antagonist 5-amino-7-(2-phenyl ethyl)-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo [1,5-c]pyrimidine (SCH 58261; 20 nM) and by yohimbine (1 microM). Yohimbine 192-201 adenosine A2a receptor Rattus norvegicus 43-65 17558432-1 2007 BACKGROUND AND PURPOSE: Rodent alpha(2A)-adrenoceptors bind the classical alpha(2)-antagonists yohimbine and rauwolscine with lower affinity than the human alpha(2A)-adrenoceptor. Yohimbine 95-104 adrenoceptor alpha 2A Homo sapiens 31-53 17558432-1 2007 BACKGROUND AND PURPOSE: Rodent alpha(2A)-adrenoceptors bind the classical alpha(2)-antagonists yohimbine and rauwolscine with lower affinity than the human alpha(2A)-adrenoceptor. Yohimbine 109-120 adrenoceptor alpha 2A Homo sapiens 31-53 17637181-11 2007 While aminoguanidine and ascorbic acid also attenuated the LPS-induced increase in p38 MAPK, iNOS and COX-2 proteins in the aorta and lymphocytes, trazodone and yohimbine inhibited only the increase in p38 MAPK, iNOS and COX-2 proteins in lymphocytes. Yohimbine 161-170 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 102-107 17637181-11 2007 While aminoguanidine and ascorbic acid also attenuated the LPS-induced increase in p38 MAPK, iNOS and COX-2 proteins in the aorta and lymphocytes, trazodone and yohimbine inhibited only the increase in p38 MAPK, iNOS and COX-2 proteins in lymphocytes. Yohimbine 161-170 nitric oxide synthase 2 Rattus norvegicus 212-216 17637181-11 2007 While aminoguanidine and ascorbic acid also attenuated the LPS-induced increase in p38 MAPK, iNOS and COX-2 proteins in the aorta and lymphocytes, trazodone and yohimbine inhibited only the increase in p38 MAPK, iNOS and COX-2 proteins in lymphocytes. Yohimbine 161-170 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 221-226 17123717-2 2007 In the present study we have checked the effects of yohimbine on morphine-induced alterations of the expression of key proteins (glial fibrillary acidic protein, GFAP) and genes (alpha(2)-adrenoceptors) in rat brain areas known to be relevant in opioid dependence, addiction and individual vulnerability to drug abuse. Yohimbine 52-61 glial fibrillary acidic protein Rattus norvegicus 162-166 17363407-12 2007 CONCLUSIONS: In endotoxaemic mice, yohimbine improved delayed gastric emptying and gastrointestinal transit, possibly by downregulating lipopolysaccharide-induced increased expression of iNOS. Yohimbine 35-44 nitric oxide synthase 2, inducible Mus musculus 187-191 17157293-0 2007 Morphine and yohimbine regulate midkine gene expression in the rat hippocampus. Yohimbine 13-22 midkine Rattus norvegicus 32-39 17157293-3 2007 The present work tries to examine a possible link between yohimbine reversal of morphine effects and pleiotrophin/midkine activation in the rat hippocampus by studying the levels of expression of pleiotrophin and midkine in response to acute and chronic administration of morphine, yohimbine and combinations of both drugs. Yohimbine 58-67 pleiotrophin Rattus norvegicus 101-113 17157293-3 2007 The present work tries to examine a possible link between yohimbine reversal of morphine effects and pleiotrophin/midkine activation in the rat hippocampus by studying the levels of expression of pleiotrophin and midkine in response to acute and chronic administration of morphine, yohimbine and combinations of both drugs. Yohimbine 58-67 midkine Rattus norvegicus 114-121 17157293-3 2007 The present work tries to examine a possible link between yohimbine reversal of morphine effects and pleiotrophin/midkine activation in the rat hippocampus by studying the levels of expression of pleiotrophin and midkine in response to acute and chronic administration of morphine, yohimbine and combinations of both drugs. Yohimbine 58-67 pleiotrophin Rattus norvegicus 196-208 17157293-3 2007 The present work tries to examine a possible link between yohimbine reversal of morphine effects and pleiotrophin/midkine activation in the rat hippocampus by studying the levels of expression of pleiotrophin and midkine in response to acute and chronic administration of morphine, yohimbine and combinations of both drugs. Yohimbine 58-67 midkine Rattus norvegicus 213-220 17157293-5 2007 Chronic administration of yohimbine alone also increased midkine expression levels, whereas yohimbine and morphine administered together exhibited summatory effects on the upregulation of midkine expression levels. Yohimbine 26-35 midkine Rattus norvegicus 57-64 17157293-5 2007 Chronic administration of yohimbine alone also increased midkine expression levels, whereas yohimbine and morphine administered together exhibited summatory effects on the upregulation of midkine expression levels. Yohimbine 92-101 midkine Rattus norvegicus 188-195 17157293-6 2007 The data suggest that midkine could play a role in the prevention of opioid-induced neuroadaptations in hippocampus by yohimbine. Yohimbine 119-128 midkine Rattus norvegicus 22-29 17123717-7 2007 Yohimbine was found to efficiently prevent morphine-induced GFAP upregulation. Yohimbine 0-9 glial fibrillary acidic protein Rattus norvegicus 60-64 17115069-12 2007 Blockade of alpha(2)-adrenoceptors (1 microM rauwolscine) increased these purinergic pressor responses to 296+/-112% (1 Hz) in WT but not in alpha(2A)-KO mice. Yohimbine 45-56 adrenergic receptor, alpha 2a Mus musculus 12-34 17096083-7 2007 RESULTS: A high dose of yohimbine yielded smaller P13 amplitudes to both clicks, consistent with presynaptic action. Yohimbine 24-33 H3 histone pseudogene 6 Homo sapiens 50-53 18463421-11 2007 The inhibited lymphocyte proliferation and IFN-gamma and IL-4 production by clonidine were blocked by yohimbine, an alpha(2)-AR antagonist. Yohimbine 102-111 interferon gamma Rattus norvegicus 43-52 18463421-11 2007 The inhibited lymphocyte proliferation and IFN-gamma and IL-4 production by clonidine were blocked by yohimbine, an alpha(2)-AR antagonist. Yohimbine 102-111 interleukin 4 Rattus norvegicus 57-61 17096083-8 2007 However, a moderate yohimbine dose yielded increased P13 amplitudes to both clicks. Yohimbine 20-29 H3 histone pseudogene 6 Homo sapiens 53-56 16873606-0 2006 Tethered yohimbine analogs as selective human alpha2C-adrenergic receptor ligands. Yohimbine 9-18 adrenoceptor alpha 2C Homo sapiens 46-73 16968802-0 2006 Salivary alpha-amylase levels after yohimbine challenge in healthy men. Yohimbine 36-45 amylase alpha 1A Homo sapiens 0-22 16968802-2 2006 OBJECTIVE: The aim of this study was to assess cardiovascular effects and sAA and catecholamine secretion after iv injection of yohimbine. Yohimbine 128-137 amylase alpha 1A Homo sapiens 74-77 16968802-8 2006 RESULTS: Yohimbine induced increases of sAA activity and output in comparison to placebo (P = 0.034). Yohimbine 9-18 amylase alpha 1A Homo sapiens 40-43 16968802-11 2006 CONCLUSIONS: The results indicate that yohimbine administration activates not only autonomic parameters but also sAA via adrenergic mechanisms, suggesting that sAA might be an indirect indicator of the central sympathetic system. Yohimbine 39-48 amylase alpha 1A Homo sapiens 113-116 16968802-11 2006 CONCLUSIONS: The results indicate that yohimbine administration activates not only autonomic parameters but also sAA via adrenergic mechanisms, suggesting that sAA might be an indirect indicator of the central sympathetic system. Yohimbine 39-48 amylase alpha 1A Homo sapiens 160-163 16962210-4 2006 Angiotensin II (0.3-100 nM) enhanced tritium overflow more markedly, up to 64%, under conditions that favor alpha2-autoinhibition, observed when stimulation consisted of 100 pulses at 8 Hz, than under poor alpha2-autoinhibition conditions, only up to 14%, observed when alpha2-adrenoceptors were blocked with yohimbine (1 microM) or when stimulation consisted of 20 pulses at 50 Hz. Yohimbine 309-318 angiotensinogen Rattus norvegicus 0-14 16873606-2 2006 In an earlier report, we demonstrated that dimeric yohimbine analogs containing methylene and methylene-diglycine tethers were highly selective human alpha(2C)-AR ligands. Yohimbine 51-60 adrenoceptor alpha 2C Homo sapiens 150-162 16873606-5 2006 The profiles of pharmacological activity for the yohimbine analogs on the three human alpha(2)-AR subtypes expressed in Chinese hamster ovary cells were examined using receptor binding and cAMP inhibition assays. Yohimbine 49-58 adrenoceptor alpha 2C Homo sapiens 86-97 17045647-10 2006 Yohimbine (alpha(2)-AR antagonist) blocked only the effects exerted by Ang II on the PTZ seizure threshold in non-stressed mice. Yohimbine 0-9 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 71-77 16341025-0 2006 The anxiogenic drug yohimbine reinstates palatable food seeking in a rat relapse model: a role of CRF1 receptors. Yohimbine 20-29 corticotropin releasing hormone receptor 1 Rattus norvegicus 98-102 16341025-8 2006 The corticotropin-releasing factor1 (CRF1) receptor antagonist antalarmin attenuated the reinstatement induced by yohimbine, but not pellet priming. Yohimbine 114-123 corticotropin releasing hormone receptor 1 Rattus norvegicus 37-41 16359808-6 2006 Exposure of rats to the environmental stressors footshock, restraint or social defeat, or the pharmacological stressors yohimbine or FG-7142 increased levels of the mRNAs for c-fos and CRF in the brain in a number of areas previously shown to be responsive to stressors. Yohimbine 120-129 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 175-180 16359808-8 2006 The two stressors we have previously shown to be effective in inducing reinstatement of alcohol seeking, footshock and yohimbine, induced c-fos mRNA in the shell of the nucleus accumbens, and the basolateral and central amygdalar nuclei. Yohimbine 119-128 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 138-143 16246906-10 2005 KX-induced changes of glucoregulatory hormone levels such as insulin, GH, ACTH, and corticosterone were significantly altered by yohimbine, whereas the glucagon levels remained unaffected. Yohimbine 129-138 gonadotropin releasing hormone receptor Rattus norvegicus 70-72 16077714-7 2005 This was due to a potent stimulation of alpha2A-AR since co-incubation with NA and the alpha2-AR-inhibitor yohimbine restored NA-induced lipolysis. Yohimbine 107-116 adrenoceptor alpha 2A Homo sapiens 40-50 16077714-7 2005 This was due to a potent stimulation of alpha2A-AR since co-incubation with NA and the alpha2-AR-inhibitor yohimbine restored NA-induced lipolysis. Yohimbine 107-116 adrenoceptor alpha 2A Homo sapiens 48-50 16228990-8 2005 Retrograde neural tracing demonstrated that neurons activated by YO at 5.0 mg/kg BW included medullary and pontine neurons that project to the central nucleus of the amygdala and to the lateral bed nucleus of the stria terminalis, the latter region receiving comparatively greater input by Fos-positive neurons. Yohimbine 65-67 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 290-293 16084587-3 2005 We have shown previously that microinjection of the GAL antagonist M40 into central amygdala blocked an anxiolytic response to acute stress on the elevated plus maze when rats were pretreated with yohimbine, suggesting an anxiolytic effect of GAL. Yohimbine 197-206 galanin and GMAP prepropeptide Rattus norvegicus 52-55 16040158-2 2005 Blockade of alpha2-adrenoceptors with yohimbine (1 microM) attenuated the facilitation mediated by adenosine A 2B-receptors and by direct activation of adenylyl cyclase with forskolin but not that mediated by beta2-adrenoceptors or by direct activation of protein kinase A with 8-bromoadenosine-3",5"-cyclicAMP. Yohimbine 38-47 protein kinase cAMP-activated catalytic subunit alpha Rattus norvegicus 256-272 16085362-7 2005 In contrast, yohimbine reversed the inhibitory effects of clonidine (1 microM) on K+-evoked norepinephrine release with pIC50 (Imax) of 6.50+/-0.34 (77.6+/-10.9%); orexin A was ineffective. Yohimbine 13-22 hypocretin neuropeptide precursor Rattus norvegicus 164-172 15936527-2 2005 In the present study, we aimed to examine the potential protective effect of yohimbine, a alpha(2)-adrenoceptor antagonist, against glial fibrillary acidic protein (GFAP) alterations elicited by chronic morphine treatment. Yohimbine 77-86 glial fibrillary acidic protein Rattus norvegicus 165-169 16083388-2 2005 A total of 36 children with anxiety disorders and other children were administered yohimbine, an alpha-sub-2-adrenoreceptor antagonist, in response to which anxiety-prone children have blunted output of growth hormone. Yohimbine 83-92 growth hormone 1 Homo sapiens 203-217 15878998-7 2005 This compound could be visualized on aortic endothelial cells, and its binding could be prevented by rauwolscine, providing direct evidence for the presence of alpha(2)-adrenoceptors on the endothelium. Yohimbine 101-112 adrenergic receptor, alpha 2a Mus musculus 160-182 15878998-8 2005 Norepinephrine reduced tone in the alpha(1D)-adrenoceptor knockout and controls, an effect blocked by rauwolscine and L-NAME but not by prazosin. Yohimbine 102-113 adrenergic receptor, alpha 1d Mus musculus 35-57 15936527-4 2005 Pretreatment with yohimbine (2 mg kg(-1), i.p., 30 min before each morphine injection) provided protection against morphine-induced GFAP upregulation. Yohimbine 18-27 glial fibrillary acidic protein Rattus norvegicus 132-136 15719216-0 2005 Yohimbine disrupts prepulse inhibition in rats via action at 5-HT1A receptors, not alpha2-adrenoceptors. Yohimbine 0-9 5-hydroxytryptamine receptor 1A Rattus norvegicus 61-67 15719216-9 2005 The 5-HT1A antagonist WAY100,635 (0.1, 0.3 mg/kg) significantly prevented the yohimbine-induced disruption of PPI. Yohimbine 78-87 5-hydroxytryptamine receptor 1A Rattus norvegicus 4-10 15719216-10 2005 CONCLUSIONS: These findings indicate that (1) yohimbine disrupts PPI in rats and (2) the yohimbine-induced disruption of PPI is largely due to the 5-HT1A partial agonist properties of yohimbine. Yohimbine 89-98 5-hydroxytryptamine receptor 1A Rattus norvegicus 147-153 15719216-10 2005 CONCLUSIONS: These findings indicate that (1) yohimbine disrupts PPI in rats and (2) the yohimbine-induced disruption of PPI is largely due to the 5-HT1A partial agonist properties of yohimbine. Yohimbine 89-98 5-hydroxytryptamine receptor 1A Rattus norvegicus 147-153 15920038-0 2005 Genetic variation at the human alpha2B-adrenergic receptor locus: role in blood pressure variation and yohimbine response. Yohimbine 103-112 adrenoceptor alpha 2B Homo sapiens 31-58 15949713-9 2005 Co-administration of NE and YHB, however, significantly attenuated IL-1beta and IL-10 production. Yohimbine 28-31 interleukin 1 beta Rattus norvegicus 67-75 15949713-9 2005 Co-administration of NE and YHB, however, significantly attenuated IL-1beta and IL-10 production. Yohimbine 28-31 interleukin 10 Rattus norvegicus 80-85 15920038-3 2005 Because initial results with 173 individuals implicated a possible association of yohimbine response with genetic variation at a site in the alpha2B-AR gene, but not at sites in the other 2 alpha2-AR, we sequenced the alpha2B-AR gene (4.4 kb, including 1.2 kb upstream and 1.9 kb distal to the coding sequence) in those subjects and an additional 81 individuals to search for other alpha2B-AR variants. Yohimbine 82-91 adrenoceptor alpha 2B Homo sapiens 141-151 15920038-3 2005 Because initial results with 173 individuals implicated a possible association of yohimbine response with genetic variation at a site in the alpha2B-AR gene, but not at sites in the other 2 alpha2-AR, we sequenced the alpha2B-AR gene (4.4 kb, including 1.2 kb upstream and 1.9 kb distal to the coding sequence) in those subjects and an additional 81 individuals to search for other alpha2B-AR variants. Yohimbine 82-91 adrenoceptor alpha 2B Homo sapiens 218-228 15920038-3 2005 Because initial results with 173 individuals implicated a possible association of yohimbine response with genetic variation at a site in the alpha2B-AR gene, but not at sites in the other 2 alpha2-AR, we sequenced the alpha2B-AR gene (4.4 kb, including 1.2 kb upstream and 1.9 kb distal to the coding sequence) in those subjects and an additional 81 individuals to search for other alpha2B-AR variants. Yohimbine 82-91 adrenoceptor alpha 2B Homo sapiens 218-228 15726019-8 2005 The stimulating effect of NE on the TRH secretion was abolished by icv antagonist of adrenergic alpha2-receptor, yohimbine (40 nmol/L). Yohimbine 113-122 thyrotropin releasing hormone Rattus norvegicus 36-39 15944024-4 2005 We showed previously that enhancing stress-activation of the NE system by yohimbine (YOH) pretreatment induced the release of GAL in central amygdala (CeA) to exert an anxiolytic effect on the elevated plus-maze. Yohimbine 74-83 galanin and GMAP prepropeptide Homo sapiens 126-129 15944024-4 2005 We showed previously that enhancing stress-activation of the NE system by yohimbine (YOH) pretreatment induced the release of GAL in central amygdala (CeA) to exert an anxiolytic effect on the elevated plus-maze. Yohimbine 85-88 galanin and GMAP prepropeptide Homo sapiens 126-129 15685206-19 2005 Corynanthine produced a greater increase in nasal blockage when in combination with bradykinin compared to its combination with R-alpha-MeH. Yohimbine 0-12 kininogen 1 Homo sapiens 84-94 15716703-7 2005 However, treatment with yohimbine (an alpha2-adrenoreceptor antagonist, 5 mg/kg per day) significantly increased CGRP level and vascular NGF content. Yohimbine 24-33 calcitonin-related polypeptide alpha Rattus norvegicus 113-117 15716703-8 2005 Combined administration of prazosin and yohimbine not only significantly elevated the synthesis and release of CGRP and arterial NGF content, but also completely normalized blood pressure. Yohimbine 40-49 calcitonin-related polypeptide alpha Rattus norvegicus 111-115 15639000-6 2005 The same dose of trazodone, a chloropiperazinylbenzene-type antidepressant, and yohimbine, an alpha(2)-adrenoceptor antagonist, reduced IL-1beta and TNF-alpha, but it could not inhibit hyperglycaemia. Yohimbine 80-89 interleukin 1 beta Rattus norvegicus 136-144 15639000-6 2005 The same dose of trazodone, a chloropiperazinylbenzene-type antidepressant, and yohimbine, an alpha(2)-adrenoceptor antagonist, reduced IL-1beta and TNF-alpha, but it could not inhibit hyperglycaemia. Yohimbine 80-89 tumor necrosis factor Rattus norvegicus 149-158 15205164-5 2004 Periarterial nerve stimulation in the presence of both l-NAME and yohimbine prevented the previously observed decrease in NPY, indicating that the cause of this decrease was, as predicted, due to alpha(2)-adrenoceptor activation. Yohimbine 66-75 neuropeptide Y Rattus norvegicus 122-125 15288580-3 2004 administration of methysergide (3 and 10 microg) and yohimbine (3 microg), but not of prazosin (0.3 and 1 microg) prevented the antinociceptive action of MPCA and PPCA (500 micromol/kg, s.c.). Yohimbine 53-62 cathepsin A Mus musculus 163-167 15331355-11 2004 Intestinal manipulation resulted in significant iNOS mRNA induction in the intestinal muscularis, which was markedly attenuated after yohimbine treatment. Yohimbine 134-143 nitric oxide synthase 2 Rattus norvegicus 48-52 15262904-6 2004 Blockade of norepinephrine transporter or alpha2-adrenoceptors using desipramine or rauwolscine reduced the losartan-induced shifts in the ED50 values of noradrenaline by 63% and 21%, respectively. Yohimbine 84-95 solute carrier family 6 member 2 Rattus norvegicus 12-38 12871653-2 2003 The memory enhancing action of noradrenaline injected into the basal ganglia (lobus parolfactorius-LPO) was reduced in the presence of the alpha(2)-adrenoceptor antagonist yohimbine, but when noradrenaline was injected into the multi-modal association area (intermediate medial hyperstriatum ventrale-IMHV), yohimbine failed to prevent memory enhancement. Yohimbine 172-181 lactoperoxidase Gallus gallus 99-102 15249992-10 2004 However, pre-treatment with alpha2-adrenoceptor antagonist, yohimbine (1 mg/kg intraperitoneally), 20 min before naloxone administration to morphine-dependent rats antagonized Fos expression and the enhancement of NA turnover in the heart. Yohimbine 60-69 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 176-179 14978721-8 2004 Feeding Tbetah(nM18) larvae yohimbine, an agent that inhibits the activity of Drosophila tyramine receptors, also improved some locomotion parameters. Yohimbine 28-37 Tyramine beta hydroxylase Drosophila melanogaster 8-14 14625151-2 2003 We previously reported that baseline plasma neuropeptide-Y levels, as well as neuropeptide-Y responses to yohimbine, were lower in combat veterans with posttraumatic stress disorder, but we were unable to determine whether this was attributable to posttraumatic stress disorder or trauma exposure. Yohimbine 106-115 neuropeptide Y Homo sapiens 78-92 12871653-4 2003 The timing of the inhibitory effect of yohimbine in the LPO suggested that alpha(2)-adrenoceptor involvement occurs 10-15 min after training, and that stimulation of alpha(2)-ARs in LPO is necessary for subsequent consolidation of memory. Yohimbine 39-48 lactoperoxidase Gallus gallus 56-59 15289791-0 2004 Human sympathetic activation by alpha2-adrenergic blockade with yohimbine: Bimodal, epistatic influence of cytochrome P450-mediated drug metabolism. Yohimbine 64-73 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 107-122 15289791-16 2004 CONCLUSIONS: We conclude that heterogeneous, bimodally distributed yohimbine metabolism depends on common genetic variation in both CYP2D6 and CYP3A4 and contributes to differences in sympathetic neuronal response to alpha2-blockade. Yohimbine 67-76 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 132-138 15289791-16 2004 CONCLUSIONS: We conclude that heterogeneous, bimodally distributed yohimbine metabolism depends on common genetic variation in both CYP2D6 and CYP3A4 and contributes to differences in sympathetic neuronal response to alpha2-blockade. Yohimbine 67-76 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 143-149 14757119-0 2004 Yohimbine inhibits firing activities of rat dorsal root ganglion neurons by blocking Na+ channels and vanilloid VR1 receptors. Yohimbine 0-9 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 112-115 14757119-5 2004 We found that yohimbine inhibited tetrodotoxin-sensitive Na(+) channels (Na(V)1.2), the tetrodotoxin-resistant Na(+) channels, including both slow inactivating (Na(V)1.8) and persistent (Na(V)1.9) Na(+) channels, and capsaicin-sensitive vanilloid VR1 receptors. Yohimbine 14-23 sodium voltage-gated channel alpha subunit 10 Rattus norvegicus 161-169 14757119-5 2004 We found that yohimbine inhibited tetrodotoxin-sensitive Na(+) channels (Na(V)1.2), the tetrodotoxin-resistant Na(+) channels, including both slow inactivating (Na(V)1.8) and persistent (Na(V)1.9) Na(+) channels, and capsaicin-sensitive vanilloid VR1 receptors. Yohimbine 14-23 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 247-250 15143490-3 2004 Phentolamine, prazosin eliminated the simulative effect of TRH, yohimbine resulted in additional gain of effect, which seems to testify 1) presynaptic action of TRH or 2) increase of the output of norepinephrine, which is potentiated by alpha 2-adrenoceptor antagonists. Yohimbine 64-73 thyrotropin releasing hormone Rattus norvegicus 59-62 15143490-3 2004 Phentolamine, prazosin eliminated the simulative effect of TRH, yohimbine resulted in additional gain of effect, which seems to testify 1) presynaptic action of TRH or 2) increase of the output of norepinephrine, which is potentiated by alpha 2-adrenoceptor antagonists. Yohimbine 64-73 thyrotropin releasing hormone Rattus norvegicus 161-164 12871653-4 2003 The timing of the inhibitory effect of yohimbine in the LPO suggested that alpha(2)-adrenoceptor involvement occurs 10-15 min after training, and that stimulation of alpha(2)-ARs in LPO is necessary for subsequent consolidation of memory. Yohimbine 39-48 lactoperoxidase Gallus gallus 182-185 12871653-2 2003 The memory enhancing action of noradrenaline injected into the basal ganglia (lobus parolfactorius-LPO) was reduced in the presence of the alpha(2)-adrenoceptor antagonist yohimbine, but when noradrenaline was injected into the multi-modal association area (intermediate medial hyperstriatum ventrale-IMHV), yohimbine failed to prevent memory enhancement. Yohimbine 308-317 lactoperoxidase Gallus gallus 99-102 12871653-3 2003 Yohimbine injected into the LPO prevented, whereas the alpha(2)-adrenoceptor agonists oxymetazoline and clonidine enhanced, consolidation of memory. Yohimbine 0-9 lactoperoxidase Gallus gallus 28-31 12584108-9 2003 Administration of yohimbine (4 mg/kg), an alpha(2)-adrenergic receptor antagonist, also abolished NMU-induced acid inhibition (P < 0.01). Yohimbine 18-27 neuromedin U Rattus norvegicus 98-101 12730340-7 2003 In addition, the inhibition of the EPSC amplitude induced by NPY, but not PYY, was attenuated partially by pretreatment with the alpha2 adrenoceptor antagonist yohimbine (10 micro M), and occluded partially by the alpha2 adrenoceptor agonist UK14,304 (10 micro M) as well as by pretreatment with reserpine. Yohimbine 160-169 neuropeptide Y Rattus norvegicus 61-64 12730340-8 2003 Pretreatment with a combination of BIBP3226 and yohimbine almost completely antagonized the NPY-mediated effects on EPSCs. Yohimbine 48-57 neuropeptide Y Rattus norvegicus 92-95 12595959-10 2003 However, in the presence of yohimbine, atropine shifted the Ang II-induced curves to the right of the control curve with no E(max) decrease. Yohimbine 28-37 angiotensinogen Rattus norvegicus 60-66 12626658-10 2003 UK14304-mediated inhibition of SERT function was yohimbine-sensitive, as was inhibition triggered by norepinephrine, and was abolished in the absence of added Ca2+. Yohimbine 49-58 solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 Mus musculus 31-35 12721093-14 2003 Rauwolscine and phentolamine increased tritium overflow evoked by 120 pulses at 3 Hz up to seven-fold in WT and alpha(2B)KO tissues, three-fold in alpha(2A)KO and alpha(2C)KO tissues, and two-fold in alpha(2AC)KO tissues. Yohimbine 0-11 adrenergic receptor, alpha 2b Mus musculus 112-120 12721093-14 2003 Rauwolscine and phentolamine increased tritium overflow evoked by 120 pulses at 3 Hz up to seven-fold in WT and alpha(2B)KO tissues, three-fold in alpha(2A)KO and alpha(2C)KO tissues, and two-fold in alpha(2AC)KO tissues. Yohimbine 0-11 adrenergic receptor, alpha 2a Mus musculus 147-155 12721093-14 2003 Rauwolscine and phentolamine increased tritium overflow evoked by 120 pulses at 3 Hz up to seven-fold in WT and alpha(2B)KO tissues, three-fold in alpha(2A)KO and alpha(2C)KO tissues, and two-fold in alpha(2AC)KO tissues. Yohimbine 0-11 adrenergic receptor, alpha 2c Mus musculus 163-171 12591093-7 2003 Yohimbine and idazoxan were the most potent alpha(2A)-adrenoceptor antagonists, yohimbine and iloperidone were the most potent alpha(2C)-adrenoceptor antagonists, and haloperidol and olanzapine were the most potent dopamine D(2) receptor antagonists. Yohimbine 0-9 adrenoceptor alpha 2A Homo sapiens 44-66 12654340-6 2003 In addition, dramatic increases in [(3)H]rauwolscine binding were seen in the nerve layer of the olfactory bulb, the molecular layer of the cerebellum, and the ventricular system of alpha(2C)-AR-overexpressing mice, representing "ectopic" alpha(2C)-AR expression. Yohimbine 41-52 adrenergic receptor, alpha 2c Mus musculus 182-190 12511226-5 2003 RESULTS: Platelet aggregation mediated by subthreshold concentrations of PAF (5-8 nmol/L) plus epinephrine (0.5-2 micromol/L) was inhibited by ?2-receptor blocker, yohimbine, and PAF receptor antagonist WEB 2086. Yohimbine 164-173 PCNA clamp associated factor Homo sapiens 73-76 12511226-5 2003 RESULTS: Platelet aggregation mediated by subthreshold concentrations of PAF (5-8 nmol/L) plus epinephrine (0.5-2 micromol/L) was inhibited by ?2-receptor blocker, yohimbine, and PAF receptor antagonist WEB 2086. Yohimbine 164-173 PCNA clamp associated factor Homo sapiens 179-182 12654340-4 2003 In control mice, [(3)H]rauwolscine binding was most abundant in the olfactory tubercle, accumbens and caudate putamen nuclei, and in the CA1 field of the hippocampus. Yohimbine 23-34 carbonic anhydrase 1 Mus musculus 137-140 12528832-6 2003 Yohimbine caused prolonged increases in plasma norepinephrine and insulin levels compared to atipamezole, possibly because of its longer half-life elimination. Yohimbine 0-9 insulin Canis lupus familiaris 66-73 12619890-10 2003 It further increased up to 48 h. The effect of NE on IL-6 mRNA was abolished by the beta-adrenoceptor blockers propranolol, metoprolol (beta1) and ICI 118.551 (beta2), but not by the alpha-adrenoceptor blockers prazosin (alpha1) and yohimbine (alpha2). Yohimbine 233-242 interleukin 6 Rattus norvegicus 53-57 12654340-5 2003 A mouse strain with overexpression of alpha(2C)-AR regulated by a gene-specific promoter showed approximately two- to four-fold increased levels of [(3)H]rauwolscine binding in these regions. Yohimbine 154-165 adrenergic receptor, alpha 2c Mus musculus 38-50 12654340-6 2003 In addition, dramatic increases in [(3)H]rauwolscine binding were seen in the nerve layer of the olfactory bulb, the molecular layer of the cerebellum, and the ventricular system of alpha(2C)-AR-overexpressing mice, representing "ectopic" alpha(2C)-AR expression. Yohimbine 41-52 adrenergic receptor, alpha 2c Mus musculus 239-247 12185387-5 2002 Pretreatment with 80 nmol/ micro l yohimbine or prazosin into the MSA also reduced the ANGII-induced water intake (3.0 +/- 0.4 and 3.1 +/- 0.2 ml/120 min, respectively). Yohimbine 35-44 angiotensinogen Rattus norvegicus 87-92 12438517-0 2002 Yohimbine dimers exhibiting selectivity for the human alpha 2C-adrenoceptor subtype. Yohimbine 0-9 adrenoceptor alpha 2C Homo sapiens 54-75 12438517-3 2002 Initial studies showed that yohimbine was about 4- and 15-fold more selective for the human alpha2C-adrenoceptor in comparison with the alpha2A- and alpha2B-adrenoceptors, respectively. Yohimbine 28-37 adrenoceptor alpha 2C Homo sapiens 92-112 12438517-9 2002 These findings demonstrate that the addition of spacer linkages to bivalent yohimbine molecules provides a successful approach to the development of ligands that are potent and highly selective for the alpha2C-adrenoceptor. Yohimbine 76-85 adrenoceptor alpha 2C Homo sapiens 202-222 12185387-6 2002 Yohimbine + prazosin + clonidine injected into the MSA abolished the ANGII-induced water intake (0.2 +/- 0.1 and 0.2 +/- 0.1 ml/120 min, respectively). Yohimbine 0-9 angiotensinogen Rattus norvegicus 69-74 12185387-10 2002 Yohimbine injected into the MSA also abolished the inhibitory effects of ANGII. Yohimbine 0-9 angiotensinogen Rattus norvegicus 73-78 12185387-11 2002 Yohimbine + clonidine attenuated the inhibitory effects of ANGII. Yohimbine 0-9 angiotensinogen Rattus norvegicus 59-64 12152120-4 2002 We essentially found that yohimbine not only blocks contractions induced by adrenergic agonists, but also by non-adrenergic substances, such as ET-1. Yohimbine 26-35 endothelin-1 Oryctolagus cuniculus 144-148 12152120-6 2002 Conversely, our data suggest that yohimbine counteracts ET-1-induced contractions by interfering with NO release from the endothelium. Yohimbine 34-43 endothelin-1 Oryctolagus cuniculus 56-60 12323115-6 2002 Pre-exercise yohimbine administration has the potential to down-regulate the lipoprotein lipase activity of visceral adipocytes, increase lipolysis in refractory gynoid fat depots, and improve the impaired lipolytic response to exercise in the elderly. Yohimbine 13-22 lipoprotein lipase Homo sapiens 77-95 12034375-3 2002 Berberine-induced IL-12 p40 production and activation of p38 mitogen-activated protein kinase (MAPK) in dose-dependent manners, which were significantly inhibited by p38 MAPK inhibitors and yohimbine, indicating that p38 MAPK and alpha(2)-adrenergic receptor were involved in the induction of IL-12 p40 production in mouse macrophages by berberine. Yohimbine 190-199 interleukin 12b Mus musculus 24-27 12034375-3 2002 Berberine-induced IL-12 p40 production and activation of p38 mitogen-activated protein kinase (MAPK) in dose-dependent manners, which were significantly inhibited by p38 MAPK inhibitors and yohimbine, indicating that p38 MAPK and alpha(2)-adrenergic receptor were involved in the induction of IL-12 p40 production in mouse macrophages by berberine. Yohimbine 190-199 mitogen-activated protein kinase 14 Mus musculus 57-60 12034375-3 2002 Berberine-induced IL-12 p40 production and activation of p38 mitogen-activated protein kinase (MAPK) in dose-dependent manners, which were significantly inhibited by p38 MAPK inhibitors and yohimbine, indicating that p38 MAPK and alpha(2)-adrenergic receptor were involved in the induction of IL-12 p40 production in mouse macrophages by berberine. Yohimbine 190-199 interleukin 12b Mus musculus 299-302 11999719-5 2002 Treatment with prazosin and yohimbine prevented the pheromonal restoration of cyclic activity, the drop of LHRH and the rise of plasma concentration of the studied hormones induced by male urine, while saline or propranolol did not. Yohimbine 28-37 gonadotropin releasing hormone 1 Rattus norvegicus 107-111 11804625-6 2002 The alpha 2-adrenoceptor antagonist, yohimbine, also reduced Ang II-stimulated transcription factors significantly in both nuclei. Yohimbine 37-46 angiotensinogen Rattus norvegicus 61-67 11830175-5 2002 However, yohimbine pretreatment before stress produced a paradoxical anxiolytic response, which we hypothesized was attributable to galanin release in CeA. Yohimbine 9-18 carcinoembryonic antigen gene family 4 Rattus norvegicus 151-154 11830175-6 2002 Microdialysis verified that yohimbine amplified NE release in CeA during immobilization stress, and also showed that whereas there was no detectable change in galanin release in CeA during stress alone, there was an increase during immobilization stress after yohimbine pretreatment. Yohimbine 28-37 carcinoembryonic antigen gene family 4 Rattus norvegicus 62-65 11818770-8 2002 The alpha2-adrenoceptor antagonist yohimbine inhibited isoflurane antinociception, and this effect was mediated by spinal alpha2 adrenoceptors. Yohimbine 35-44 adrenergic receptor, alpha 2a Mus musculus 122-142 11819028-6 2002 The alpha(2)-adrenoceptor antagonist yohimbine (0.2 mg/kg) significantly elevated both basal plasma levels and the nerve stimulation-evoked overflow of noradrenaline and NPY-LI. Yohimbine 37-46 neuropeptide Y Sus scrofa 170-173 12222743-8 2002 Liver UCP2 mRNA expression was significantly decreased by yohimbine (p < 0.05). Yohimbine 58-67 uncoupling protein 2 Rattus norvegicus 6-10 12020040-4 2002 The comparative biochemical studies using specific agonist (clonidine) and antagonist (yohimbine) of alpha2-adrenergic receptors ligands have shown that observed biochemical effects were similar to those produced by alpha2-adrenergic antagonist, yohimbine. Yohimbine 87-96 UDP glucuronosyltransferase 1 family, polypeptide A7C Rattus norvegicus 101-107 11903811-5 2002 Under short days, treatment with WB4101 (alpha-1 adenoceptor antagonist), and rauwolscine (alpha-2 antagonist), consistently increased PRL secretion in control, but not in HPD rams. Yohimbine 78-89 prolactin Ovis aries 135-138 11476962-6 2001 Moreover, the effects of NE and yohimbine on TNF-alpha production was further examined using an isolated perfused liver preparation. Yohimbine 32-41 tumor necrosis factor Rattus norvegicus 45-54 11534851-11 2001 When a greater degree of autoinhibition was produced in atria and vasa deferentia by stimulation with 120 pulses, both disruption of the alpha2A/D gene and disruption of the alpha2C gene but not disruption of the alpha2B gene attenuated the overflow-enhancing effects of phentolamine and rauwolscine. Yohimbine 288-299 adrenergic receptor, alpha 2c Mus musculus 174-181 11534851-13 2001 In alpha2A/DKO atria and vasa deferentia, the relative potencies of phentolamine and rauwolscine indicated that the autoinhibition-mediating receptors were alpha2C, whereas in alpha2CKO atria and vasa deferentia the relative potencies indicated that the autoinhibition-mediating receptors were alpha2D. Yohimbine 85-96 adrenergic receptor, alpha 2c Mus musculus 156-163 11461172-8 2001 Beta-adrenergic activity suppresses transcription of LPL in adipocytes; this phenomenon may contribute to the favorable impact of exercise training on visceral obesity; conceivably, preadministration of safe drugs that boost catecholamine activity (caffeine, yohimbine) could potentiate this beneficial effect of exercise. Yohimbine 259-268 lipoprotein lipase Homo sapiens 53-56 11476962-8 2001 Similarly, intraportal infusion of NE in vivo or in isolated livers increased TNF-alpha synthesis and release which was inhibited by co-infusion of yohimbine. Yohimbine 148-157 tumor necrosis factor Rattus norvegicus 78-87 11476962-9 2001 Furthermore, the increased cellular levels of TNF-alpha in Kupffer cells after in vivo administration of NE was also blocked by yohimbine. Yohimbine 128-137 tumor necrosis factor Rattus norvegicus 46-55 18968085-10 2000 Isoproterenol, yohimbine, diphenhydramine, chlorpromazine and atropine, which activate AdC and hinder Ca-PPI, cause conformational changes of albumin similar to basic transitions. Yohimbine 15-24 albumin Homo sapiens 142-149 11880925-6 2001 This Leu-Enk-evoked insulin release was significantly (p < 0.05) blocked by atropine, naloxone and yohimbine (all at 10(-6)M). Yohimbine 102-111 proenkephalin Rattus norvegicus 9-12 11880925-8 2001 Atropine, yohimbine but not naloxone significantly (p < 0.05) inhibited Leu-Enk-evoked glucagon release from normal rat pancreas. Yohimbine 10-19 proenkephalin Rattus norvegicus 79-82 11247759-7 2001 CVC at Yoh-PR sites was significantly reduced beginning at TSK of 33.0 +/- 0.01 degrees C (P < 0.05). Yohimbine 7-10 tsukushi, small leucine rich proteoglycan Homo sapiens 59-62 11259564-6 2001 The antinociceptive response to [Dmt1]DALDA was significantly attenuated by the alpha(2)-adrenergic antagonist yohimbine. Yohimbine 111-120 RoBo-1 Rattus norvegicus 33-37 11095445-4 2000 We hypothesized that yohimbine (an alpha2-adrenergic antagonist) would have stimulatory action on non-HPA CRH neurons, whereas naloxone (a mu-opioid receptor antagonist) would not have this effect. Yohimbine 21-30 corticotropin releasing hormone Homo sapiens 106-109 11095445-9 2000 Although yohimbine robustly increased CSF NE levels and appeared to increase CSF CRH levels, these effects were not seen after naloxone or placebo administration. Yohimbine 9-18 corticotropin releasing hormone Homo sapiens 81-84 11095445-12 2000 Although both yohimbine and naloxone stimulated the HPA axis, only yohimbine appeared to have stimulatory effects on central NE and non-HPA CRH. Yohimbine 67-76 corticotropin releasing hormone Homo sapiens 140-143 11023712-2 2000 We found that platelet aggregation mediated by subthreshold concentrations of histamine (1-4 microm) plus adrenaline (0.5-2 microm) is inhibited by both an alpha(2)-adrenoceptor blocker (yohimbine) and a histamine (H1) receptor antagonist (diphenhydramine). Yohimbine 187-196 histamine receptor H1 Homo sapiens 204-227 10985598-8 2000 Mean maximal binding (Bmax) of the alpha2-adrenoceptor antagonist [3H]rauwolscine to platelet membranes was significantly reduced (P < 0.001) after exposure to chronic hypoxia [SLB: 172.6 (48.5) fmol x mg(-1) protein versus SLA: 136.8 (56.1) fmol x mg(-1) protein] without change in the dissociation constant (K(D)). Yohimbine 70-81 Src like adaptor Homo sapiens 227-230 10974488-7 2000 The injection of yohimbine (an alpha-2-adrenergic antagonist) and prazosin (an alpha-1-adrenergic antagonist) into the LH, which was done before injecting ANGII into the LV, also reduced the water intake induced by ANGII. Yohimbine 17-26 angiotensinogen Rattus norvegicus 215-220 10974488-9 2000 Previous treatment with clonidine attenuated the action of ANGII in reducing the sodium, potassium and urinary volume, whereas previous treatment with yohimbine attenuated the effects of ANGII but with less intensity than that caused by clonidine. Yohimbine 151-160 angiotensinogen Rattus norvegicus 187-192 10974488-11 2000 The injection of yohimbine and prazosin, which was done before the injection of clonidine, attenuated the effect of clonidine on the ANGII mechanism. Yohimbine 17-26 angiotensinogen Rattus norvegicus 133-138 11131179-8 2000 The effects of IMB on the P13 potential were reduced by pre-treatment with the alpha-2 adrenergic receptor blocker yohimbine (YOH). Yohimbine 115-124 H3 histone pseudogene 6 Homo sapiens 26-29 11131179-8 2000 The effects of IMB on the P13 potential were reduced by pre-treatment with the alpha-2 adrenergic receptor blocker yohimbine (YOH). Yohimbine 126-129 H3 histone pseudogene 6 Homo sapiens 26-29 10886521-0 2000 Downregulation of tyrosinase activity in human melanocyte cell cultures by yohimbine. Yohimbine 75-84 tyrosinase Homo sapiens 18-28 10910785-5 2000 Yohimbine-stimulated Deltamax growth hormone (GH) for children with anxiety disorders (mean=-1.5 ng/ml, SD=5.9) was significantly reduced compared to that of normal comparison children (mean=2.7 ng/ml, SD=4.5). Yohimbine 0-9 growth hormone 1 Homo sapiens 30-44 10949101-3 2000 METHODS: Using PET, the CBF changes after intravenous yohimbine, an alpha2-adrenoreceptor antagonist that produces adrenergic activation, were compared with placebo in nine healthy humans. Yohimbine 54-63 CCAAT enhancer binding protein zeta Homo sapiens 24-27 10949101-6 2000 Among scan results, yohimbine produced a significant decrease in whole-brain absolute CBF; regional decreases were greatest in cortical areas. Yohimbine 20-29 CCAAT enhancer binding protein zeta Homo sapiens 86-89 10856266-11 2000 Plasma ANP was dose-dependently increased by moxonidine and was inhibited by pretreatment with efaroxan (220.8+/-36.9 versus 100.3+/-31.7 pg/mL, P<0.03) but not by yohimbine. Yohimbine 167-176 natriuretic peptide A Rattus norvegicus 7-10 10825384-7 2000 On the other hand, benazoline and other I(1) receptor-selective imidazolines decreased forskolin-stimulated cAMP level in the cells expressing I(1)R, in a rauwolscine- and pertussis toxin-insensitive manner. Yohimbine 155-166 nischarin Rattus norvegicus 143-148 10718926-4 2000 The in-vitro prolactin release-inhibiting effect of noradrenaline (10-7 mol/l) was not blocked by the dopamine antagonists pimozide (D2) or SCH23390 (D1) but was blocked by each of the adrenoceptor antagonists (alpha1-adrenoceptor antagonists prazosin and WB4101, the alpha2-adrenoceptor antagonist yohimbine and the beta-adrenoceptor antagonist propranolol). Yohimbine 299-308 prolactin Ovis aries 13-22 10742288-8 2000 The selective alpha(2)-adrenoceptor ligand rauwolscine antagonized acidification rate changes with an affinity independent of the agonist used; the affinity (mean pK(B)) against noradrenaline was 8.43. Yohimbine 43-54 AKT serine/threonine kinase 1 Homo sapiens 163-168 10733010-4 2000 The 5-HT2B agonist alpha-methyl 5-HT (40 nM) produced rapid transient increases in [Ca2+]i in astrocytes from all three brain regions studied, and these responses were blocked by the selective 5-HT2B antagonist rauwolscine (1 microM). Yohimbine 211-222 5-hydroxytryptamine receptor 2B Rattus norvegicus 4-10 10762283-9 2000 Compared to the control test, however, the ACTH response to the CRH + AVP test performed during yohimbine infusion significantly decreased in the control subjects whereas a tendency to a further increase occurred in the obese groups and, specifically, in the A-BFD group significantly (P < 0.05) more than in the P-BFD group. Yohimbine 96-105 corticotropin releasing hormone Homo sapiens 64-67 10733010-4 2000 The 5-HT2B agonist alpha-methyl 5-HT (40 nM) produced rapid transient increases in [Ca2+]i in astrocytes from all three brain regions studied, and these responses were blocked by the selective 5-HT2B antagonist rauwolscine (1 microM). Yohimbine 211-222 5-hydroxytryptamine receptor 2B Rattus norvegicus 193-199 10231022-4 1999 The synergistic interaction of 5-HT (1-5 microM) and epinephrine (0.5-2 microM) was inhibited by alpha2-adrenoceptor blocker (yohimbine; IC50= 0.4 microM), calcium channel blockers (verapamil and diltiazem with IC50 of 10 and 48 mM, respectively), PLC inhibitor (U73122; IC50=6 microM) and nitric oxide (NO) donor, SNAP (IC50=1.6 microM)). Yohimbine 126-135 heparan sulfate proteoglycan 2 Homo sapiens 248-251 10715359-0 2000 Low baseline and yohimbine-stimulated plasma neuropeptide Y (NPY) levels in combat-related PTSD. Yohimbine 17-26 neuropeptide Y Homo sapiens 45-59 10715359-0 2000 Low baseline and yohimbine-stimulated plasma neuropeptide Y (NPY) levels in combat-related PTSD. Yohimbine 17-26 neuropeptide Y Homo sapiens 61-64 10715359-3 2000 METHODS: In the following study, plasma NPY responses to yohimbine and placebo were measured in a subgroup of 18 subjects with PTSD and 8 healthy control subjects who participated in the previous study of the effect of yohimbine on plasma MHPG. Yohimbine 57-66 neuropeptide Y Homo sapiens 40-43 10715359-4 2000 RESULTS: The PTSD subjects had lower baseline plasma NPY and blunted yohimbine-stimulated increases in plasma NPY compared with the healthy control subjects. Yohimbine 69-78 neuropeptide Y Homo sapiens 110-113 10789888-2 2000 However, yohimbine is also an agonist at serotonin (5-HT)1A receptors, suggesting the possibility that the antinociceptive effects of yohimbine might be mediated via these receptors. Yohimbine 9-18 5-hydroxytryptamine receptor 1A Rattus norvegicus 52-59 10789888-2 2000 However, yohimbine is also an agonist at serotonin (5-HT)1A receptors, suggesting the possibility that the antinociceptive effects of yohimbine might be mediated via these receptors. Yohimbine 134-143 5-hydroxytryptamine receptor 1A Rattus norvegicus 52-59 10651985-0 2000 Downregulation of tyrosinase activity in human melanocyte cell cultures by yohimbine. Yohimbine 75-84 tyrosinase Homo sapiens 18-28 10651985-1 2000 Treatment of human melanocyte cell cultures with the alpha-2 adrenergic receptor antagonist yohimbine results in a marked down-regulation of tyrosinase activity. Yohimbine 92-101 tyrosinase Homo sapiens 141-151 10651985-4 2000 The yohimbine-induced decrease in tyrosinase activity is reversible, with enzyme levels returning to 90% of control values 48 h after removal of drug. Yohimbine 4-13 tyrosinase Homo sapiens 34-44 10651985-5 2000 Although tyrosinase activity is markedly suppressed by yohimbine, the compound has no effect on cell proliferation, cellular translation, or DNA synthesis. Yohimbine 55-64 tyrosinase Homo sapiens 9-19 10651985-6 2000 Treatment of melanocyte cultures with yohimbine blocks the increase in tyrosinase activity by either 3-isobutyl-1-methylxanthine, dibutyryl cAMP, or forskolin. Yohimbine 38-47 tyrosinase Homo sapiens 71-81 10651985-8 2000 Tyrosinase inhibition by yohimbine does not involve a decrease in substrate availability since tyrosine uptake studies show that yohimbine has no effect on the amount of tyrosine entering the cell. Yohimbine 25-34 tyrosinase Homo sapiens 0-10 10651985-12 2000 These findings suggest that yohimbine acts through an as yet unidentified signaling pathway to lower the catalytic activity of pre-existing tyrosinase molecules present in melanocytes. Yohimbine 28-37 tyrosinase Homo sapiens 140-150 10891619-9 2000 In summary, each of the anxiogenic drugs tested (FG-7142, yohimbine, m-chlorophenyl piperazine, caffeine and BOC-CCK(4)) increased Fos expression in a restricted number of hindbrain regions, including the periaqueductal gray and locus coeruleus. Yohimbine 58-67 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 131-134 10629439-2 2000 Pretreatment with the PKC activator phorbol dibutyrate revealed an agonist-stimulated PLD activity which was blocked by the alpha(2)-receptor-selective antagonist rauwolscine and by pertussis toxin treatment. Yohimbine 163-174 protein kinase C, gamma Rattus norvegicus 22-25 10215671-6 1999 Yohimbine did not significantly influence most parameters but significantly potentiated the rise in insulin, blunted the increase in glucose, and prevented the fall in noradrenaline. Yohimbine 0-9 insulin Homo sapiens 100-107 10492004-5 1999 Importantly, TrkB activation was also observed following pharmacological activation of brain-stem noradrenergic neurons, which synthesize and anterogradely transport BDNF; treatment with yohimbine led to activation of cortical TrkB receptors within 30 min. Yohimbine 187-196 neurotrophic receptor tyrosine kinase 2 Homo sapiens 13-17 10492004-5 1999 Importantly, TrkB activation was also observed following pharmacological activation of brain-stem noradrenergic neurons, which synthesize and anterogradely transport BDNF; treatment with yohimbine led to activation of cortical TrkB receptors within 30 min. Yohimbine 187-196 brain derived neurotrophic factor Homo sapiens 166-170 10492004-5 1999 Importantly, TrkB activation was also observed following pharmacological activation of brain-stem noradrenergic neurons, which synthesize and anterogradely transport BDNF; treatment with yohimbine led to activation of cortical TrkB receptors within 30 min. Yohimbine 187-196 neurotrophic receptor tyrosine kinase 2 Homo sapiens 227-231 10611634-5 2000 In vivo, agonist actions of yohimbine at 5-HT(1A) sites are revealed by WAY100,635-reversible induction of hypothermia in the rat. Yohimbine 28-37 5-hydroxytryptamine receptor 1A Rattus norvegicus 41-48 10611634-6 2000 In guinea pigs, antagonist actions of yohimbine at 5-HT(1B) receptors are revealed by blockade of hypothermia evoked by the 5-HT(1B) agonist, GR46,611. Yohimbine 38-47 5-hydroxytryptamine receptor 1B Rattus norvegicus 51-58 10611634-6 2000 In guinea pigs, antagonist actions of yohimbine at 5-HT(1B) receptors are revealed by blockade of hypothermia evoked by the 5-HT(1B) agonist, GR46,611. Yohimbine 38-47 5-hydroxytryptamine receptor 1B Rattus norvegicus 124-131 10611634-15 2000 However, in contrast to the selective alpha(2)-AR antagonist, fluparoxan, the 5-HT(1A) agonist actions of yohimbine suppress 5-HT levels alone and underlie its inability to augment the influence of fluoxetine upon 5-HT levels. Yohimbine 106-115 5-hydroxytryptamine receptor 1A Rattus norvegicus 78-85 10457081-8 1999 Pretreating the tissues with the 5-HT1B-selective antagonist isamoltane (200 microM) and the 5-HT2B-selective antagonist rauwolscine (200 microM) inhibited the rapid transient phase by 55 and 45 %, whereas the sustained phase could only be blocked by rauwolscine. Yohimbine 121-132 5-hydroxytryptamine receptor 2B Rattus norvegicus 93-99 10457081-8 1999 Pretreating the tissues with the 5-HT1B-selective antagonist isamoltane (200 microM) and the 5-HT2B-selective antagonist rauwolscine (200 microM) inhibited the rapid transient phase by 55 and 45 %, whereas the sustained phase could only be blocked by rauwolscine. Yohimbine 251-262 5-hydroxytryptamine receptor 2B Rattus norvegicus 93-99 10221756-0 1999 Prevention by 5-HT1A receptor agonists of restraint stress- and yohimbine-induced release of cholecystokinin in the frontal cortex of the freely moving rat. Yohimbine 64-73 5-hydroxytryptamine receptor 1A Rattus norvegicus 14-20 10221756-0 1999 Prevention by 5-HT1A receptor agonists of restraint stress- and yohimbine-induced release of cholecystokinin in the frontal cortex of the freely moving rat. Yohimbine 64-73 cholecystokinin Rattus norvegicus 93-108 10221756-1 1999 In line with the idea that cholecystokinin (CCK) is involved in anxiety-related behaviours, previous investigations showed that stressful conditions and an "anxiogenic" drug, yohimbine, increased the cortical release of CCK like-material (CCKLM) in awake rats, and that this effect could be prevented by diazepam. Yohimbine 175-184 cholecystokinin Rattus norvegicus 27-42 10221756-1 1999 In line with the idea that cholecystokinin (CCK) is involved in anxiety-related behaviours, previous investigations showed that stressful conditions and an "anxiogenic" drug, yohimbine, increased the cortical release of CCK like-material (CCKLM) in awake rats, and that this effect could be prevented by diazepam. Yohimbine 175-184 cholecystokinin Rattus norvegicus 44-47 10221756-1 1999 In line with the idea that cholecystokinin (CCK) is involved in anxiety-related behaviours, previous investigations showed that stressful conditions and an "anxiogenic" drug, yohimbine, increased the cortical release of CCK like-material (CCKLM) in awake rats, and that this effect could be prevented by diazepam. Yohimbine 175-184 cholecystokinin Rattus norvegicus 220-223 26735121-6 1998 Co-treatment with yohimbine dissolved in the tap water (70 mg/l) decreased the number of jumps upon naloxone challenge, an effect which did not seem to be related with a sedative or toxic effect of the drug. Yohimbine 18-27 transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) Mus musculus 45-48 9879729-3 1998 This inhibitory effect of nociceptin was enhanced in the presence of the alpha2-adrenoceptor antagonist rauwolscine (maximum inhibition by 25% and 50% in the absence and presence of rauwolscine, respectively). Yohimbine 104-115 prepronociceptin Rattus norvegicus 26-36 9879729-3 1998 This inhibitory effect of nociceptin was enhanced in the presence of the alpha2-adrenoceptor antagonist rauwolscine (maximum inhibition by 25% and 50% in the absence and presence of rauwolscine, respectively). Yohimbine 182-193 prepronociceptin Rattus norvegicus 26-36 9699562-9 1998 Yohimbine, a specific alpha2-adrenergic antagonist, completely prevented the induction of ERK phosphorylation. Yohimbine 0-9 Eph receptor B1 Rattus norvegicus 90-93 9745899-1 1998 The report describes the results of a study the effect of pH and binding of six physiologically active compounds (isoproterenol, yohimbine, theophylline, propranolol, clonidine and carbachol) on the molecular structure of human serum albumin (HSA) using dynamic light scattering. Yohimbine 129-138 albumin Homo sapiens 228-241 9750005-8 1998 Yohimbine-induced [35S]GTPgammaS binding was inhibited by the selective 5-HT1A receptor antagonist WAY 100,635. Yohimbine 0-9 5-hydroxytryptamine receptor 1A Homo sapiens 72-87 9750005-14 1998 Conversely, yohimbine was tenfold selective for h alpha2A versus h5-HT1A adrenoceptors but 4.2-fold selective for r alpha2A versus r5-HT1A receptors. Yohimbine 12-21 5-hydroxytryptamine receptor 1A Homo sapiens 66-72 9750005-14 1998 Conversely, yohimbine was tenfold selective for h alpha2A versus h5-HT1A adrenoceptors but 4.2-fold selective for r alpha2A versus r5-HT1A receptors. Yohimbine 12-21 5-hydroxytryptamine receptor 1A Homo sapiens 132-138 9608581-0 1998 Plasma neuropeptide Y (NPY) increases in humans in response to the alpha 2 antagonist yohimbine. Yohimbine 86-95 neuropeptide Y Homo sapiens 7-21 9608581-0 1998 Plasma neuropeptide Y (NPY) increases in humans in response to the alpha 2 antagonist yohimbine. Yohimbine 86-95 neuropeptide Y Homo sapiens 23-26 9608581-2 1998 We herein report that yohimbine also increases plasma neuropeptide Y (NPY) in healthy human subjects. Yohimbine 22-31 neuropeptide Y Homo sapiens 54-68 9608581-2 1998 We herein report that yohimbine also increases plasma neuropeptide Y (NPY) in healthy human subjects. Yohimbine 22-31 neuropeptide Y Homo sapiens 70-73 9608581-7 1998 This study therefore suggests that yohimbine challenge may be useful in assessing NPY and noradrenergic system interactions in neuropsychiatric disorders such as panic disorder or post traumatic stress disorder in which noradrenergic system dysfunction has been observed. Yohimbine 35-44 neuropeptide Y Homo sapiens 82-85 9459568-9 1998 In simultaneous experiments using identical tissue samples, [3H]rauwolscine labeled 783+/-10 fmol of 5-HT2B receptors/mg of protein, as compared to 733+/-14 fmol of 5-HT2B receptors/mg of protein for [3H]5-HT binding. Yohimbine 64-75 5-hydroxytryptamine receptor 2B Homo sapiens 101-107 9489742-4 1998 In contrast, the inhibitory effect of NA on CRH secretion from slices cultured in steroid-free medium was markedly reversed by the alpha2-adrenoreceptor antagonist yohimbine, by pretreatment with pertussin toxin, or by the addition of 4-aminopyridine, a K+-channel blocker. Yohimbine 164-173 corticotropin releasing hormone Homo sapiens 44-47 9638593-9 1998 The injection of yohimbine (80 nmol/microL) prior to clonidine blocked the effect of clonidine on the effect of ANG II (27 +/- 2 mmHg). Yohimbine 17-26 angiotensinogen Rattus norvegicus 112-118 10684495-8 1998 Yohimbine and nifedipine blocked HSP70 mRNA expression, whereas isoproterenol, mecamylamine, and reserpine had no effect. Yohimbine 0-9 heat shock protein family A (Hsp70) member 1B Rattus norvegicus 33-38 9711460-5 1998 In the presence of rauwolscine, clonidine-induced inhibition of electrically evoked [3H]noradrenaline release was counteracted by 1 microM of the selective CB1 receptor antagonist SR141716A (N-[piperidin-1-yl]-5-[4-chlorophenyl]-1-[2,4-dichlorophenyl] -4-methyl-1H-pyrazole-3-carboxamide). Yohimbine 19-30 cannabinoid receptor 1 Rattus norvegicus 156-159 9459568-10 1998 At 0 degrees C, where the conditions for [3H]5-HT binding should label mostly the agonist high affinity state of the human 5-HT2B receptor, [3H]rauwolscine (Bmax = 951+/-136 fmol/mg), again labeled significantly more receptors than [3H]5-HT (Bmax = 615+/-34 fmol/mg). Yohimbine 144-155 5-hydroxytryptamine receptor 2B Homo sapiens 123-138 9459568-11 1998 The affinity of [3H]rauwolscine for the human 5-HT2B receptor at 0 degrees C did not change, Kd = 4.93+/-1.27 nM, while that for [3H]5-HT increased greatly (Kd at 37 degrees C = 7.76+/-1.06 nM; Kd at 0 degrees C = 0.0735+/-0.0081 nM). Yohimbine 20-31 5-hydroxytryptamine receptor 2B Homo sapiens 46-61 9473133-4 1997 The stimulatory effect of ondansetron (10(-6) M) on electrically evoked contractions was antagonized by yohimbine, a 5-HT2B receptor antagonist, but not by SDZ 205-557 (2-methoxy-4-amino-5-chloro-benzoic acid 2-[diethylamino] ethyl ester), a 5-HT4 receptor antagonist. Yohimbine 104-113 5-hydroxytryptamine receptor 2B Rattus norvegicus 117-123 9421826-0 1997 Alprazolam, diazepam, yohimbine, clonidine: in vivo CA1 hippocampal norepinephrine and serotonin release profiles under chloral hydrate anesthesia. Yohimbine 22-31 carbonic anhydrase 1 Rattus norvegicus 52-55 9421826-13 1997 Time course studies showed that the alpha 2-adrenergic antagonist, yohimbine, an anxiogenic agent, increased both NE and 5-HT release in CA1 region of hippocampus; the alpha 2-adrenergic agonist, clonidine, decreased NE release and increased 5-HT release in the same region. Yohimbine 67-76 carbonic anhydrase 1 Rattus norvegicus 137-140 9148895-9 1997 However, incubation of RG20 cells with the alpha2-adrenergic antagonist rauwolscine or with pertussis toxin increased membrane PLD activity and restored activation of PLD by PMA. Yohimbine 72-83 adrenoceptor alpha 2A Rattus norvegicus 23-27 9227603-7 1997 Whereas prazosin and yohimbine attenuated the increases in plasma IL-6 caused by LPS, phentolamine completely blocked the peripheral effects of central LPS. Yohimbine 21-30 interleukin 6 Rattus norvegicus 66-70 9058482-9 1997 The surface expression of GPIIb/IIIa was markedly decreased in platelets from NR after stimulation by epinephrine, in comparison with those from R. The resting level and epinephrine stimulated increase in cAMP were not significantly different between NR and R. Incubating R platelets with a half saturating dose of yohimbine rendered them insensitive to epinephrine. Yohimbine 315-324 integrin subunit alpha 2b Homo sapiens 26-31 9075465-1 1997 BACKGROUND: We have previously reported an increase in symptoms of anxiety in patients with posttraumatic stress disorder (PTSD) following administration of the beta 2-antagonist yohimbine, which stimulates brain norepinephrine release. Yohimbine 179-188 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 161-167 9437760-5 1997 In living chicks clonidine suppressed the nocturnal activity of cyclic AMP-dependent serotonin N-acetyltransferase, a rate-limiting enzyme in melatonin biosynthesis, the effect being prevented by yohimbine. Yohimbine 196-205 aralkylamine N-acetyltransferase Gallus gallus 85-114 9016931-5 1996 In the presence of atropine, both SDZ 205-557 and yohimbine, a 5-HT2B receptor antagonist, inhibited the contraction. Yohimbine 50-59 5-hydroxytryptamine receptor 2B Rattus norvegicus 63-69 8948062-7 1996 Aggregation and rise in [Ca2+]i under low shear in the presence of epinephrine was abolished by monoclonal antibodies against A1 domain of vWF or GP Ib, like aggregation and the rise in [Ca2+]i occurred under high shear rate (10,800 s-1), alpha 2-receptor blockade yohimbine completely antagonized the enhancing effects of epinephrine. Yohimbine 265-274 von Willebrand factor Homo sapiens 139-142 8970356-9 1996 Peak tumor necrosis factor-alpha levels were decreased from 1,305 +/- 333 to 493 +/- 155 pg/ml (p < 0.05) in animals pretreated with rauwolscine. Yohimbine 136-147 tumor necrosis factor Rattus norvegicus 5-32 8958787-7 1996 Phentolamine, a non-selective alpha-adrenergic receptor antagonist, prazosin, an alpha 1-receptor antagonist, and yohimbine, an alpha 2-receptor antagonist, overcame the inhibitory effect of PRL on iGnRH release in a concentration-dependent fashion. Yohimbine 114-123 prolactin Rattus norvegicus 191-194 8819507-7 1996 Ka values for rauwolscine and WB-4101, drugs distinguishing the alpha-2D from the alpha-2A adrenoceptor subtype, were significantly higher in blocking relaxation of rat arteries compared with pig arteries, suggesting the alpha-2D adrenoceptor subtype mediates NO-induced relaxation in rat arteries. Yohimbine 14-25 adrenoceptor alpha 2A Rattus norvegicus 82-103 8897928-6 1996 When antisense oligodeoxyribonucleotides to Mn-SOD were added to myocyte cultures, the increase in Mn-SOD activity (U/mg total protein) and the attenuation of CK release after the addition of NE in the presence of propranolol and yohimbine were not observed. Yohimbine 230-239 superoxide dismutase 2 Homo sapiens 44-50 8981080-4 1996 Idaxozan and yohimbine induced a concentration-dependent potentiation of the contractile response to 0.2-Hz transmural stimulation in the epididymal and prostatic portion of the vas. Yohimbine 13-22 arginine vasopressin Rattus norvegicus 178-181 8815881-4 1996 Higher dosage of yohimbine inhibited the baseline expression of bFGF. Yohimbine 17-26 fibroblast growth factor 2 Rattus norvegicus 64-68 8951963-4 1996 On the other hand, long-term treatment with the monoamine oxidase type-A inhibiting antidepressant, clorgyline (1 mg/kg/day) and the alpha 2-noradrenergic antagonists, yohimbine and 1-phenylpiperazine (1 mg/kg/day, each) did not modify clonidine"s effect. Yohimbine 168-177 monoamine oxidase A Rattus norvegicus 48-72 8733577-16 1996 These findings may be explained on the basis that yohimbine is an alpha 2-adrenoceptor antagonist with affinity for 5-HT1A receptors and that the effects of 5-HT1A receptors may modulate the sexual behaviour responses to alpha 2-receptor antagonism in some models. Yohimbine 50-59 5-hydroxytryptamine receptor 1A Rattus norvegicus 116-122 8709108-1 1996 A series of potent, selective 5HT2B receptor antagonists has been identified based upon yohimbine, with SAR studies resulting in a 1000-fold increase in 5HT2B receptor affinity relative to the starting structure (-log KBS > 10.0 have been obtained). Yohimbine 88-97 5-hydroxytryptamine receptor 2B Rattus norvegicus 30-35 8709108-1 1996 A series of potent, selective 5HT2B receptor antagonists has been identified based upon yohimbine, with SAR studies resulting in a 1000-fold increase in 5HT2B receptor affinity relative to the starting structure (-log KBS > 10.0 have been obtained). Yohimbine 88-97 5-hydroxytryptamine receptor 2B Rattus norvegicus 153-158 8858563-5 1996 The receptor encoded by the bovine gene was expressed in the retina and its photoreceptors with the typical pharmacological characteristics established for the rat alpha 2D-AR subtype: The receptor bound rauwolscine with a KD of 14 nM in the retina and with that of 19 nM in the photoreceptor cells; the binding association rate constant, k+1, for the ligand was 0.012 min-1, the dissociation rate constant, k-1, was 0.14 min-1 and the half-time for dissociation was 5 min. Yohimbine 204-215 adrenoceptor alpha 2A Rattus norvegicus 164-175 8780034-0 1996 Stress- and yohimbine-induced release of cholecystokinin in the frontal cortex of the freely moving rat: prevention by diazepam but not ondansetron. Yohimbine 12-21 cholecystokinin Rattus norvegicus 41-56 8738251-2 1996 Prazosin (an alpha 1-adrenergic receptor antagonist) and yohimbine (an alpha 2-adrenergic receptor antagonist) antagonized the water ingestion, Na+, K+, and urine excretion induced by ANG II. Yohimbine 57-66 angiotensinogen Homo sapiens 184-190 8738251-4 1996 Previous treatment with prazosin and yohimbine reduced the pressor responses to ANG II. Yohimbine 37-46 angiotensinogen Homo sapiens 80-86 8692287-3 1996 A low antagonistic potency of yohimbine indicated that the response to noradrenaline did not involve alpha 2-adrenoceptors, and the subtype-selective antagonists 5-methylurapidil, tamsulosin and chloroethylclonidine indicated mediation via an alpha 1A-adrenoceptor. Yohimbine 30-39 adrenoceptor alpha 1A Rattus norvegicus 243-264 8846821-12 1996 Spinal administration of yohimbine, an alpha 2-adrenoceptor-selective antagonist, significantly attenuated the analgesic effect of Tyr-W-MIF-1. Yohimbine 25-34 predicted gene 4924 Mus musculus 137-142 8842867-7 1996 Phentolamine (50 nM) and prazosin (1 - 10 nM) produced an inhibition of these responses that was significantly greater in SD arteries, whereas that produced by yohimbine (0.5-1 microM) was higher in TGR arteries. Yohimbine 160-169 thioredoxin reductase 3 Mus musculus 199-202 8820174-0 1996 The effect of Yohimbine, an alpha2 adrenergic receptor antagonist, on the growth hormone response to apomorphine in normal subjects. Yohimbine 14-23 growth hormone 1 Homo sapiens 74-88 9813614-4 1996 However, when the cells were pretreated with yohimbine, UK14,304 induced a transient change in ion concentrations, which consisted of a rapid increase of intracellular Cl, Na and a decrease of K at 1 and 5 minutes. Yohimbine 45-54 kynurenine aminotransferase 1 Homo sapiens 193-205 8904737-10 1996 While CGS19281A (20 mg/kg), SKF64139 (50 mg/kg) and yohimbine (5 mg/kg) inhibited GH secretion, the peripherally active PNMT inhibitor SKF29661 (50 mg/kg) did not. Yohimbine 52-61 phenylethanolamine-N-methyltransferase Rattus norvegicus 120-124 8744988-8 1995 Rat brain levels of tribulin, a postulated endocoid indicator of anxiety, assessed in terms of endogenous monoamine oxidase (MAO) A and B inhibitor activity, were increased by both MTV and yohimbine. Yohimbine 189-198 monoamine oxidase A Rattus norvegicus 106-137 7557142-8 1995 Yohimbine but not indomethacin or propranolol eliminated apo A-IV--induced inhibition of acid. Yohimbine 0-9 apolipoprotein A4 Rattus norvegicus 57-65 9053735-5 1995 In the presence of indometacin and yohimbine, sulprostone (an agonist at EP1/EP3 receptors) and misoprostol (an agonist at EP2/EP3 receptors) reduced the noradrenaline overflow evoked by stimulation at 3 Hz maximally by about 80% (EC50: 6 nmol/l and 11 nmol/l, respectively). Yohimbine 35-44 prostaglandin E receptor 1 Rattus norvegicus 73-90 7673275-10 1995 The adverse effect of yohimbine and domperidone on lesion formation is probably mediated through the release of catecholamines, which subsequently act on the beta 2- and alpha 1-adrenoceptors respectively. Yohimbine 22-31 adrenoceptor beta 2 Rattus norvegicus 158-191 7476894-2 1995 Because some P-gp inhibitors (e.g., verapamil and nifedipine) can increase mdr1 and P-gp expression in human colon carcinoma cell lines, we used our reserpine/yohimbine analogues to determine whether there was a structural requirement for this induction. Yohimbine 159-168 ATP binding cassette subfamily B member 1 Homo sapiens 13-17 8539318-3 1995 Yohimbine"s 5-HT1A agonist properties may be responsible for this substitution. Yohimbine 0-9 5-hydroxytryptamine receptor 1A Rattus norvegicus 12-18 7623774-6 1995 In addition, these mice have markedly reduced [3H]rauwolscine binding in their caudate putamen and in other brain regions normally expressing Adra2c binding sites. Yohimbine 50-61 adrenergic receptor, alpha 2c Mus musculus 142-148 7582481-16 1995 On the basis of a higher affinity for ketanserin and a lower affinity for yohimbine the human 5-HT2B receptor also appeared to differ from the rat 5-HT2B receptor. Yohimbine 74-83 5-hydroxytryptamine receptor 2B Homo sapiens 94-109 7476894-0 1995 A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of mdr1 and P-glycoprotein in a human colon carcinoma cell line. Yohimbine 54-63 ATP binding cassette subfamily B member 1 Homo sapiens 117-121 7476894-0 1995 A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of mdr1 and P-glycoprotein in a human colon carcinoma cell line. Yohimbine 54-63 ATP binding cassette subfamily B member 1 Homo sapiens 126-140 7476894-1 1995 We previously showed that there is a structure-function relationship among reserpine and yohimbine analogues in their ability to inhibit the function of P-glycoprotein (P-gp) and reverse multidrug resistance (MDR). Yohimbine 89-98 ATP binding cassette subfamily B member 1 Homo sapiens 153-167 7476894-1 1995 We previously showed that there is a structure-function relationship among reserpine and yohimbine analogues in their ability to inhibit the function of P-glycoprotein (P-gp) and reverse multidrug resistance (MDR). Yohimbine 89-98 ATP binding cassette subfamily B member 1 Homo sapiens 169-173 8748977-4 1995 Induction of c-fos was blocked completely by the alpha 1-adrenergic antagonist prazosin, partially by the alpha 2-adrenergic antagonist yohimbine, and not at all by the beta-adrenergic antagonist propranolol. Yohimbine 136-145 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 13-18 7478230-3 1995 Clonidine (alpha 2 agonist) and yohimbine (alpha 2 antagonist) injected into LH previous to injection of ANGII into LV also abolished the inhibitory effect of ANGII. Yohimbine 32-41 angiotensinogen Rattus norvegicus 105-110 7478230-3 1995 Clonidine (alpha 2 agonist) and yohimbine (alpha 2 antagonist) injected into LH previous to injection of ANGII into LV also abolished the inhibitory effect of ANGII. Yohimbine 32-41 angiotensinogen Rattus norvegicus 159-164 7712012-9 1995 The estimated pKB value for rauwolscine (8.28 +/- 0.19, n = 10) is consistent with inhibition of alpha 2-adrenoceptors. Yohimbine 28-39 AKT serine/threonine kinase 1 Sus scrofa 14-17 7601207-4 1995 Neuropeptide Y, but not peptide YY, inhibited the high K(+)-stimulated tetrodotoxin-resistant release of acetylcholine, while the inhibitory effect of neuropeptide Y disappeared after treatment with yohimbine. Yohimbine 199-208 pro-neuropeptide Y Cavia porcellus 0-14 7601207-4 1995 Neuropeptide Y, but not peptide YY, inhibited the high K(+)-stimulated tetrodotoxin-resistant release of acetylcholine, while the inhibitory effect of neuropeptide Y disappeared after treatment with yohimbine. Yohimbine 199-208 pro-neuropeptide Y Cavia porcellus 151-165 7599919-4 1995 Application of yohimbine, a 5-HT1 and 5-HT2B receptor antagonist, also induced a rightward shift of the response curve to 5-HT, yielding a pA2 estimate of 8.10. Yohimbine 15-24 5-hydroxytryptamine receptor 2B Homo sapiens 38-53 7568629-6 1995 Data are discussed in relation to the possible involvement of 5-HT1A receptor mechanisms in the observed anxiolytic-like effects of yohimbine in the murine plus-maze. Yohimbine 132-141 5-hydroxytryptamine (serotonin) receptor 1A Mus musculus 62-77 7794579-5 1995 In normotensive animals, yohimbine (0.5 mg/kg, intravenous [iv]) doubled plasma NE, EPI, and NPY levels in basal conditions and in response to the hemorrhage. Yohimbine 25-34 neuropeptide Y Rattus norvegicus 93-96 7616690-5 1995 The increased gastric acid secretion and contraction in response to TRH were significantly augmented by pretreatment with yohimbine but not with prazosin. Yohimbine 122-131 thyrotropin releasing hormone Rattus norvegicus 68-71 7616690-8 1995 TRH-induced gastric mucosal lesions were significantly aggravated by yohimbine and adrenalectomy. Yohimbine 69-78 thyrotropin releasing hormone Rattus norvegicus 0-3 22298401-9 1995 Bradykinin and yohimbine increased rat brain tribulin activity, the effect on the MAO A inhibitor component being more marked than that on the MAO B inhibitor component. Yohimbine 15-24 monoamine oxidase A Rattus norvegicus 82-87 7881740-6 1995 Yohimbine, which exhibits negligible affinity for rat 5-HT2C receptors but has high 5-HT2B receptor affinity, acted as a potent but non-surmountable antagonist (pA2 > or = 7.3) in rat jugular vein. Yohimbine 0-9 5-hydroxytryptamine receptor 2C Rattus norvegicus 54-60 7881740-6 1995 Yohimbine, which exhibits negligible affinity for rat 5-HT2C receptors but has high 5-HT2B receptor affinity, acted as a potent but non-surmountable antagonist (pA2 > or = 7.3) in rat jugular vein. Yohimbine 0-9 5-hydroxytryptamine receptor 2B Rattus norvegicus 84-90 7829539-6 1994 Basal gastrin under fasting conditions was significantly reduced by medetomidine and increased by yohimbine. Yohimbine 98-107 gastrin Canis lupus familiaris 6-13 8903941-3 1995 In membranes containing 5-HT1Dbeta receptors, 5-CT and sumatriptan stimulated binding to a similar extent as 5-HT while yohimbine, metergoline and 8-OHDPAT were partial agonists. Yohimbine 120-129 5-hydroxytryptamine receptor 1B Homo sapiens 24-34 7988454-4 1994 In contrast, yohimbine, an alpha 2-selective antagonist, partially suppressed the high dose LPS-induced hypertriglyceridemia by inhibiting the decrease in postheparin lipoprotein lipase activity. Yohimbine 13-22 lipoprotein lipase Rattus norvegicus 167-185 7892112-3 1994 Activation of alpha 2-adrenoceptors by clonidine (an alpha 2-adrenoceptor agonist) or noradrenaline (a non-selective alpha-adrenoceptor agonist), both in the presence of 0.1 microM prazosin to block alpha 1-adrenoceptors, caused a slow and sustained increase in [Ca2+]i which was inhibited by 0.1 microM rauwolscine (an alpha 2-adrenoceptor antagonist). Yohimbine 304-315 adrenoceptor alpha 2A Rattus norvegicus 14-35 7838134-5 1995 alpha 2-Adrenoceptor blockade with yohimbine augmented the effects of morphine on proteins identified by antibodies against CYP2C11 and CYP3A, indicating an involvement or influence of the alpha 2-adrenergic receptor system. Yohimbine 35-44 cytochrome P450, subfamily 2, polypeptide 11 Rattus norvegicus 124-131 7838134-5 1995 alpha 2-Adrenoceptor blockade with yohimbine augmented the effects of morphine on proteins identified by antibodies against CYP2C11 and CYP3A, indicating an involvement or influence of the alpha 2-adrenergic receptor system. Yohimbine 35-44 cytochrome P450, family 3, subfamily a, polypeptide 62 Rattus norvegicus 136-141 7829539-2 1994 The purpose of the present study was to analyse the effects of the alpha 2-adrenoceptor agonist medetomidine and the antagonist yohimbine on gastrin release in conscious dogs. Yohimbine 128-137 gastrin Canis lupus familiaris 141-148 7829539-8 1994 2-deoxy-D-glucose-induced gastrin increase was fully inhibited by medetomidine; this effect was antagonized by yohimbine. Yohimbine 111-120 gastrin Canis lupus familiaris 26-33 7816863-6 1994 Taken together with our previous finding that the desipramine-induced enhancement of aggressive behavior can be blocked by yohimbine, an alpha 2-adrenoceptor antagonist, the present results indicate that not only alpha 2- but also beta 2-adrenoceptor stimulation plays important roles in modulation of aggressive behavior in long-term isolated mice. Yohimbine 123-132 adrenergic receptor, beta 2 Mus musculus 231-250 7842383-8 1994 In a separate experiment, 10(-7) M yohimbine, a relatively specific antagonist of alpha 2-adrenergic receptors, reversed the resistance increment due to ANG II, but not that due to norepinephrine. Yohimbine 35-44 angiotensinogen Rattus norvegicus 153-159 7842383-9 1994 When yohimbine was applied before norepinephrine and ANG II, it did not affect the response to norepinephrine, but again blocked potentiation of the response by ANG II. Yohimbine 5-14 angiotensinogen Rattus norvegicus 161-167 7811353-3 1994 A limitation of the conformational freedom in certain regions of the torsional subspace of the potential energy function, differences in the reactivity of the protonated species towards a model proton acceptor and the quality of the superposition with the rigid template for alpha 1 antagonists, corynanthine, are examined and discussed in order to select a candidate bioactive form and possible features which act as modulators of the recognition process at the alpha 1-adrenoceptors. Yohimbine 296-308 adrenoceptor alpha 1D Homo sapiens 275-282 8156394-7 1994 Although yohimbine alone increased plasma renin activity and concentration, it did not prevent the suppressive effects of fenfluramine. Yohimbine 9-18 renin Rattus norvegicus 42-47 8155646-4 1994 The concentration of agonist producing half-maximal binding of [32P]-AA-GTP by G(i)alpha-3 [5-HT, 48 +/- 1 nM; 8-OH-DPAT, 28 +/- 1 nM; ipsapirone, 22 +/- 6 nM] compared to G(i)alpha-2 [5-HT, 124 +/- 38 nM; 8-OH-DPAT, 40 +/- 1 nM, ipsapirone, 82 +/- 7 nM] was lower with all agonists except rauwolscine, where the EC50"s were similar (G(i)alpha-2, 604 +/- 145 nM; Gi alpha-3, 708 +/- 130 nM). Yohimbine 290-301 G protein subunit alpha i3 Homo sapiens 79-90 8177507-0 1994 Effect of yohimbine on nerve growth factor mRNA and protein levels in rat hippocampus. Yohimbine 10-19 nerve growth factor Rattus norvegicus 23-42 8177507-4 1994 It was found that yohimbine caused a 3-fold increase of NGF mRNA levels at 24 h. Protein levels, however, were unaltered at this time. Yohimbine 18-27 nerve growth factor Rattus norvegicus 56-59 7952871-10 1994 In prazosin-treated preparations ET-1 increased the residual mATP-sensitive responses and this effect was more pronounced after yohimbine. Yohimbine 128-137 endothelin-1 Oryctolagus cuniculus 33-37 7952871-12 1994 In mATP-treated preparations ET-1 increased the residual electrically-induced contractions and this increase was abolished after yohimbine. Yohimbine 129-138 endothelin-1 Oryctolagus cuniculus 29-33 7945735-0 1994 Yohimbine impairs P50 auditory sensory gating in normal subjects. Yohimbine 0-9 nuclear factor kappa B subunit 1 Homo sapiens 18-21 7945735-8 1994 Yohimbine, but not placebo, caused a significant but transient decrease in P50 auditory gating in these subjects. Yohimbine 0-9 nuclear factor kappa B subunit 1 Homo sapiens 75-78 8062098-7 1994 However, inhibition of alpha 2 adrenergic receptor with yohimbine increased GnRH mRNA levels but did not affect NMDA-induced GnRH mRNA levels. Yohimbine 56-65 gonadotropin releasing hormone 1 Rattus norvegicus 76-80 8282383-6 1994 Depressor responses to neuropeptide Y, which was administered after yohimbine pretreatment, were also less in Wistar-Kyoto rats than in spontaneously hypertensive rats. Yohimbine 68-77 neuropeptide Y Rattus norvegicus 23-37 8153089-3 1993 The stimulatory effect of NE on hCG secretion could be abolished by the alpha 1-receptor specific antagonist prazosin (10(-4) M) and partly diminished by the beta 1-receptor specific antagonist atenolol (10(-4) M), but was not influenced by the alpha 2-receptor specific antagonist yohimbine (10(-4) M). Yohimbine 282-291 chorionic gonadotropin subunit beta 5 Homo sapiens 32-35 7904423-6 1993 In a second experiment, the presence of 10 pM angiotensin II, which was subthreshold for constriction, increased phenylephrine sensitivity 10-fold, UK-14,304 sensitivity 16-fold, and the UK-14,304 maximal response by 63%; the half maximum effective concentration response to UK-14,304 was now abolished by rauwolscine at a concentration that did not inhibit phenylephrine constriction. Yohimbine 306-317 angiotensinogen Rattus norvegicus 46-60 7901854-5 1993 Compared with vehicle-injected controls, blockade of alpha 2-adrenergic receptors with either idazoxan (20 mg/kg body wt sc) or yohimbine (5 mg/kg body wt sc) decreased serum growth hormone concentrations before as well as after feeding. Yohimbine 128-137 growth hormone 1 Homo sapiens 175-189 8134313-13 1993 The increase in MAP following PYY (IT) was partially attenuated in the presence of yohimbine. Yohimbine 83-92 peptide YY Rattus norvegicus 30-33 8026715-12 1994 We conclude that AMPH-induced preference for tap water over saline is unrelated to hyperdipsia but, being also induced by yohimbine, it may depend on noradrenergic mechanisms. Yohimbine 122-131 SEC14-like lipid binding 2 Rattus norvegicus 45-48 8153089-4 1993 The involvement of the alpha-receptor in the regulation of hCG secretion was further confirmed by addition of the alpha-receptor agonist clonidine (10(-6) M) which had a similar stimulatory effect on hCG release but the effect was antagonized by both prazosin and yohimbine. Yohimbine 264-273 chorionic gonadotropin subunit beta 5 Homo sapiens 59-62 8254183-8 1993 The alpha 2- and beta 2-adrenoceptor characteristics were determined with [3H]-rauwolscine and [125I]-(-1)cyanopindolol, respectively. Yohimbine 79-90 adrenoceptor beta 2 Homo sapiens 4-36 8277227-4 1993 When employed at a high concentration (1 mumol/l), adrenaline caused a sustained inhibition of glucose-induced insulin secretion, which could be relieved by the addition of the alpha 2-antagonist yohimbine (10 mumol/l). Yohimbine 196-205 insulin Homo sapiens 111-118 8103640-8 1993 Microinjection of yohimbine bilaterally into the NTS did not alter the slope of baroreflex control of RSNA for phenylephrine but normalized the slope for AVP (-2.85 +/- 0.54) to that of phenylephrine. Yohimbine 18-27 arginine vasopressin Homo sapiens 154-157 8103576-3 1993 This effect of neurotensin was inhibited by stimulation of alpha 2-adrenoceptors: noradrenaline, clonidine, xylazine or dexmedetomidine (alpha 2-adrenoceptor agonists) inhibited neurotensin-induced release of acetycholine (ACh) as well as the contractions, while CH-38083 or yohimbine (alpha 2-adrenoceptor antagonist) prevented this inhibitory effect. Yohimbine 275-284 neurotensin/neuromedin N Cavia porcellus 15-26 8335198-6 1993 Atropine, hexamethonium, ICS205-930, BRL43694, phentolamine, yohimbine, and propranolol significantly inhibited motilin-induced contractions. Yohimbine 61-70 motilin Canis lupus familiaris 112-119 8393664-6 1993 The alpha 2A-adrenergic-receptor antagonists oxymetazoline (500 microM) and yohimbine (1 mM) completely abolished DIDS-induced responses. Yohimbine 76-85 adrenoceptor alpha 2A Homo sapiens 4-32 8517875-0 1993 Partial agonist properties of rauwolscine and yohimbine for the inhibition of adenylyl cyclase by recombinant human 5-HT1A receptors. Yohimbine 30-41 5-hydroxytryptamine receptor 1A Homo sapiens 116-122 8517875-0 1993 Partial agonist properties of rauwolscine and yohimbine for the inhibition of adenylyl cyclase by recombinant human 5-HT1A receptors. Yohimbine 46-55 5-hydroxytryptamine receptor 1A Homo sapiens 116-122 8517875-1 1993 Previous studies by another group have suggested that the alpha 2-adrenergic receptor antagonist rauwolscine may function as an agonist at the serotonin1A (5-HT1A) receptor expressed in human brain. Yohimbine 97-108 5-hydroxytryptamine receptor 1A Homo sapiens 143-172 8517875-6 1993 These studies demonstrated that rauwolscine and yohimbine are partial agonists for the human 5-HT1A receptor. Yohimbine 32-43 5-hydroxytryptamine receptor 1A Homo sapiens 93-108 8517875-6 1993 These studies demonstrated that rauwolscine and yohimbine are partial agonists for the human 5-HT1A receptor. Yohimbine 48-57 5-hydroxytryptamine receptor 1A Homo sapiens 93-108 8361548-8 1993 The profile of the minor component of [125I]GTI binding is best characterised as that of a 5-HT1D site: 5-CT > PAPP > or = sumatriptan > rauwolscine > (-)pindolol > or = CP 93129. Yohimbine 146-157 5-hydroxytryptamine receptor 1D Rattus norvegicus 91-97 8361548-7 1993 The pharmacological profile of the major binding component was typical of the 5-HT1B type: 5-CT > CP 93129 > or = (-)pindolol > sumatriptan > or = PAPP > rauwolscine. Yohimbine 169-180 5-hydroxytryptamine receptor 1B Rattus norvegicus 78-84 7694432-7 1993 Yohimbine inhibited GH release induced by UK 14304, GAL and GHRH. Yohimbine 0-9 gonadotropin releasing hormone receptor Rattus norvegicus 20-22 8361548-6 1993 In addition, by blocking the 5-HT1B sites with 100 nM CP 93129, the remaining population of [125I]GTI binding sites could be studied and was found to have high affinity for PAPP, rauwolscine and 8-OH-DPAT. Yohimbine 179-190 5-hydroxytryptamine receptor 1B Rattus norvegicus 29-35 7694432-7 1993 Yohimbine inhibited GH release induced by UK 14304, GAL and GHRH. Yohimbine 0-9 galanin and GMAP prepropeptide Rattus norvegicus 52-55 7694432-7 1993 Yohimbine inhibited GH release induced by UK 14304, GAL and GHRH. Yohimbine 0-9 growth hormone releasing hormone Rattus norvegicus 60-64 7694432-8 1993 Neostigmine-induced GH secretion was partially inhibited by yohimbine and phenoxybenzamine. Yohimbine 60-69 gonadotropin releasing hormone receptor Rattus norvegicus 20-22 8483795-5 1993 Yohimbine, an alpha 2-adrenergic antagonist, attenuated the excitatory response of rat duodenum following NPY (IV) but did not alter the duodenal response to PP (IV). Yohimbine 0-9 neuropeptide Y Rattus norvegicus 106-109 8387366-1 1993 alpha 2 Adrenoceptors in membrane preparations of human and calf frontal cortex and of calf retina can be labelled by the antagonists [3H]idazoxan, [3H]rauwolscine and [3H]RX 821002. Yohimbine 152-163 adrenoceptor alpha 2A Bos taurus 0-21 8385783-7 1993 The affinities of DPAT, yohimbine, and NAN-190 for the 5-HT1A and alpha 2-adrenergic receptors, respectively, were sufficiently high to lead to some ambiguity of interpretation of the behavioral data. Yohimbine 24-33 5-hydroxytryptamine receptor 1A Rattus norvegicus 55-61 8483795-9 1993 The response of the duodenum to the excitatory effect of PYY (IV) was enhanced in the presence of yohimbine. Yohimbine 98-107 peptide YY Rattus norvegicus 57-60 8461977-0 1993 Effect of locus coeruleus lesion on c-fos expression in the cerebral cortex caused by yohimbine injection or stress. Yohimbine 86-95 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 36-41 8461977-1 1993 The injection of the alpha-2 adrenoceptor antagonist, yohimbine, has been shown to increase c-fos immunoreactivity in the rat cerebral cortex. Yohimbine 54-63 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 92-97 8461977-5 1993 It is concluded that the noradrenergic system plays a necessary role in the above c-fos responses in the cortex to yohimbine and to stress. Yohimbine 115-124 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 82-87 8383905-6 1993 Yohimbine did not affect serum GH levels in separated two-day-old pups (i.e. basal levels of the hormone), but prevented the nursing-induced increase in serum GH concentration. Yohimbine 0-9 gonadotropin releasing hormone receptor Rattus norvegicus 159-161 8383905-7 1993 In two-day-old pups, clonidine had no effect on basal GH levels but, like yohimbine, prevented the increase in serum GH normally associated with nursing. Yohimbine 74-83 gonadotropin releasing hormone receptor Rattus norvegicus 117-119 8383905-10 1993 In eight-day-old pups, yohimbine prevented the nursing-induced increase in serum GH and decreased GH levels below the saline-injected, separated control. Yohimbine 23-32 gonadotropin releasing hormone receptor Rattus norvegicus 81-83 8383905-10 1993 In eight-day-old pups, yohimbine prevented the nursing-induced increase in serum GH and decreased GH levels below the saline-injected, separated control. Yohimbine 23-32 gonadotropin releasing hormone receptor Rattus norvegicus 98-100 8472627-5 1993 During the clonidine infusion midaglizole did not elicit any significant rise in plasma insulin, whereas yohimbine increased plasma insulin significantly. Yohimbine 105-114 insulin Canis lupus familiaris 132-139 8472627-8 1993 These results obtained in the present experiments revealed a different mechanism of insulin releasing action of midaglizole from that of yohimbine. Yohimbine 137-146 insulin Canis lupus familiaris 84-91 8472627-4 1993 The administration of yohimbine, a classical alpha 2-antagonist (1.11 mg/kg) revealed a similar increase in plasma insulin to that with midaglizole of equimolar amount. Yohimbine 22-31 insulin Canis lupus familiaris 115-122 1359017-6 1992 Yohimbine, an alpha 2-adrenergic antagonist, blocked NPY inhibition of isoproterenol-stimulated cAMP accumulation. Yohimbine 0-9 neuropeptide Y Rattus norvegicus 53-56 8093725-0 1993 Rauwolscine induces contraction in the dog mesenteric artery precontracted with KCl and endothelin-1: mediation via 5-hydroxytryptamine1-like receptors. Yohimbine 0-11 endothelin 1 Canis lupus familiaris 88-100 8093725-1 1993 Rauwolscine, a selective alpha-2 adrenoceptor antagonist, elicited a sustained contraction in the dog mesenteric artery precontracted with 20 mM KCl or 10(-9) M endothelin-1. Yohimbine 0-11 endothelin 1 Canis lupus familiaris 161-173 8093725-5 1993 These data suggest that rauwolscine is a partial agonist with a lower intrinsic activity than 5-HT and acts at the same 5-HT1-like receptors as 5-HT, most probably 5-HT1D receptors, in the dog mesenteric artery precontracted with KCl. Yohimbine 24-35 5-hydroxytryptamine receptor 1D Canis lupus familiaris 164-170 1328844-9 1992 Examples of the 5-HT1D-like pharmacology displayed by RH-2 include high affinity for the 5-HT1D-selective compound sumatriptan (Ki = 9.4 nM) and for the alpha 2-adrenergic receptor antagonist rauwolscine (Ki = 47 nM). Yohimbine 192-203 5-hydroxytryptamine receptor 1D Homo sapiens 16-22 1359109-6 1992 Thus, the discrimination data are explicable in terms of a direct action of yohimbine and some other alpha 2 adrenoceptor antagonists upon 5-HT1A receptors. Yohimbine 76-85 5-hydroxytryptamine receptor 1A Rattus norvegicus 139-145 1359109-10 1992 First, the present data suggest that rats trained with yohimbine as a discriminative stimulus generalize to drugs with minimal affinity for the alpha 2 adrenoceptor but with high affinity for 5-HT1A receptors. Yohimbine 55-64 5-hydroxytryptamine receptor 1A Rattus norvegicus 192-198 1284575-1 1992 The effects of the alpha 2-adrenoceptor agonist clonidine and antagonist yohimbine were investigated on 3,4-diaminopyridine(DAP)-evoked [3H]norepinephrine ([3H]NE) release from rat hippocampal slices in the presence and absence of extracellular Ca2+. Yohimbine 73-82 death-associated protein Rattus norvegicus 124-127 1284575-4 1992 Clonidine and yohimbine inhibited and enhanced the 3,4-DAP-evoked [3H]NE release in a concentration-dependent manner both in the presence and absence of extracellular Ca2+. Yohimbine 14-23 death-associated protein Rattus norvegicus 55-58 1360316-4 1992 Yohimbine, atipamezole and restraint stress each was found to cause increases in c-fos-like immunoreactivity (c-fos-li). Yohimbine 0-9 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 81-86 1360316-4 1992 Yohimbine, atipamezole and restraint stress each was found to cause increases in c-fos-like immunoreactivity (c-fos-li). Yohimbine 0-9 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 110-115 1360316-5 1992 Western blot analysis revealed increased c-fos protein in the cortex after yohimbine treatment. Yohimbine 75-84 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 41-46 1360316-6 1992 The c-fos-li response to yohimbine was blocked by prior administration of the beta receptor antagonist, dl-propranolol, and to a lesser degree by the alpha-1 antagonist, prazosin. Yohimbine 25-34 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 4-9 1360396-10 1992 Pretreatment of iris root/ciliary bodies with SKF 104078 or rauwolscine reversed the inhibitory effect of UK on isoproterenol- and VIP-induced accumulation of cAMP. Yohimbine 60-71 VIP peptides Oryctolagus cuniculus 131-134 1358385-2 1992 In agreement with the literature, correlation of the ability of a series of agonists and antagonists to displace [3H]-rauwolscine binding shows the alpha 2-adrenoceptors of HT29 cells, NG108-15 cells, OK cells and homogenates of rat sublingual gland to represent four distinct subtypes. Yohimbine 118-129 adrenoceptor alpha 2C Homo sapiens 148-169 1383833-7 1992 When rats were pretreated with the beta 2-adrenoceptor agonist clenbuterol (0.3 mg.kg-1, s.c., twice daily, 14 days), a treatment which desensitizes beta-adrenoceptor-mediated facilitation of noradrenaline release (Kazanietz and Enero 1989), the facilitatory effect of forskolin and IBMX in the presence of yohimbine was abolished. Yohimbine 307-316 adrenoceptor beta 2 Rattus norvegicus 35-54 1328844-9 1992 Examples of the 5-HT1D-like pharmacology displayed by RH-2 include high affinity for the 5-HT1D-selective compound sumatriptan (Ki = 9.4 nM) and for the alpha 2-adrenergic receptor antagonist rauwolscine (Ki = 47 nM). Yohimbine 192-203 Rh associated glycoprotein Homo sapiens 54-58 1482247-9 1992 In sinoaortically denervated dogs, yohimbine elicited elevation of both catecholamines and neuropeptide Y whatever the dose used. Yohimbine 35-44 neuropeptide Y Canis lupus familiaris 91-105 1327843-0 1992 Expression of Fos-like immunoreactivity by yohimbine and clonidine in the rat brain. Yohimbine 43-52 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 14-17 1463373-7 1992 Yohimbine, at concentrations of 1, 3 or 10 microM, significantly decreased the EC50 values for endothelin-1 to 16.4 +/- 1.02 nM, 16.1 +/- 1.60 nM and 8.09 +/- 1.15 nM, respectively. Yohimbine 0-9 endothelin 1 Rattus norvegicus 95-107 1463373-9 1992 However, a modulation of the endothelin-1 effects by yohimbine, rather than by clonidine, via postjunctional mechanisms, cannot be excluded. Yohimbine 53-62 endothelin 1 Rattus norvegicus 29-41 1327843-5 1992 suppressed the Fos expression by yohimbine in these nuclei, and clonidine (100 micrograms/kg, i.p.) Yohimbine 33-42 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 15-18 1313699-3 1992 It was found that the treatment of platelets with insulin decreased alpha 2 adrenergic receptors number of these cells from 413 +/- 92/platelet to 206 +/- 84/platelet as determined by Scatchard analysis of [3H]yohimbine binding. Yohimbine 210-219 insulin Homo sapiens 50-57 1620243-9 1992 In sinoaortically denervated dogs, yohimbine elicited elevation of both catecholamines and NPY-LI whatever the dose used. Yohimbine 35-44 neuropeptide Y Canis lupus familiaris 91-94 1372048-3 1992 In the presence of either 20 mM KCl or 10(-9) M endothelin-1, which had small contractile effects, UK-14304 produced a biphasic concentration-response curve; 10(-7) M rauwolscine inhibited the responses to low concentrations of UK-14304 and 10(-7) M prazosin blocked the responses to high concentrations of UK-14304. Yohimbine 167-178 endothelin 1 Canis lupus familiaris 48-60 1326092-4 1992 The CD50 dose of yohimbine (dose required to produce clonic seizures in 50% of the mice) was determined to be 25.5 mg/kg (s.c.). Yohimbine 17-26 intercellular adhesion molecule 5, telencephalin Mus musculus 4-8 1372048-7 1992 The presence in the medium of 20 mM KCl, 10(-11) M endothelin-1 or 10(-9) M Bay K 8644, which increased resting tension less than 10% of the KCl maximal response, markedly enhanced the responses to UK-14304 primarily at concentrations lower than 10(-6) M. The enhancement of responses were prazosin (10(-7) M)-resistant and rauwolscine (10(-7) M)-sensitive. Yohimbine 324-335 endothelin 1 Canis lupus familiaris 51-63 1359387-1 1992 We have provided a detailed protocol for the synthesis of a yohimbine-agarose matrix that has been shown to be effective for isolation of the alpha 2A-adrenergic receptor from human platelet and purification of the alpha 2A-adrenergic receptor to apparent homogeneity from porcine brain cortex using chromatography on only two sequential yohimbine-agarose columns. Yohimbine 60-69 adrenoceptor alpha 2A Homo sapiens 142-170 1352382-4 1992 In the presence of angiotensin II (0.05 mumol/l), which itself produced a transient contraction, rauwolscine (0.1 mumol/l) produced a rightward shift of the UK-14,304 concentration-response curve while prazosin (0.1 mumol/l) had no effect. Yohimbine 97-108 angiotensinogen Homo sapiens 19-33 1610485-0 1992 Evidence for hypothalamo-growth hormone dysfunction in panic disorder: profile of growth hormone (GH) responses to clonidine, yohimbine, caffeine, glucose, GRF and TRH in panic disorder patients versus healthy volunteers. Yohimbine 126-135 growth hormone 1 Homo sapiens 98-100 1610485-5 1992 Although stress-mediated increases in GH are thought to be a common correlate of stress in humans, our findings indicate that panic disorder patients have significantly blunted GH responses to clonidine, yohimbine, growth-hormone releasing factor, and caffeine compared to normal control subjects. Yohimbine 204-213 growth hormone 1 Homo sapiens 177-179 1359387-1 1992 We have provided a detailed protocol for the synthesis of a yohimbine-agarose matrix that has been shown to be effective for isolation of the alpha 2A-adrenergic receptor from human platelet and purification of the alpha 2A-adrenergic receptor to apparent homogeneity from porcine brain cortex using chromatography on only two sequential yohimbine-agarose columns. Yohimbine 60-69 adrenoceptor alpha 2A Homo sapiens 215-243 1359387-1 1992 We have provided a detailed protocol for the synthesis of a yohimbine-agarose matrix that has been shown to be effective for isolation of the alpha 2A-adrenergic receptor from human platelet and purification of the alpha 2A-adrenergic receptor to apparent homogeneity from porcine brain cortex using chromatography on only two sequential yohimbine-agarose columns. Yohimbine 338-347 adrenoceptor alpha 2A Homo sapiens 142-170 1683737-13 1991 The results indicate that there is a yohimbine-sensitive mechanism involved in the cerebrovasodilating effect of thyrotropin-releasing hormone in anaesthetized rabbits. Yohimbine 37-46 thyrotropin releasing hormone Oryctolagus cuniculus 113-142 1608292-9 1992 Icv injections of the antagonist of alpha 2-adrenoceptors yohimbine prevented both clonidine and alpha N-acetyl beta-endorphin-(1-31) from reducing the jumping behaviour displayed by morphine-abstinent mice. Yohimbine 58-67 proopiomelanocortin Homo sapiens 112-126 1667606-3 1991 [3H]Rauwolscine, besides binding to alpha 2 adrenoceptors, also binds to 5-HT1A receptors. Yohimbine 4-15 5-hydroxytryptamine receptor 1A Homo sapiens 73-79 1667606-8 1991 The regional distribution of 5-HT1A receptors labelled by [3H]rauwolscine is in agreement with previous studies using [3H]8-OH-DPAT. Yohimbine 62-73 5-hydroxytryptamine receptor 1A Homo sapiens 29-35 1836757-5 1991 Transient expression of this clone demonstrated high-affinity binding of [3H]5-HT with a pharmacological profile corresponding to that of the 5-HT1B subtype: 5-CT, 5-HT greater than propranolol greater than methysergide greater than rauwolscine greater than 8-OH-DPAT. Yohimbine 233-244 5-hydroxytryptamine receptor 1B Rattus norvegicus 142-148 1357711-1 1992 Previous studies have shown that discriminative stimulus control established with the 5HT1A receptor agonist, 8-OH-DPAT, generalizes to other 5HT1A agonists and partial agonists but also to the alpha 2-adrenoceptor antagonist, yohimbine. Yohimbine 227-236 5-hydroxytryptamine receptor 1A Rattus norvegicus 86-91 1719824-2 1991 [3H]rauwolscine bound to a single class of alpha 2-adrenoceptors with high affinity [Kd = 1.7 +/- 0.3 nM, maximum binding (Bmax) = 45.2 +/- 10.8 fmol/mg protein]. Yohimbine 4-15 adrenoceptor alpha 2A Homo sapiens 43-64 1719824-3 1991 alpha 2-Adrenoceptor ligands inhibited [3H]rauwolscine binding with a rank order of potency characteristic of interaction with the alpha 2B-adrenoceptor [inhibitory constant (Ki) values (in nM) rauwolscine (1.95) greater than ARC-239 (8.52) greater than prazosin (237) greater than oxymetazoline (30,000)]. Yohimbine 43-54 adrenoceptor alpha 2B Rattus norvegicus 131-152 1665390-6 1991 The stimulated release of noradrenaline and NPY was increased by the alpha 2-adrenergic receptor antagonist yohimbine, and attenuated by the alpha 2-adrenergic receptor agonist B-HT 920, respectively. Yohimbine 108-117 pro-neuropeptide Y Cavia porcellus 44-47 1797315-11 1991 Yohimbine transiently increased plasma insulin and the effect was dose-dependent. Yohimbine 0-9 insulin Canis lupus familiaris 39-46 1797315-20 1991 Yohimbine also induced a transient increase in plasma insulin level and increased heart rate and blood pressure. Yohimbine 0-9 insulin Canis lupus familiaris 54-61 1659347-7 1991 doses of yohimbine rose plasma NPY concentrations. Yohimbine 9-18 neuropeptide Y Canis lupus familiaris 31-34 1744378-11 1991 Pretreatment with yohimbine caused a three to four-fold increase in plasma delta NPY-LI, which was slightly reduced both in the presence of isoprenaline (-39%) and propranolol (-27%). Yohimbine 18-27 pro-neuropeptide Y Cavia porcellus 81-84 1680719-0 1991 [3H]rauwolscine behaves as an agonist for the 5-HT1A receptors in human frontal cortex membranes. Yohimbine 4-15 5-hydroxytryptamine receptor 1A Homo sapiens 46-52 1662744-4 1991 Both yohimbine injection and stressful stimulation, two treatments causing brain norepinephrine (NE) release, were found to cause a parallel, transient activation of at least 5 IEGs (c-fos, nur77, tis-7, zif-268 and tis-21) in the rat cortex. Yohimbine 5-14 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 183-188 1662744-4 1991 Both yohimbine injection and stressful stimulation, two treatments causing brain norepinephrine (NE) release, were found to cause a parallel, transient activation of at least 5 IEGs (c-fos, nur77, tis-7, zif-268 and tis-21) in the rat cortex. Yohimbine 5-14 nuclear receptor subfamily 4, group A, member 1 Rattus norvegicus 190-195 1662744-4 1991 Both yohimbine injection and stressful stimulation, two treatments causing brain norepinephrine (NE) release, were found to cause a parallel, transient activation of at least 5 IEGs (c-fos, nur77, tis-7, zif-268 and tis-21) in the rat cortex. Yohimbine 5-14 early growth response 1 Rattus norvegicus 204-211 1662744-4 1991 Both yohimbine injection and stressful stimulation, two treatments causing brain norepinephrine (NE) release, were found to cause a parallel, transient activation of at least 5 IEGs (c-fos, nur77, tis-7, zif-268 and tis-21) in the rat cortex. Yohimbine 5-14 BTG anti-proliferation factor 2 Rattus norvegicus 216-222 1683291-0 1991 Sympatholytic action of yohimbine mediated by 5-HT1A receptors. Yohimbine 24-33 5-hydroxytryptamine receptor 1A Homo sapiens 46-52 1683291-9 1991 These data indicate that high doses of yohimbine inhibit sympathetic nerve activity via a 5HT1A agonist action. Yohimbine 39-48 5-hydroxytryptamine receptor 1A Homo sapiens 90-95 1645350-11 1991 In competition binding studies the potency order of competing ligands for RG20 is phentolamine greater than idazoxan greater than yohimbine greater than rauwolscine greater than prazosin. Yohimbine 130-139 adrenoceptor alpha 2A Rattus norvegicus 74-78 1645350-11 1991 In competition binding studies the potency order of competing ligands for RG20 is phentolamine greater than idazoxan greater than yohimbine greater than rauwolscine greater than prazosin. Yohimbine 153-164 adrenoceptor alpha 2A Rattus norvegicus 74-78 1677361-8 1991 In contrast, pretreatment with yohimbine significantly (P less than 0.05) blunted the pyridostigmine-induced enhancement of GHRH-elicited GH release. Yohimbine 31-40 growth hormone releasing hormone Homo sapiens 124-128 1677361-8 1991 In contrast, pretreatment with yohimbine significantly (P less than 0.05) blunted the pyridostigmine-induced enhancement of GHRH-elicited GH release. Yohimbine 31-40 growth hormone 1 Homo sapiens 124-126 1719290-5 1991 The affinities of yohimbine (alpha 2-adrenoceptor antagonist) for the receptors mediating responses to B-HT 933 were 7.46 +/- 0.13 (pKB) and 7.57 +/- 0.10 (pA2), respectively. Yohimbine 18-27 AKT serine/threonine kinase 1 Homo sapiens 132-135 1680719-10 1991 This suggests that [3H]rauwolscine is a 5-HT1A receptor agonist and this conclusion is compatible with earlier functional studies, indicating that rauwolscine (as well as yohimbine) has agonistic properties at the level of 5-HT autoreceptors. Yohimbine 23-34 5-hydroxytryptamine receptor 1A Homo sapiens 40-55 1679709-4 1991 Inhibition of VIP-stimulated cyclic AMP production by epinephrine and paraaminoclonidine in tissues from both normal and denervated eyes was blocked by the alpha 2-adrenergic antagonist yohimbine but not by the alpha 1-adrenergic antagonist prazosin. Yohimbine 186-195 VIP peptides Oryctolagus cuniculus 14-17 1852113-4 1991 Corynanthine pretreatment attenuated the vasopressin response to H2 in males, potentiated this response in proestrous females, but had no effect in estrous females. Yohimbine 0-12 arginine vasopressin Rattus norvegicus 41-52 1878751-5 1991 Yohimbine alone tended to increase the NPY mRNA level after 24h. Yohimbine 0-9 neuropeptide Y Rattus norvegicus 39-42 1678730-5 1991 In male rats treated with FEN, IDZ and CLO, a significant decrease of plasma PRL was produced, but YOH further enhanced PRL secretion. Yohimbine 99-102 prolactin Rattus norvegicus 120-123 1885256-1 1991 Oral yohimbine administration (0.2 mg/kg) induced lipid mobilization (increase in plasma non-esterified fatty acids, NEFA) in fasting non-obese women (body mass index BMI = 20.2 +/- 0.5, age 35.5 +/- 2.7 years) without significant action on plasma glucose, insulin levels, heart rate or blood pressure during the time-course of the experiment (240 min). Yohimbine 5-14 insulin Homo sapiens 257-264 1364850-9 1991 Transmitter release evoked by 100 microM 4-AP could be blocked by the alpha 2-adrenoceptor agonist, UK 14,304 (0.1 microM) and by the A1-receptor agonist R-N6-phenylisopropyl adenosine (R-PIA, 1 microM) and increased by the alpha 2-adrenoceptor antagonist, yohimbine (1 microM), both in 0.25 and 1.3 mM Ca(2+)-containing medium. Yohimbine 257-266 ribose 5-phosphate isomerase A Rattus norvegicus 134-191 1675498-4 1991 The highest yohimbine infusion (50 nmol/kg/min) blocked the clonidine-induced responses of glucagon, insulin and glucose. Yohimbine 12-21 LOC105613195 Ovis aries 101-108 1849767-6 1991 The GH response to DMI was inhibited by prior administration of idazoxan (1 mg kg-1) or yohimbine (0.5 mg kg-1), but not by atropine (10 micrograms kg-1), sulpiride (5 mg kg-1) or prazosin (1 mg kg-1). Yohimbine 88-97 gonadotropin releasing hormone receptor Rattus norvegicus 4-6 1982556-3 1990 Rauwolscine 1 mumol/l antagonized the effects of both noradrenaline and UK 14,304, but potentiated the effects of [Met5]enkephalin and [D-Ala2, D-Leu5]enkephalin. Yohimbine 0-11 proenkephalin Rattus norvegicus 120-130 1979809-6 1990 In pineal gland, the suppressive effects of bromocriptine and quinpirole on NAT activity were blocked by yohimbine, a selective alpha-2 adrenergic receptor antagonist, but not by spiperone, a D2-dopamine receptor antagonist. Yohimbine 105-114 arylamine N-acetyltransferase, liver isozyme Gallus gallus 76-79 1982556-3 1990 Rauwolscine 1 mumol/l antagonized the effects of both noradrenaline and UK 14,304, but potentiated the effects of [Met5]enkephalin and [D-Ala2, D-Leu5]enkephalin. Yohimbine 0-11 proenkephalin Rattus norvegicus 151-161 2169395-8 1990 Yohimbine significantly reduced the ACTH response. Yohimbine 0-9 proopiomelanocortin Homo sapiens 36-40 2166759-8 1990 This augmentation in TNF mRNA accumulation was blocked by yohimbine. Yohimbine 58-67 tumor necrosis factor Homo sapiens 21-24 2377281-6 1990 A small series of adrenergic agents competed for the [3H]dihydroalprenolol, [3H]yohimbine, and [3H]praz binding sites in a fashion suggesting the presence of alpha 1-, alpha 2-, beta 1-, and beta 2-receptors on the vessels within human pia. Yohimbine 80-89 adrenoceptor alpha 1D Homo sapiens 158-197 19215376-3 1990 The GH-releasing effect of clonidine (0.15 mg infused iv over 10 min), an alpha(2)-adrenergic agonist, was significantly blunted by yohimbine (30 mg orally at -50 min), a relatively specific alpha(2)-adrenergic antagonist area under the response curve, mean+/-SEM: 672.6 +/- 143.0 versus 219.6 +/- 16.7 mug/l/h; P<0.05). Yohimbine 132-141 growth hormone 1 Homo sapiens 4-6 1970497-2 1990 Saturation experiments indicated that [3H]-yohimbine binding was specific, saturable and labelled a single population of sites in rat cerebral cortex (Kd 5.3 +/- 0.9 nM, Bmax 121 +/- 10 fmol mg-1 protein) and human platelets (Kd 0.7 +/- 0.1 nM, Bmax 152 +/- 10 fmol mg-1 protein). Yohimbine 43-52 Mg1 protein Rattus norvegicus 191-204 2173006-5 1990 Instead, yohimbine increased feed intake over NPY-induced feeding by 52 to 55%. Yohimbine 9-18 pro-neuropeptide Y Ovis aries 46-49 1972139-7 1990 We also found that yohimbine significantly increased the plasma insulin concentration in these fasted subjects (9.4 +/- 2.4 vs. 14.5 +/- 1.4 ng/ml, p less than 0.05) without inducing hypoglycemia. Yohimbine 19-28 insulin Homo sapiens 64-71 2159978-6 1990 Noradrenergic inhibition of 3-isobutyl-1-methylxanthine-augmented cAMP levels and NAT activity was reversed by yohimbine (an alpha 2-adrenergic antagonist) but not by prazosin (an alpha 1-adrenergic antagonist). Yohimbine 111-120 aralkylamine N-acetyltransferase Gallus gallus 82-85 1970497-2 1990 Saturation experiments indicated that [3H]-yohimbine binding was specific, saturable and labelled a single population of sites in rat cerebral cortex (Kd 5.3 +/- 0.9 nM, Bmax 121 +/- 10 fmol mg-1 protein) and human platelets (Kd 0.7 +/- 0.1 nM, Bmax 152 +/- 10 fmol mg-1 protein). Yohimbine 43-52 Mg1 protein Rattus norvegicus 266-279 1970497-14 1990 The ability of 8-OH-DPAT, RU 24969 and methysergide in addition to prazosin and oxymetazoline to differentiate [3H]-yohimbine binding provides additional pharmacological evidence for heterogeneity within rat cortical alpha 2-adrenoceptors. Yohimbine 116-125 adrenoceptor alpha 2A Rattus norvegicus 217-238 2164166-3 1990 NPY-induced inhibition of [3H]NE release was unaffected by pretreatment of tissues with atropine (100 nM) plus yohimbine (100 nM) and was non-additive with the maximal prejunctional effects of carbamycholine or clonidine, indicating that NPY acts independently of prejunctional muscarinic or alpha 2-adrenergic receptor activity to reduce [3H]NE overflow. Yohimbine 111-120 neuropeptide Y Oryctolagus cuniculus 0-3 1970494-9 1990 Blockade of either alpha 2-adrenoceptors with 0.1 microM yohimbine or alpha 1-adrenoceptors with 0.1 microM prazosin caused shifts to the right of the noradrenaline concentration-response curves and the shifts in pD2 were 0.69 and 0.61, respectively. Yohimbine 57-66 PAF1 homolog, Paf1/RNA polymerase II complex component Homo sapiens 213-216 2407671-3 1990 Additionally, yohimbine, a selective alpha 2-adrenoceptor antagonist, has been shown to increase the plasma VP level and blood pressure (BP) in man. Yohimbine 14-23 arginine vasopressin Homo sapiens 108-110 2170253-11 1990 Many classical pharmacological agents including guanethidine, clonidine, yohimbine, angiotensin II, nicotine and desipramine influence NPY release. Yohimbine 73-82 neuropeptide Y Homo sapiens 135-138 2252308-9 1990 5-HT1D receptors show high to intermediate affinities to compounds such as PAPP, DP-5-CT, 8-OH-DPAT, yohimbine and rauwolscine, whereas 5-HT1B receptors have very low affinities for these compounds. Yohimbine 101-110 5-hydroxytryptamine receptor 1D Homo sapiens 0-6 2252308-9 1990 5-HT1D receptors show high to intermediate affinities to compounds such as PAPP, DP-5-CT, 8-OH-DPAT, yohimbine and rauwolscine, whereas 5-HT1B receptors have very low affinities for these compounds. Yohimbine 115-126 5-hydroxytryptamine receptor 1D Homo sapiens 0-6 1983458-6 1990 Our results indicate that natriuresis occurs even in the absence of changes in glomerular filtration rate and demonstrate an inhibitory natriuretic effect of an alpha-1 blocker (prazosin) injected into the LHA before adrenaline, while an alpha-2 antagonist (yohimbine) yielded a potentiating effect. Yohimbine 258-267 adrenoceptor alpha 1D Homo sapiens 161-168 2153389-3 1990 The yohimbine induced potentiation of the APZ effect was counteracted both by the selective alpha 1-adrenoceptor antagonist prazosin (0.25 mg/kg) and the beta-adrenoceptor antagonist propranolol (2.0 mg/kg), but not by the selective beta 1-adrenoceptor antagonist metoprolol (2.0 mg/kg). Yohimbine 4-13 adrenoceptor beta 1 Rattus norvegicus 233-252 33798290-9 2021 The functions of alpha2AR within the NTS in modulating MBP and HR were verified by microinjection of its agonist (clonidine) and antagonist (yohimbine) separately. Yohimbine 141-150 adenosine A2a receptor Rattus norvegicus 17-25 1980144-6 1990 Concurrent administration of clonidine with the selective alpha-2 antagonist yohimbine prevented the clonidine-induced changes in plasma adrenocorticotropin and hypothalamic corticotropin-releasing factor, consistent with the clonidine effect being mediated through alpha-2 receptors. Yohimbine 77-86 corticotropin releasing hormone Homo sapiens 174-204 1965048-2 1990 Yohimbine (YOH), an alpha 2-receptor blocker, reversed the effect of AII. Yohimbine 0-9 angiotensinogen Rattus norvegicus 69-72 1965048-2 1990 Yohimbine (YOH), an alpha 2-receptor blocker, reversed the effect of AII. Yohimbine 11-14 angiotensinogen Rattus norvegicus 69-72 2255749-0 1990 Plasma 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) and growth hormone responses to yohimbine in panic disorder patients and normal controls. Yohimbine 87-96 growth hormone 1 Homo sapiens 59-73 34965503-5 2022 The alpha2-ADR antagonist rauwolscine rescues the prothrombotic phenotype in BDNFMet/Met mice and reduces procoagulant activity and platelet generation in cells transfected with BDNFMet plasmid or exposed to pro-BDNFMet peptide. Yohimbine 26-37 G protein-coupled receptor 162 Mus musculus 4-10 35248961-7 2022 Similar to yohimbine and SB204741, which are prototypic antagonists of ADRA2B and HTR2B, respectively, carbaryl increased the heart rate of zebrafish larvae. Yohimbine 11-20 adrenoceptor alpha 2B Danio rerio 71-77 34265299-10 2021 Further, yohimbine significantly reduced the levels of dihydrotestosterone, prostatic acid phosphatase, prostate-specific antigen, proliferating cell nuclear antigen, and steroid 5alpha-reductase, suggesting that it exerts beneficial effects against BPH by modulating the steroid 5alpha-reductase pathway. Yohimbine 9-18 acid phosphatase 3 Rattus norvegicus 76-102 34265299-10 2021 Further, yohimbine significantly reduced the levels of dihydrotestosterone, prostatic acid phosphatase, prostate-specific antigen, proliferating cell nuclear antigen, and steroid 5alpha-reductase, suggesting that it exerts beneficial effects against BPH by modulating the steroid 5alpha-reductase pathway. Yohimbine 9-18 proliferating cell nuclear antigen Rattus norvegicus 131-165 34975560-7 2021 Participants received a 10 mg single dose of the alpha-2 antagonist yohimbine that increases noradrenergic activity or placebo on 2 separate days, with ECG recordings before and after drug administration at defined intervals. Yohimbine 68-77 glycoprotein hormone subunit alpha 2 Homo sapiens 49-56 34506777-8 2021 We found that an alpha2-adrenoceptor (alpha2-AR) antagonist (yohimbine) completely aborted DEX-induced B1R and B2R regulation; an adenylyl cyclase (AC) agonist (forskolin) blocked B1R downregulation, while a phosphatidylinositol 3-kinase (PI3K) inhibitor (LY294002) blocked B2R upregulation. Yohimbine 61-70 adenosine A2a receptor Rattus norvegicus 38-47 34506777-8 2021 We found that an alpha2-adrenoceptor (alpha2-AR) antagonist (yohimbine) completely aborted DEX-induced B1R and B2R regulation; an adenylyl cyclase (AC) agonist (forskolin) blocked B1R downregulation, while a phosphatidylinositol 3-kinase (PI3K) inhibitor (LY294002) blocked B2R upregulation. Yohimbine 61-70 bradykinin receptor B1 Rattus norvegicus 103-106 34506777-8 2021 We found that an alpha2-adrenoceptor (alpha2-AR) antagonist (yohimbine) completely aborted DEX-induced B1R and B2R regulation; an adenylyl cyclase (AC) agonist (forskolin) blocked B1R downregulation, while a phosphatidylinositol 3-kinase (PI3K) inhibitor (LY294002) blocked B2R upregulation. Yohimbine 61-70 bradykinin receptor B2 Rattus norvegicus 111-114 34506777-8 2021 We found that an alpha2-adrenoceptor (alpha2-AR) antagonist (yohimbine) completely aborted DEX-induced B1R and B2R regulation; an adenylyl cyclase (AC) agonist (forskolin) blocked B1R downregulation, while a phosphatidylinositol 3-kinase (PI3K) inhibitor (LY294002) blocked B2R upregulation. Yohimbine 61-70 bradykinin receptor B2 Rattus norvegicus 274-277 34597607-8 2021 Intrathecally injected MOR antagonist CTAP, norepinephrine depletor 6-OHDA and alpha2-adrenoceptor (alpha2-AR) antagonist yohimbine partially antagonized dezocine, pentazocine and tapentadol antinociception. Yohimbine 122-131 adenosine A2a receptor Homo sapiens 100-109 34224852-1 2021 Previous work introduced the (11C)yohimbine as a suitable ligand of central alpha2-adrenoreceptors (alpha2-ARs) for PET imaging. Yohimbine 34-43 glycoprotein hormone subunit alpha 2 Homo sapiens 76-82 34224852-1 2021 Previous work introduced the (11C)yohimbine as a suitable ligand of central alpha2-adrenoreceptors (alpha2-ARs) for PET imaging. Yohimbine 34-43 glycoprotein hormone subunit alpha 2 Homo sapiens 100-106 34224852-14 2021 CONCLUSION: The results add experimental support for the suitability of (11C)yohimbine PET in the quantitative assessment of alpha2-ARs occupancy in vivo in the human brain. Yohimbine 77-86 glycoprotein hormone subunit alpha 2 Homo sapiens 125-131 34237977-7 2021 RESULTS: Compared with the Sham group, the rats in I/R, I/R + Dex, I/R + Yoh + Dex, and I/R + SP600125 groups developed hemiparesis of the left forelimb at different levels with a higher neurological deficit score, brain water content, infarct volume, and markedly upregulated expression of cleaved caspase-3, p-JNK (P<0.05). Yohimbine 73-76 caspase 3 Rattus norvegicus 299-308 34237977-7 2021 RESULTS: Compared with the Sham group, the rats in I/R, I/R + Dex, I/R + Yoh + Dex, and I/R + SP600125 groups developed hemiparesis of the left forelimb at different levels with a higher neurological deficit score, brain water content, infarct volume, and markedly upregulated expression of cleaved caspase-3, p-JNK (P<0.05). Yohimbine 73-76 mitogen-activated protein kinase 8 Rattus norvegicus 312-315 35248961-7 2022 Similar to yohimbine and SB204741, which are prototypic antagonists of ADRA2B and HTR2B, respectively, carbaryl increased the heart rate of zebrafish larvae. Yohimbine 11-20 5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled Danio rerio 82-87 35238961-1 2022 PURPOSE: To investigate the suitability of microdosed oral omeprazole for predicting CYP2C19 activity in vivo in combination with simultaneous assessment of CYP3A and CYP2D6 activity using both microdosed midazolam and yohimbine. Yohimbine 219-228 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 167-173 35471719-4 2022 Intradermal injection of the alpha2 adrenoceptor (alpha2AR) antagonist yohimbine and agonist dexmedetomidine in the forearm attenuated the cardiac adjustment by ES. Yohimbine 71-80 adenosine A2a receptor Rattus norvegicus 50-58 35457136-7 2022 Dexmedetomidine-induced EGFR tyrosine and JNK phosphorylation were inhibited by rauwolscine, PP1, PP2, GM6001, and AG1478. Yohimbine 80-91 epidermal growth factor receptor Rattus norvegicus 24-28 35457136-7 2022 Dexmedetomidine-induced EGFR tyrosine and JNK phosphorylation were inhibited by rauwolscine, PP1, PP2, GM6001, and AG1478. Yohimbine 80-91 mitogen-activated protein kinase 8 Rattus norvegicus 42-45 35401264-13 2022 In contrast, alpha2A-adrenoceptor antagonist Yohimbine, at the dose of 1 mg/kg, increased the distance traveled by DAT-KO rats and elevated the number of perseverative reactions and the time spent in the error zones. Yohimbine 45-54 adrenoceptor alpha 2A Rattus norvegicus 13-33 35401264-13 2022 In contrast, alpha2A-adrenoceptor antagonist Yohimbine, at the dose of 1 mg/kg, increased the distance traveled by DAT-KO rats and elevated the number of perseverative reactions and the time spent in the error zones. Yohimbine 45-54 solute carrier family 6 member 3 Rattus norvegicus 115-118 35224877-5 2022 Yohimbine, RX821002, RS79948, and atipamezole are high affinity non-selective alpha2-antagonists. Yohimbine 0-9 glycoprotein hormone subunit alpha 2 Homo sapiens 78-84